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Heme (iron protoporphyrin IX) is an essential but inherently cytotoxic metallocofactor and 
signaling molecule. Although essential for life, heme and its biosynthetic precursors may also act 
as toxins, necessitating that cells carefully handle the synthesis and trafficking of this compound. 
The hydrophobicity and redox activity of heme causes it to disrupt membrane structure, become 
mis-associated with certain proteins, and deleteriously oxidize various biomolecules. Despite the 
tremendous importance of heme in physiology, the cellular and molecular mechanisms that govern 
the safe assimilation of heme from its sites of synthesis or uptake into metabolism remain poorly 
understood. Herein, we utilized genetically encoded fluorescent heme sensors to identify factors 
that regulate heme uptake, trafficking, and bioavailability. 
In this thesis, we describe genetic screens in Baker’s yeast to identify factors that regulate a. 
steady-state heme availability, b. the dynamics of heme mobilization to different subcellular 
compartments as it is being synthesized, and c. heme uptake. Regarding steady-state heme 
availability, the Saccharomyces cerevisiae haploid gene deletion library was transformed with 
cytosolic heme sensors and mutants with altered heme availability were discovered in order to 
identify possible heme transporters, trafficking factors, and buffering proteins. The screen 
identified 114 strains with high cytosolic heme and 323 strains with low cytosolic heme.   
Amongst the deletion mutants with high heme, we found that the glycolytic enzyme 
glyceraldehyde phosphate dehydrogenase (GAPDH) is responsible for buffering intracellular 
heme and regulating the activity of the nuclear heme-dependent transcription factor heme activator 
protein (Hap1p). Additionally, we found that a conserved His residue, His53 in human and His51 
in yeast, is responsible for heme binding to GAPDH and its cellular role in heme buffering and 
activation of Hap1. Amongst the deletion mutants with low heme, we found that Golgi-to-vacuolar 
 xxiii 
vesicular trafficking is a key requirement to for ensuring heme is accessible to the cytosol. We 
propose a model in which heme is transported from endosomes into the cytosol. Altogether, for 
the first time, we identified genome-wide determinants of heme bioavailability. 
In order to probe heme distribution dynamics as heme is being synthesized, we developed a 
live-cell assay in yeast to monitor inter-compartmental heme trafficking kinetics to different 
subcellular compartments, including the mitochondrial matrix, cytosol, or nucleus. Surprisingly, 
we found that heme trafficking rates from the matrix side of the IM, where heme is made, to the 
mitochondrial matrix and cytosol are similar, while trafficking to the nucleus is ~25% faster. These 
data indicate that heme is distributed from the mitochondrial IM to other locales simultaneously 
via multiple parallel pathways rather than sequentially. Moreover, we discovered that the heme 
biosynthetic enzyme, aminolevulinic acid synthase (ALAS) negatively regulates mitochondrial-
nuclear heme trafficking, highlighting the close coordination of heme synthesis and trafficking. In 
addition, we identified GTPases that directly (Gem1) and indirectly (Dnm1 and Mgm1) regulate 
ERMES as being modulators of nuclear heme transport. Based on our results, we propose a model 
in which heme is trafficked via ER- mitochondrial membrane contact sites to other organelles such 
as the nucleus.  
Most eukaryotes have the capacity to both make and import heme. We used fluorescent heme 
sensors in Saccharomyces cerevisiae to determine if heme availability and utilization differs 
whether heme is derived from exogenous or endogenous sources. Our results demonstrate that S. 
cerevisiae is capable of acquiring and utilizing exogenous heme under high concentrations but not 
in an efficient way. Biosynthesized heme is more available than exogenous heme and is more 
efficient at activating heme dependent processes such as catalase activity and Hap1 activity, a 
heme dependent transcription factor. We observed conditions such as iron starvation promoted 
 xxiv 
heme availability from exogenous sources in a heme oxygenase (HO) dependent manner. In 
addition, we screened the yeast deletion collection for factors that altered heme uptake and 
utilization and identified 33 deletion mutants that displayed an improvement in heme uptake, 
including mfm1∆ cells, which lacks a magnesium transporter and has a defect in mitochondrial 
membrane potential. 
Overall, our work probing heme homeostasis with genetically encoded heme sensors have 
identified a host of new factors that regulate heme trafficking dynamics and availability from both 
endogenous and exogenous heme sources. The tools and approaches described herein to identify 
new heme trafficking factors in Baker’s yeast are now being applied to probe heme homeostasis 
in human cell lines, where defects in heme metabolism cause a number of diseases, and in bacterial 






CHAPTER 1. INTRODUCTION  
Heme (iron protoporphyrin IX, heme b) is an essential metallonutrient required for virtually 
all aerobic life. (Figure 1.1) Biology exploits the Lewis acidity, redox activity and hydrophobicity 
of heme to act as a protein cofactor and signaling molecule. As a cofactor, heme facilitates several 
processes that span electron transfer, chemical catalysis, gas synthesis, storage and transport3. As 
a signaling molecule, heme handles a set of proteins that collectively control pathways spanning 
iron homeostasis, oxygen sensing, the oxidative stress response, mitochondrial respiration and 
biogenesis, mitophagy, apoptosis, circadian rhythms, cell cycle progression, proliferation, and 
protein translation and degradation2, 4. There are three major types of heme in eukaryotes: heme a, 
heme b,  and heme c, which differ in the nature of the substituents on the porphryin ring5. Heme b 
it is the most ubiquitous form and constitutes the cofactor of most hemoprotein such as myoglobin 
and hemoglobin5. Heme a is only found in cytochrome c oxidase of the electron transport chain5. 
Heme c is different from heme b in that it is covalently bound to proteins via a thioether linkage 
and is found in respiratory proteins such as cytochrome c and the bc1 complex5. Since heme b is 
the most abundant form of heme, and the pre-cursor for hemes c and a, we will be discussing heme 










Figure 1.1- Heme b chemical structure, which is the most common form of heme.  
 2 
The very same properties of heme that make it essential for life also render it potentially 
toxic if mishandled by cells. For instance, the misincorporation of heme into various biomolecules, 
including certain proteins and lipid membranes, alters macromolecular structure and function6, 7. 
Moreover, heme is capable of catalyzing the formation of reactive oxygen species (ROS), thereby 
damaging DNA, lipid membranes and the cytoskeleton8, 9. Therefore, heme concentration and 
bioavailability must be tightly regulated. Heme concentration is regulated by its biosynthesis and 
degradation, two well-understood processes. However, the molecules and mechanisms governing 
heme bioavailability, including its transport and trafficking, to hemoproteins residing in every 
subcellular compartment are not well understood. In this chapter, we will discuss the role of heme 
in cell biology, heme biosynthesis and degradation, heme toxicity and detoxification, heme related 
pathologies such as, porphyria and Alzheimer’s disease, and what is currently known about heme 
transport and trafficking.  
 Heme in Cell Biology 
The canonical role of heme in cell biology is as a protein cofactor10. For example, in 
hemoglobin and myoglobin heme is used for oxygen transport and storage respectively1, 2, 4. Other 
biological functions for heme include its ability to facilitate electron transfer and catalysis. In 
addition, heme can act as a dynamic signaling molecule in the regulation of transcription factors, 
ion channels, kinases, and cell surface receptors1, 2, 4. Heme in biology is composed of two major 
pools, an exchange inert heme pool and an exchange labile heme pool2, 4. Exchange inert heme is 
tightly bound to high affinity hemoproteins like goblins and cytochromes and cannot exchange 
between various proteins.  Labile heme is readily exchangeable between proteins and represents 
the mobile pool of heme accessible for trafficking and signaling. Studies with activity and 
fluorescence-based heme reporters in Saccharomyces cerevisiae and various non-erythroid human 
 3 
cell lines estimated the labile heme pool in the cytosol to be ~25-300 nM3, 11, 12, which corresponds 
to 10% of the total cellular heme concentration.  
In order to reduce heme toxicity, heme concentration and heme availability need to be tightly 
regulated in the cells. Heme concentration is regulated by its synthesis and degradation. Eukaryotic 
heme biosynthesis is a very well understood highly conserved pathway, called the Shemin 
pathway, and involves eight enzymatic steps that take place in between the cytosol and 
mitochondria13. (Figure 1.2) This pathway starts with the condensation of glycine and succinyl-
CoA to form 5-aminolevulinic acid (5-ALA), which is catalyzed by ALA synthase (ALAS) in the 
mitochondrial matrix. ALAS is the rate limiting step of heme biosynthesis. 5-aminolevulinic acid 
is then transported from the mitochondrial matrix into the cytosol, where it is condensed by ALA 
dehydratase (ALAD) to form porphobilinogen (PBG). Four PBG molecules are condensed into 
hydroxymethylbilane via the cytosolic enzyme PBG deaminase (PBGD).  Next, 
hydroxymethylbilane is then cyclized by uroporphyrinogen synthase (UROS) to make 
uroporphyrinogen III. For the final cytosolic biosynthesis step, uroporphyrinogen III is 
decarboxylated to form coproporphyrinogen III via uroporphyrinogen decarboxylase (UROD). 
Coproporphyrinogen III is then trafficked to the mitochondrial intermembrane space (IMS) for 
oxidation to protoporphyrinogen IX helped by coproporphyrinogen oxidase (CPOX). 
Protoporphyrinogen IX is mobilized to the matrix and consequently oxidized to protoporphyrin IX 
by protoporphyrinogen oxidase (PPOX). In the the last step of heme synthesis, iron is inserted into 
protoporphyrin IX in a reaction catalyzed by ferrochelatase (FECH).  
Heme degradation is facilitated by heme oxygenase (HO), which catalyzes the O2-dependent 
catabolism of heme into biliverdin, carbon monoxide (CO) and free iron1, 4, 14. HO dependent heme 
degradation starts with the formation of a ferric heme-HO complex in which the iron center gets 
 4 
reduced to its ferrous state by the first electron donated from NADPH-cytochrome P450 
reductase14. Molecular oxygen then binds to the complex to from a stable oxy-form, in which the 
iron bound oxygen is converted into a hydroperoxide intermediate by getting another electron from 
the reductase and a proton from water14. To finish, the terminal oxygen of the hydroperoxide 
intermediate attacks the a-carbon of the porphyrin ring to form biliverdin or ferric a-meso-
hydroxyheme14. Biliverdin is further catabolized to bilirubin by biliverdin reductase, an NADPH 
dependent oxidoreductase, 9.  
As an iron tetrapyrrole complex, heme presents characteristics of both a metal and a lipid4. 
Therefore, heme might be mobilized as a metal or a lipid or alternatively it could be mobilized in 
a specific way that combines both. As a metal, heme transport and mobilization could be governed 
by its coordination chemistry and oxidation state, which may suggest the existence of heme 
chaperones, buffers and transporters4. As a lipid, heme could be mobilized as a phospholipid-like 
molecule in which trafficking might be dictated by the hydrophobic, ionic and hydrogen bonding 
interactions of heme and putative carrier proteins4. This suggests heme is mobilized like other 
mitochondrial derived lipids through membrane tethering complexes, lipid transfer proteins, 
vesicular trafficking or organelle contact points4.  Currently, there is very little known about the 
mechanisms and factors that regulate heme homeostasis. Knowledge of these pathway would aid 

















 Heme pathology  
In cases of severe hemolysis and myolysis, which are common in diseases such as sickle 
cell, malaria and ischemia reperfusion, high amounts of toxic free heme is released, causing organ 
Figure 1.2 - Heme synthesis in eukaryotes. Heme is synthesized in eukaryotes via the 
Shemin pathway consisting of eight highly conserved enzymes, four in the mitochondria 
and four in the cytoplasm. Figure adapted with permission from: Donegan, R. K., et al. 
(2019). "Handling heme: The mechanisms underlying the movement of heme within 
and between cells." Free Radic Biol Med 133: 88-100. Copyright Ó 2019 Elsevier Inc.  
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and tissue damage. During these cases, the large amount of heme that accumulates overwhelms 
the HO-mediated system for heme detoxification. This leads to a variety of heme toxicity 
mechanisms, a major mode being from its ability to catalyze peroxidation reactions and hydroxyl 
radical production via Fenton chemistry. Deleterious heme-dependent redox reactions in part 
contribute to vascular disorders like hemolytic anemia, vasculitis, reperfusion injury and 
arteriosclerosis. The generation of ROS by heme has also being implicated in lipid oxidation, DNA 
damage, apoptosis and protein degradation that causes aggregates9. Another pathway for heme 
toxicity is through its ability to aggregate in lipid membranes, disrupting membrane structure and 
permeability, which can lead to cell lysis and death. This is common in hemolysis in which the red 
cell membranes gets oxidized and disrupted to the point that stimulates potassium loss and 
swelling9. Heme also has the ability to alter the conformation of the cytoskeleton, which can 
damage red blood cells9. Heme, acting as a pro-inflammatory signaling molecule, can also 
reorganize the neutrophil cytoskeleton by increasing the polymerization of actin 9.  
Another mode of heme toxicity is its missincorporation into certain proteins, such as in 
Alzheimer’s disease.  Amyloid-b (Ab), the pathogenic protein that causes AD, can bind heme 
contributing toward the cytotoxicity of the disease through the peroxidase activity of the heme 
complex6. Moreover, heme sequestration by Ab leads to cells feeling heme starved, causing them 
to turn on heme synthesis. Another aspect of AD is that there is increased heme and hemoglobin 
in the brain due to a weakened blood brain barrier, which further makes Ab more toxic due to 
deleterious heme interactions. 7, 15-17. Indeed, tissue analysis of patients demonstrated an increase 
of heme in the temporal lobe7 and high amount of hemoglobin mRNA in other specific parts of 
the brain18. Moreover, heme accumulates and colocalizes with Ab deposits in the brain tissues of 
Alzheimer’s disease patients18. Additionally, heme and hemoglobin have been observed to bind 
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Ab and alter its aggregation state7, 15, 16. Recent data demonstrated heme and hemoglobin 
significantly decrease the Ab-mediated expression of pro-inflammatory cytokines in astrocytes19. 
Altogether, these results indicate a new heme-related perspective in the cytotoxicity of 
Alzheimer’s disease that has not been fully appreciated.  
To protect the cells from heme toxicity, a number of detoxification mechanisms have 
evolved, including the heme oxygenase system for degrading heme and heme scavenging systems 
such as hemopexin, albumin and reduced glutathione (GSH)9.  HO protects cells by not only 
degrading excess heme, but also the products of heme degradation, such as biliverdin and bilirubin, 
are themselves cytoprotective by acting as antioxidants and anti-inflammatory agents. Carbon 
monoxide, another heme degradation product, can stimulate the expression of the iron storage 
protein, ferritin, to prevent the toxicity associated with iron release from heme degradation. 
Bilirubin is capable of scavenging peroxyl radicals, CO inhibits pro-inflammatory cytokines and 
ferritin scavenge free iron.  
In terms of heme scavenging, hemopexin is a high affinity heme binding protein that reduces 
the toxicity of heme by forming a complex with it9. The role of this protein is binding free heme 
in the blood and transporting it to the liver for degradation20. Albumin, like hemopexin, also 
scavenges heme, but acts more like a heme buffer in the serum. Rather than being directed for 
degradation in the liver, albumin buffers heme until more hemopexin is available for heme 
detoxification.  Reduced glutathione (GSH) is capable of protecting against heme-induced 
oxidative stress by not only scavenging ROS generated by heme but also by being able to non-
enzymatically degrade heme in the presence of oxygen and at neutral pH21.  
Proper regulation of heme synthesis is also important to maintain heme homeostasis. 
Abnormal function of any of the eight enzymes responsible for heme biosynthesis results in the 
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accumulation of toxic heme biosynthetic intermediates, leading to a family of disorders called 
porphyrias. Porphyrias are a group of eight metabolic disorders in the heme biosynthesis pathway 
that cause symptoms such as skin lesions due to the build up of photo-sensitive porphyrin and 
porphyrin precursors, as well as zinc-protoporphyrin in one case. Moreover, the lack of heme leads 
to decreases in liver and gastrointestinal function. All of the porphyrias are associated with partial 
enzyme deficiencies, accounting for why patients survive to adulthood.  
 Other situations in which heme is important in physiology is in infectious diseases. 
Pathogenic bacteria and fungi require iron for survival and evolved a number of pathways for iron 
uptake. Since heme represents the major form of iron in humans, they contain sophisticated 
machineries for heme uptake that contribute to virulence 22. The majority of these pathogens uptake 
heme and degrades it in order to use the iron22. Better understanding of heme acquisition and 
utilization in infectious disease will allow us to design heme-based therapeutics. 
 Heme Mobilization and Trafficking 
 Once heme is made on the matrix side of the inner-membrane of the mitochondria, it must 
be delivered to hemoproteins throughout the cell, including cytochromes in the mitochondrial 
respiratory complexes, globins in the cytosol, catalases in peroxisomes, P450 enzymes in the ER, 
NADPH oxidases at the plasma membrane, and heme-regulated transcription factors in the 
nucleus, e.g. p53, Bach1, and Reverb. The hierarchy for heme distribution, i.e. which organelles 
acquire heme the fastest and/or prioritize holding on to heme the longest in the face of heme 
depletion, is not known. Also, very little is known about the transport and trafficking of heme and 










In the context of our model that conceptualizes total cellular heme as being the sum of 
exchange inert and labile heme, one can envision two primary pathways for heme trafficking and 
mobilization. One pathway is that there may be post-translational modifications that cause a 
hemoprotein that does not otherwise dissociate heme to release heme. For instance, S-nitrosation 
of heme ligating thiolates were previously found to cause heme dissociation of certain thiolate-
coordinating heme enzymes1, 4. The second pathway for heme transfer consists of the exchange of 
labile heme between buffering factors, heme chaperones, transporters and apo-hemoproteins 
through differences in their expression level and/or affinity for heme. (Figure 1.3) 
As an iron-protoporphyrin IX complex, heme displays characteristics of a transition metal 
and a lipid4. Therefore, it could be mobilized as a metal, as a lipid or in a hybrid way. As a metal 
Figure 1.3 – Model of eukaryotic heme transport and trafficking. After heme synthesis is 
done in the mitochondrial matrix, heme must be transported out of it and incorporated into a 
multitude of hemoproteins found in different compartments. Proteins previously implicated 
in heme transport, trafficking, or buffering are identified, and trafficking pathways that are 
currently unknown are marked with question marks. Figure adapted with permission from: 
Hanna, D. A., et al. (2017). Biochemistry 56(13): 1815-1823. Copyright Ó 2017 American 
Chemical Society.  
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heme transport and mobilization would be dependent on the presence of heme chaperones, buffers 
and transporters4. Since the dissociation of heme is the rate-limiting step of ferrochelatse (FECH), 
we can suggest the idea of heme binding proteins or chaperones that catalase the transfer of heme 
from FECH (45). Protein such as the progesterone membrane receptor component 1 (PGRMC1), 
a heme chaperone, was found to interact with FECH as part of a heme biosynthetic complex or 
heme metabolon, possibly accepting heme prior its mobilization23, 24. As a lipid, heme would be 
mobilized like phospholipids, with trafficking being dictated by the hydrophobic, ionic and 
hydrogen bonding interactions between the porphyrin and client proteins4. In that case and given 
the hydrophobic nature heme, it would be mobilized like other mitochondrial derived lipids, 
through membrane tethering complexes like the ER-mitochondria encounter structure (ERMES) 
or mitochondrial associates membranes (MAMs), lipid transfer proteins, vesicular trafficking or 
organelle contact points4.  Heme could be mobilized to other organelles via the ER and trans Golgi 
network and secretory pathways1. Alternatively, heme could be mobilized in ER or Golgi-derived 
vesicles that fuse into different organelles to deliver heme to the hemoproteins throughout the cell1. 
1.3.1 Heme Transporters 
Over the years, a few heme transporters have been identified, including Feline Leukemia 
Subgroup C Cellular Receptors (FLVCR)25, heme responsive genes HRG1 and HRG4 26, and 
multidrug resistance protein 5 (MRP-5)27. The FLVCRs are proteins that are members of the major 
facilitator superfamily (MFS) involved in heme import and heme export, in which two splice 
variants have been identified: FLVCR1a and FLVCR1b28. FLVCR1a, the plasma membrane 
exporter, is a ~60 kDa protein predicted to have the common MFS protein twelve hydrophobic 
transmembrane domains29. In the case of the mitochondrial heme exporter, FLVCR1b, is a ~28 
kDa with a six predicted transmembrane domain30. The expression of these heme exporters in 
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mammals is present in high levels in the brain, liver, kidney, intestine and bone marrow25. 
Although the expression of the transporter FLVCRb have been demonstrated to be crucial for 
erythroid cell differentiation, presumably because it enables the export of mitochondrial heme and 
its delivery to globins, direct evidence that it transports heme and its precise localization is still not 
known25.  
The heme transporter, MRP5, was first identified on Caenorhabditis elegans as a necessary 
heme exporter in the intestines27. MRP5 seems to be crucial for the transport of heme from the 
cytosol into the secretory pathway in which can subsequently be mobilized to hemoproteins within 
the pathway, to the cellular membrane or to the extracellular space27.  Two other heme transporters 
identified in C. elegans are the HRG-1 and HRG-4, important for transport and utilization of 
exogenous heme26. These two heme transporters are ~19 kDa with four predicted transmembrane 
domains. HRG-1 is localized in the membranes of endosomal/ lysosomal compartments 
transporting exogenous heme into the cytosol and necessary for the recycling of heme by 
macrophages31. HRG-4 mobilized heme across the plasma membrane into the cytosol primarily 
involved in the heme uptake of the intestines26. 
1.3.2 Heme Buffering Factors 
The cytosol is the organelle with the highest concentration of labile heme in the cell consisting 
of 20-340 nM, which is more than the < 1 nM found in the nucleus or the mitochondria (21-23). 
Due to the relatively high concentration of cytosolic LH, heme likely must be buffered and 
trafficked with chaperones and heme binding proteins in order to mitigate the cytotoxicity of this 
biomolecule. Based on interactions with hemin-agarose or blue sepharose, a number of heme-
binding proteins have been identified and proposed to have a role in heme homeostasis, including 
heme binding proteins HBP2232 and HBP2333, glutathione S-transferase (GSH-S transferase)34, 
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HBP-1 (also known as SOUL)35 and fatty acid binding protein (FABS)36.  32. Even though these 
heme-binding proteins may prevent toxicity by binding and buffering excess of heme in the 
cytosol, the lack of in vivo and biochemical characterization raises even more questions on not 
only how these proteins play a role in heme homeostasis but also how heme is mobilized and 
transported by them throughout the cell.  
The heme binding protein HBP23, which is also the peroxiredoxin PRX1, is a recently 
characterized heme buffering factor. PRX1 is a thiol peroxidase that binds heme with an affinity 
of 170 nM and binds heme in a 1:1 stoichiometry37. This protein binds heme through the 
coordination of a cysteine, specifically Cys52, that upon heme binding loses the thiol peroxidase 
activity37. Since PRX1 is so abundant in the cytosol and is able to bind heme, this protein could be 
serving two roles, as a peroxide scavenging thiol peroxidase and as a heme buffering factor or 
storage protein1. However, in vivo experiment with PRX1 are necessary in order to demonstrate 
its role in heme homeostasis37. Overall, not much is known about the proteins that buffer heme 
and regulate heme homeostasis. The proteins that have been suggested based on their ability to 
bind heme in vitro, have not been found to regulate heme homeostasis in vivo. 
1.3.3 Exogenous Heme uptake 
Even though some organisms are capable of heme assimilation and heme acquisition, the 
cellular components required for these processes are not well understood. In order to understand 
the mechanism of heme uptake in eukaryotes, several organisms like Schizosaccharomyces pombe 
and Candida albicans have been utilized. For S. Pombe two iron acquisition pathways have been 
previously described38: one being a high affinity iron uptake complex composed of a ferrireductase 
and a ferroxidase-permease39 and the second consisting of the generation and uptake of 
siderophores40. Through the use of genome-wide studies and transcript levels under conditions of 
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iron depletion or repletion, specific genes responsible for heme uptake on S. pombe have been 
identified. Two iron regulated plasma membrane proteins known as Shu1 and Str3 were identified 
to transport heme into the yeast cell under iron starvation conditions41, 42. Shu1 is a 25 kDa GPI 
anchored transporter in which utilization of exogenous heme is dependent on the vacuolar 
transporter Abc3 and has a heme affinity of 2.2 μM41, 43. Str3 is a 12 transmembrane domain 
containing protein from the major facilitator superfamily (MFS) of transporters that was 
discovered to uptake heme in a Shu1 deficient cell42. These two proteins work by tuning their 
expression in an iron depending manner in which Str3 has a lower affinity to heme than Shu1 but 
is only expressed under high iron concentrations while the high affinity transporter Shu1 is 
expressed under low iron concentration. This data is very interesting since it demonstrate how 
tightly regulated heme uptake and heme concentration are since the cell tunes the expression of 
different affinity transporters depending on exogenous heme concentrations.  
In the case of the fungal pathogen C. albicans it can utilize heme and hemoglobin as the sole 
iron source through their recognition and binding to cell surface receptors and consequently 
transferred across the cell wall for endocytosis at the inner membrane. Rbt5, Rbt51 and Pga7 are 
C. albicans heme and hemoglobin (Hb) binding proteins that are GPI anchored within the cell wall 
and required in heme uptake by either binding heme or Hb44-46. The pathway of heme-iron 
utilization is through the recognition of heme or Hb by Rbt5 localized in the extracellular part of 
the cell membrane and then it gets transferred to the Pga7, due to the higher heme affinity, that 
will eventually get endocytosed, degraded by the heme oxygenase and made iron available by the 
vacuole iron permease44. Since proteins involved in the endosomal sorting complex required for 
transport (ESCRT) are necessary for the heme uptake in C. albicans, it is believed the transfer 
across the plasma membrane is through endocytosis46.   
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 Genetically Encoded Fluorescent Heme Sensors (HS1)  
One of the reasons for the poor understanding of heme trafficking and the factors that 
regulate subcellular heme pools is that, until recently, there were no tools available to probe labile 
heme. In order to probe heme homeostasis, the Reddi lab developed a genetically encoded 
ratiometric fluorescent heme sensor and expressed it in the model unicellular eukaryote, 
Saccharomyces cerevisiae. The heme sensor, referred to as HS1, is a tri-domain chimeric protein 
consisting of a heme binding domain, cytochrome b562 (Cyt b562), fused to a pair of fluorescent 
proteins, eGFP and mKATE2 (Figure 1.4). The fluorescence of eGFP is quenched by heme 
through a fluorescence resonance energy transfer (FRET) mechanism (Figure 1.5a). On the other 
hand, mKATE2 is not a good FRET acceptor of heme, making mKATE2 fluorescence relatively 
unaffected by heme binding (Figure 1.5b). Thus, HS1 is designed to act as an excitation-emission 
ratiomentric probe in which the ratio of heme sensitive eGFP fluorescence to heme insensitive 
mKATE2 fluorescence provides a readout of cellular heme independently of sensor concentration3 






        HS1 binds heme using His102 and Met7 of the Cyt b562 binding domain to coordinate the heme 
iron atom. Previous experiments in the lab found that HS1 has very high affinities for ferrous and 
ferric heme, sub-nanomolar heme dissociation constants, and is 100% saturated with heme in 
Figure 1.4 - Model of HS1 is derived from the X-ray structures of mKATE (PDB: 3BXB) 
and CG6 (PDB: 3U8P). Figure adapted with permission from: Hanna et al. (2016) Proc 
Natl Acad Sci USA 113(27):7539-7544.  
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cells3. The most optimal poise for a sensor is to be ~50% bound so as to best monitor both increases 
and decreases in analyte. In order to address this, the Reddi lab has also engineered a large library 
of primary binding site mutants of HS1 that have varying heme affinities. One such variant, HS1-
M7A, which has Met7 mutated to Ala, is ~20-50% bound3. As seen in Figure 1.5, HS1-M7A is 
selective for ferrous heme over ferric heme, exhibiting ferric and ferrous heme dissociation 
constants of 2 uM and 25 nM, respectively3. Thus, HS1-M7A is poised to monitor labile ferrous 
heme in cells3. In order to measure heme distribution in other compartments, the HS1 and HS1-
M7A sensors were targeted to the mitochondria and the nucleus by attaching localization 
sequences such as N-terminal COX4 mitochondrial matrix for the mitochondria and a C-terminal 















Figure 1.5 - Validation of the sensor. A. eGFP signal for an in vitro heme titration of the 
sensor showing that is getting quenched with the addition of heme. B. The mKATE2 signal 
for the in vitro heme titration of the sensor showing that is independent of heme binding. 
C. Sensor titration with ferrous and ferric heme showing the sensor binds better to ferrous 
heme. D. Change in eGFP: mKATE2 fluorescence ratios for HS1 and HS1-M7A. Figure 




 Conclusions and Scope of Thesis 
In the past, heme was viewed as a static cofactor that was tightly bound and buried in heme 
enzymes. But thanks to the development of new tools to measure and image heme and their ability 
to be integrated with biochemical, cell biological and genetic approaches revealed heme to be a 
very dynamic signaling molecule that can be mobilized to elicit adaptations to various stimuli. Our 
discovery of the existence of a labile heme pool invalidated the idea that heme is made on demand 
and any excess is degraded. However, the existence of this labile heme pool raised even more 
questions regarding how cells manage heme. What are the factors that transport, traffic, and 
mobilize labile heme for heme dependent functions throughout the cell? Overall, this thesis is 
focused on integrating genetically encoded heme sensors with yeast molecular genetics in order to 
elucidate novel heme trafficking pathways. In particular, our focus was to identify factors that 
regulate: a. steady-state cytosolic heme availability, b. the inter-compartmental distribution 
dynamics as heme is being synthesized in the mitochondria, c. and heme uptake and utilization 
from exogenous heme sources. Altogether, our work has revealed a host of proteins and pathways 








CHAPTER 2. GENOME-WIDE DETERMINANTS OF HEME 
HOMESTASIS 
 Introduction 
Heme is an essential protein cofactor and the most abundant form of iron in mammals due 
to the fundamental need in hemoglobin for oxygen binding and transport. From the 3 to 4 grams 
of total iron typically found in the human body, 95% is in the heme iron form47. Although essential 
for life, heme may also act as a toxin, necessitating that cells carefully handle this compound2, 4. 
The hydrophobicity and redox activity of heme causes it to disrupt membrane structure, become 
misincorporated into certain proteins, and deleteriously oxidize various biomolecules2, 4. Due to 
these qualities, heme concentration and mobilization from its site of synthesis in the mitochondria 
to hemoproteins present in virtually every subcellular compartment need to be carefully regulated. 
However, the mechanisms governing the mobilization of heme out of the mitochondria, and the 
spatio-temporal dynamics of these processes, are poorly understood. Additionally, only a handful 
of factors have been found to regulate inter- and intra-cellular heme concentrations.  
 The two main processes that are thought to prevent heme toxicity and regulate heme 
concentration in the cell are heme biosynthesis and degradation48. These two mechanisms are very 
well studied and understood; it is known heme biosynthesis occurs between the cytosol and the 
mitochondria in which eight heme biosynthetic proteins facilitate this process and have been very 
well characterized13. Heme is enzymatically degraded by heme oxygenase (HO), which converts 
heme into biliverdin, carbon monoxide (CO) and free iron1, 4, 14. The free iron released by heme 
catabolism is detoxified by the iron storage protein ferritin.9  Reduced glutathione (GSH) is capable 
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of non-enzymatically degrading heme. Heme can also be detoxified through scavenging systems 
such as hemopexin and albumin9. 
Based on their interactions with hemin-agarose or blue sepharose, a number of heme-binding 
proteins have been identified and proposed to have a role for heme homeostasis, such as heme 
binding proteins HBP2232 and HBP2333, glutathione S-transferase (GSH-S transferase)34, HBP-1 
(also known as SOUL)35 and fatty acid binding protein (FABS)36. Even though these proteins have 
been suggested to play a role in heme homeostasis based on their ability to bind heme in vitro, 
there is currently no in vivo evidence for their roles in regulating heme trafficking and availability. 
Herein, we utilized genetically encoded heme sensors to identify new heme homeostatic factors 
from genome wide screens in Saccharomyces cerevisiae (Baker’s yeast). 
There are several qualities that make Saccharomyces cerevisiae (Baker’s yeast) the perfect 
model organism for investigating heme trafficking. Being a single-cell eukaryote, it is inexpensive 
and fast to culture and shares many of the same metabolic pathways as higher eukaryotes. 
Importantly, given that transition metal trafficking and heme synthesis and degradation are highly 
conserved, it is very likely that factors governing heme trafficking and availability in yeast will 
also be conserved in higher organisms. Since Baker’s yeast is a very well-studied and genetically 
tractable model organism, it is amenable for genome-wide screening. S. cerevisiae has ~6,000 
genes and approximately 5,000 deletion mutants are viable and commercially available in a 
haploid yeast gene deletion collection. 
Herein, we described a genome-wide screen for heme availability using genetically encoded 
fluorescent heme sensor in combination with the commercially available yeast knockout library in 
order to identify new regulators of heme synthesis and degradation, as well as factors that regulate 
heme trafficking and distribution. Of the 5154 deletion mutants in the yeast haploid knockout 
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collection we were able to transform and stably express the heme sensor in 4470 deletion mutants. 
The screen identified 114 strains with a Z-score of +1.5 or higher, indicating that these strains had 
high cytosolic heme availability and 323 strains with a Z-score of -1.5 or lower, indicating low 
cytosolic heme availability. Functional groups like ESCRT proteins and vesicular trafficking 
proteins were identified to have an important role in heme homeostasis and distribution.  
 Results 
2.2.1 Development of High Through-put Screen for Cytosolic Heme Availability 
The commercially available yeast deletion collection was transformed in masse with 
genetically encoded fluorescent heme sensors using a liquid handling robotics system. Deletion 
mutants with altered heme availability as measured by the sensors will reveal factors regulating 
heme trafficking and distribution, as well as novel regulators of heme synthesis and degradation. 
When using sensors to measure analytes like heme, it is very important to take into consideration 
the binding affinities of the probe and the concentration of the analyte. For accurate measurements 
of increases and decreases of a specific analyte, the dissociation constant Kd of the probe must be 
similar to the concentration of the analyte to ensure the probe is 50% bound2. To address this 
concern, we utilized a moderate affinity heme sensor, HS1-M7A, that is 30-50% bound with heme 
in the cytosol, ensuring that we can optimally monitor both increases and decreases heme.  
5,154 of the ~6,000 genes in the S. cerevisiae genome can be individually deleted are 
available in the yeast knockout collection. Through the use of a high through-put transformation 
protocol employing lithium acetate49, 50, we were able to stably express the cytosolic heme sensor 
in 4,470 deletion mutants. In order to identify genes presenting a disruption in cytosolic labile 
heme availability, we screened these 4,470 deletion mutants for alterations in the fluorescence of 
HS1-M7A in the cytosol. The heme sensor is designed as an excitation-emission ratiometric probe 
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in which the ratio of heme-sensitive eGFP fluorescence to heme-insensitive mKATE2 
fluorescence provides a readout of cytosolic heme independent of sensor concentration3. The 
sensor ratios from the deletion mutants were z-scored, (Figure 2.1a), with a positive z-score 
indicating an increase in heme availability and a negative z-score indicating a decrease in heme 
availability.  
Figure 2.1a highlights the distribution in z-scores from the deletion screen. For reference, 
WT yeast exhibit a z-score close to 0, indicating that it has an amount of heme that is on par with 
the average amount of heme in a typical mutant. Heme deficient hem1∆ cells, which lack the first 
enzyme in the heme biosynthetic pathway, exhibit a z-score < - 1.5. From this screen, we were 
able to identify 114 strains with a z-score of +1.5 or higher and 323 strains with a z-score of -1.5 
or lower. The mutants identified to have altered heme availability could be regulators of heme 
trafficking, synthesis, or degradation, directly traffic heme, e.g. heme chaperones or buffering 
factors, or transport heme into or out of the cytosol. We are now just beginning to uncover the 







Figure 2.1 – Genome-wide high through-put screen data for endogenous heme availability. 
a. Z-scores were calculated from the fluorescence ratios eGFP/mKATE2 expressed on the 
mutants on which positive Z-score indicate high cytosolic labile heme and negative Z-scores 
indicate low cytosolic labile heme. b. To calculate the Z-score sensor ratios on the pates were 
average and the sensor ratio of the mutant was subtracted and divided by the standard 
deviation of the plate.  Data was calculated from duplicated samples.  
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2.2.2 Deletion Mutants with High Cytosolic Heme 
114 deletion strains displayed a z-score of +1.5 or higher. One deletion mutant that we 
identified was tdh3∆, which lacks the major isoform of glyceraldehyde phosphate dehydrogenase 
(GAPDH). We will discuss this mutant in greater detail in Chapter 3, where we describe a new 
role for GAPDH in heme trafficking and buffering. Beyond tdh3∆, we sought to determine if there 
were any common patterns in the localization or function of the genes identified that negatively 
regulate heme homeostasis. (Figure 2.2) In order to identify if there was any organelle 
prioritization by these genes, the list of 114 genes were analyzed using PANTHER 
(http://www.pantherdb.org/), which is a publicly available web-based resources that conducts gene 
ontology analysis. Locales that are enriched in the dataset of mutants with increased heme include 






 We next assessed the biological function of these genes in order to determine if there were 
common pathways that might regulate heme availability. Using PANTHER, we identified that the 
















Figure 2.2 – Cellular component enrichment for high cytosolic labile heme deletion 
mutants. Genes were submitted to the data base PANTHER (protein analysis through 
evolutionary relationship) in order to predict compartmental protein association networks. 
The enrichment is base of the number of genes coming out from a certain compartment in 
comparison to the number of possible ones.  
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genes), protein complex disassembly (12 genes) and amide metabolic process (23 genes). (Figure 
2.3) ~18 uncharacterized genes were also identified to be important for maintaining heme 
homeostasis, raising the opportunity to discover novel roles for these proteins. 
The main pathway represented in mutants with increased heme is protein translation. We 
also identified cell division (11 genes) and proteins involved in cytoskeleton structure (4 genes). 
The screen identified 5 transporters (VBA5, TPO1, SMF2, VNX1 and ACB1) that have not 
previously been reported to mobilize heme. Further work on these transporters may reveal new 
functions in heme transport. In terms of heme chaperones or buffering factors, we were able to 
identify glyceraldehyde 3-phosphate dehydrogenase as a heme buffering factors in which further 
characterization is described in Chapter 3. Identification of more heme chaperones or buffering 
factors could be facilitated by classifying this group of genes by their abundance, solubility, 
molecular weight and localization and further characterize targeted genes.  
In summary, we were able to utilize the heme sensors to identify 114 deletion mutants with 
higher cytosolic heme availability. In Chapter 3, we discuss a novel role for GAPDH, a glycolytic 
Figure 2.3 – Biological process enrichment for high cytosolic labile heme deletion 
mutants. Genes were submitted to the data base PANTHER (protein analysis through 
evolutionary relationship) in order to predict functional protein association networks. The 
enrichment is base of the number of genes coming out from a certain process or function 
in comparison to the number of possible ones. 
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protein, in heme trafficking and buffering. However, this is just the tip of the ice berg. Our lab is 
now working to determine how the transporters, translation factors, and cell division works to alter 
labile heme.   
2.2.3 Deletion Mutants with Low Cytosolic Heme 
We identified 323 deletion mutants with low cytosolic heme (z-score < -1.5). In order to 
determine if these genes were predominantly present in a specific organelle, analysis of these genes 
using PANTHER revealed that most of the mutants identified are associated with the endosomal 
sorting complex required for transport (ESCRT), endosomal membranes, and intracellular vesicles 




Figure 2.4 - Cellular component enrichment for low cytosolic labile heme deletion 
mutants. Genes were submitted to the data base PANTHER (protein analysis 
through evolutionary relationship) in order to predict compartmental protein 
association networks. The enrichment is base of the number of genes coming out 
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In terms of biological function, we find that there is considerable enrichment of factors that 
regulate vesicle formation and proteins involved with the ESCRT complex and endosomal 
transport. In addition, 20 genes were identified as having roles in ion transport, nucleotide 
mobilization, carbohydrate derivative transport, ATP transport and vacuole transport. (Figure 2.5) 
Further, a large number of metabolic enzymes, including hydrolases, isomerases, ligases, 
oxidoreductases, proteases, and transferases also deplete cytosolic heme when deleted, most 
excitingly, 50 uncharacterized genes were identified as having low heme availability, raising the 




A large numer of mutants expected to have defects in heme synthesis were also identified in 
our screen, thereby validating our approach to use genetically encoded heme sensors to fish out 
new heme homeostatic factors. It is known heme synthesis requires iron, succinyl-CoA, and 
glycine. Deletion mutants that affect availability of succinyl CoA, including mitochondrial 
Figure 2.5 – Biological process enrichment for low cytosolic labile heme deletion 
mutants. Genes were submitted to the data base PANTHER (protein analysis through 
evolutionary relationship) in order to predict functional protein association networks. The 
enrichment is base of the number of genes coming out from a certain process or function 
in comparison to the number of possible ones. 
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pyruvate transporters and pyruvate dehydrogenase, glycine, including a mitochondrial glycine 
transporter, and iron, including mitochondrial iron transporters and homeostatic factors all come 
out in our screen. In addition, factors required for the maturation of certain heme biosynthetic 
enzymes, such as mitochondrial FAD transporters, which is required for the heme biosynthetic 
enzyme porphyrinogen oxidase, and the chaperone that inserts pyridoxyl-5-phosphate into ALAS, 
the first enzyme in heme synthesis, also have low heme availability as expected.  
We also identified copper trafficking factors, ATX1, which delivers copper to the Golgi, and 
CCS1, which delivers copper to the antioxidant enzyme SOD1, as having low heme. Genes 
encoding proteins that regulate the proteasome, a protein complex that degrades proteins, were 
also identified in the screen. However, the major pathway responsible for maintaining heme 
availability in the cytosol involves the endosomal sorting complex that facilitates the formation of 




2.2.3.1 Validation of Genes with Low Heme Availability 
We were able to identify 323 deletion mutants displaying low levels of labile heme in the 
cytosol from our initial screen. In order to validate these mutants as having low heme, we re-
Figure 2.6 – Percent of heme bound to the sensor on low cytosolic labile heme deletion 
mutants related to ESCRT proteins and vacuolar function. The percent bound calculation was 
derived from the fluorescence ratiometric readouts of the mutant minus the Rmin (hem1D 
ratios) divided by Rmax (WT ratios) minus Rmin. All data represent the mean ± SD of 












































































streaked these cells to single colonies and analyzed sensor ratios from three independent clones. 
We selected 75 deletion mutants representing genes from unique non-redundant pathways in the 
initial list of 323 and verified that independent clones in these pathways did indeed have decreased 
heme. 87% of the deletion mutants were validated by assessing the ratio of sensor ratios between 
mutant and WT cells (Table 2.1). These genes will be further characterized in the future for their 
roles in heme homeostasis.  
Table 2.1 - Validation screen for heme availability prioritized by Ratio of Ratios values. 
Strain Sensor Ratio 
(HS1-M7A) 
STDEV Ratio of Ratios (Mutant/WT) 
met12∆ 7.5 0.2 N/A 
snf7∆ 11.2 1.1 N/A 
tmn3∆ 16.6 6.7 3.7 
vph1∆ 11.0 1.5 2.9 
pep12∆ 10.8 1.2 2.8 
YKL096C 13.3 3.0 2.5 
erg4∆ 13.0 0.6 2.4 
dfg16∆ 12.7 1.0 2.4 
aim11∆ 12.4 2.9 2.3 
suc2∆ 11.9 0.8 2.3 
hom6∆ 11.7 0.6 2.2 
YOR342C 7.4 1.5 2.1 
YIL015C-A 6.5 0.2 2.1 
sps4∆ 7.1 0.9 2.0 
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Table 2.1 (continued)    
YER137C 7.0 0.3 2.0 
YLR358C 10.3 0.5 2.0 
etr1∆ 9.6 0.4 1.9 
lge1∆ 10.2 2.1 1.9 
vps36∆ 10.2 0.6 1.9 
YIL055C 10.1 0.5 1.9 
sul1∆ 9.9 0.6 1.9 
irc21∆ 9.9 1.3 1.9 
tbs1∆ 5.7 0.5 1.9 
pex8∆ 6.7 1.2 1.9 
opt2∆ 9.6 2.4 1.8 
aim18∆ 6.3 0.6 1.8 
atr2∆ 9.4 0.8 1.8 
tml25∆ 9.3 0.7 1.8 
mak31∆ 9.3 0.9 1.7 
ald3∆ 9.0 0.9 1.7 
dit2∆ 9.2 1.5 1.7 
YMR181C 6.0 1.1 1.7 
hua1∆ 9.0 0.9 1.7 
gnp1∆ 10.4 0.1 1.7 
srl4∆ 8.7 2.3 1.6 
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Table 2.1 (continued)    
pex2∆ 5.9 0.6 1.6 
his7∆ 8.7 1.3 1.6 
fur4∆ 7.3 0.4 1.6 
cox15∆ 7.1 1.1 1.6 
pdr18∆ 8.4 2.5 1.6 
YJL213W 5.5 0.8 1.6 
YJL132W (Plate 44) 8.2 2.0 1.5 
YOR289W 8.2 0.6 1.5 
dcv1∆ 8.0 0.4 1.5 
pex3∆ 8.1 1.1 1.5 
tpo3∆ 8.5 0.9 1.5 
YGR050C 7.9 0.6 1.5 
YDL157C 5.3 0.5 1.5 
nst1∆ 7.7 1.7 1.4 
oca5∆ 9.4 0.7 1.4 
YOL075C 7.4 1.5 1.4 
mcs2∆ 7.2 1.3 1.4 
cys3∆ 7.2 0.1 1.4 
YNL097C-A 7.2 0.5 1.4 
ccs1∆ 6.4 0.1 1.4 
YBR090C 7.1 1.2 1.3 
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Table 2.1 (continued)    
fen2∆ 6.0 0.2 1.3 
dif1∆ 7.0 0.6 1.3 
dal4∆ 7.4 0.7 1.3 
oca6∆ 7.7 0.9 1.3 
put2∆ 6.9 1.4 1.3 
YKL075C 6.8 2.0 1.3 
mtc3∆ 6.7 0.1 1.3 
oye3∆ 6.7 1.4 1.3 
cox10∆ 6.7 0.3 1.2 
ept1∆ 6.5 0.5 1.2 
YCR016W 6.3 1.0 1.2 
enb1∆ 6.4 0.6 1.2 
sdd1∆ 6.1 0.5 1.2 
atx1∆ 6.0 0.5 1.1 
YBR184W 3.9 1.3 1.1 
tpi1∆ 3.9 1.7 1.1 
YPR195C 3.9 0.5 1.1 
YGL108C 5.2 0.3 1.0 
dia1∆ 5.0 0.5 0.9 
cmg1∆ 3.1 0.5 0.9 
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2.2.3.2 Genes that Regulate Heme Availability through Total Heme Changes 
In order to differentiate between factors that affect heme biosynthesis versus bioavailability, 
we sought to determine if the mutants with low bioavailable heme exhibited a decrease in total 
heme. Towards this end, we first determined how sensitive labile heme was to total heme by 
measuring the effects of succinylacetone (SA), a heme synthesis inhibitor, on total heme, heme 
loading of the high affinity sensor HS1, and heme loading of the weaker binding HS1-M7A sensor 
used in the screen.  In Figure 2.7a we can observe 5 µM SA is enough for the sensor fluorescence 
ratio of HS1-M7A to be similar to the hem1∆ deletion mutant that cannot make heme. The data 
indicate that a 15% reduction of the total heme concentration is sufficient to completely deplete 
heme binding to HS1-M7A. (Figure 2.7a and 2.7b) In the case of the tight binding sensor HS1, a 
60% reduction in total heme completely depleted heme loading of HS1 (Figure 2.7c and 2.7d). 
Thus, we found that labile heme levels are exquisitely sensitive to total heme and a modest ~15% 
decrease in total heme can completely deplete the HS1-M7A heme sensor.    
Total heme concentration was measured in 73 deletion mutants with low cytosolic labile 
heme. These values were then normalized to the WT heme concentration. We found that 41 of the 
73 deletion mutants exhibited WT-levels of total heme, with < 15% change in total heme. (Table 
2.2) 32 of the 73 deletion mutants with low bioavailable heme exhibited a > 15% decrease in total 
heme. (Table 2.2) Examples of mutants with unaltered total heme are the copper chaperone 
mutants, ccs1∆ and atx1∆, which exhibit WT-levels of total heme, suggesting that defects in 
copper homoeostasis can alter labile heme levels through an unknown mechanism. (Figure 2.8a) 
Examples of mutants with lowered total heme include the heme a biosynthetic mutant, cox10D and 
cox15D, suggesting that the inability to synthesize heme a may negatively feedback to attenuate 







Figure 2.7 – Labile heme sensitivity to heme depletion using the heme biosynthetic 
inhibitor, succinylacetone (SA) and affinity variants of the heme sensor. a. Labile 
heme was measured in HS1-M7A c. or HS1 expressing cells cultured in SCE media 
for 16 hours with the indicated concentration of SA prior to measurement of the 
eGFP/mKATE2 fluorescence ratios. (b) Total heme measured in the cultures depicted 
in a or in heme deficient hem1∆ cells. d. HS1 total heme data from cultures depicted 
on c. All data represent the mean ± SD of triplicate cultures and the statistical 
significance was assessed using a two-sample t-test. Black asterisks represent the 
statistical significance by a Dunnett’s multiple comparison  relative to 0 μM [SA]. * 













Table 2.2 - Total Heme measurements of low heme availability genes from the genome-wide 
screen. 
Strain Total Heme per cell STDEV Normalize to WT 
oye3∆ 9.6E-06 7.3E-07 1.3 
ccs1∆ 1.3E-05 4.01E-06 1.3 
pex3∆ 1.3E-05 1.5E-06 1.2 
atx1∆ 1.3E-05 2.2E-06 1.2 
fen2∆ 1.3E-05 1.9E-06 1.2 

























































Figure 2.8 – Total heme levels of specific functional groups of deletion mutants with low 
cytosolic heme. Total heme concentrations were measures for a. Copper chaperones, b. heme 
a maturation proteins and c. vacuolar or ESCRT proteins in order to identify if they have a 
role in heme biosynthesis or degradation. All data represent the mean ± SD of triplicate 
cultures and the statistical significance was assessed using a two-sample t-test. 
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Table 2.2 (continued)    
nst1∆ 1.2E-05 2.3E-06 1.2 
YPR195C 9.7E-06 6.1E-07 1.2 
dfg16∆ 8.2E-06 1.3E-06 1.2 
cmg1∆ 9.6E-06 2.9E-07 1.1 
YKL075C 1.5E-05 4.7E-06 1.1 
sdd1∆ 1.1E-05 4.8E-07 1.1 
dia1∆ 1.1E-05 5.6E-07 1.1 
srl4∆ 1.1E-05 1.3E-06 1.1 
hua1∆ 7.8E-06 1.8E-07 1.1 
erg4∆ 1.1E-05 -1.3E-06 1.1 
YKL096C 1.4E-05 4.3E-07 1.0 
tpi1∆ 8.6E-06 3.5E-07 1.0 
oca5∆ 7.4E-06 1.1E-06 1.0 
oca6∆ 7.4E-06 2.4E-07 1.0 
cys3∆ 7.6E-06 7.4E-08 1.0 
YCR016W 1.4E-05 2.8E-06 1.0 
gnp1∆ 4.7E-06 3.4E-07 1.0 
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Table 2.2 (continued)    
dcv1∆ 1.0E-05 1.2E-06 1.0 
vph1∆ 1.0E-05 1.1E-06 1.0 
YBR184W 8.2E-06 3.8E-06 1.0 
put2∆ 7.0E-06 3.8E-07 1.0 
pex2∆ 9.8E-06 1.8E-06 1.0 
YBR090C 1.3E-05 4.3E-07 1.0 
sps4∆ 8.0E-06 1.1E-06 1.0 
aim11∆ 9.7E-06 2.3E-07 1.0 
YJL132W (Plate 44) 1.3E-05 1.9E-06 1.0 
YGR050C 1.3E-05 7.9E-07 1.0 
opt2∆ 7.0E-06 2.3E-06 0.9 
ept1∆ 6.5E-06 4.0E-07 0.9 
lge1∆ 9.9E-06 2.8E-07 0.9 
tml25∆ 1.2E-05 4.1E-07 0.9 
irc21∆ 1.2E-05 2.0E-07 0.9 
YDL157C 7.4E-06 5.6E-07 0.9 
met12∆ 8.7E-06 1.7E-07 0.9 
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Table 2.2 (continued)    
dit2∆ 6.3E-06 6.0E-07 0.9 
atr2∆ 6.3E-06 6.2E-07 0.9 
YNL097C-A 9.1E-0.6 5.6E-07 0.8 
pdr18∆ 6.0E-06 7.1E-07 0.8 
cox10∆ 8.8E-06 1.2E-06 0.8 
ald3∆ 6.1E-06 4.0E-07 0.8 
YER137C 6.8E-06 5.7E-07 0.8 
YIL055C 1.1E-05 4.5E-07 0.8 
YOL075C 5.8E-06 3.0E-07 0.8 
pex8∆ 8.0E-06 2.6E-06 0.8 
dif1∆ 5.9E-06 6.5E-07 0.8 
sul1∆ 5.9E-06 6.5E-07 0.8 
mcs2∆ 5.8E-06 4.0E-07 0.8 
dal4∆ 7.6E-06 2.2E-07 0.8 
mak31∆ 5.4E-06 2.0E-07 0.8 
YOR342C 6.3E-06 4.2E-07 0.8 
hom6∆ 5.5E-06 2.0E-07 0.7 
 36 
Table 2.2 (continued)    
vps36∆ 7.4E-06 2.0E-07 0.7 
snf7∆ 7.3E-06 4.6E-07 0.7 
pep12∆ 7.4E-06 1.1E-06 0.7 
YJL213W 6.8E-06 4.7E-07 0.7 
tbs1∆ 5.6E-06 1.2E-06 0.7 
suc2∆ 4.9E-06 6.2E-08 0.7 
aim18∆ 6.1E-06 7.1E-08 0.6 
tpo3∆ 2.8E-06 2.1E-07 0.6 
YIL015C-A 6.0E-06 7.9E-07 0.6 
YLR358C 6.0E-06 1.4E-07 0.6 
cox15∆ 6.0E-06 9.8E-07 0.6 
YOR289W 5.1E-06 1.5E-07 0.5 
tmn3∆ 5.1E-06 1.3E-07 0.5 
his7∆ 3.3E-06 5.5E-07 0.5 
fur4∆ 4.5E-06 2.7E-07 0.4 
YMR181C 2.8E-06 1.7E-06 0.3 
etr1∆ 2.5E-06 8.7E-07 0.2 
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  Discussion 
Heme, which is an essential but cytotoxic cofactor, must be tightly regulated. The factors 
and processes involved in heme trafficking, distribution and homeostasis are not well known. 
Herein, we conducted a genome-wide screen in yeast to identify new heme homeostatic factors 
using genetically encoded heme sensors. Of the 5,000 genes available in the yeast haploid deletion 
library, we were able to transform and stably express the heme sensor in 4,470 genes. Of these, we 
identified 114 deletion mutants with a +1.5 z-score or higher, indicating high cytosolic labile heme, 
and 323 deletion mutants with a z-score of -1.5 or lower, indicating low cytosolic labile heme.  
We observed that labile heme in WT cells was higher than in the average mutant. We believe 
this result indicates that deletion of a large number of pathways can indirectly affect heme 
synthesis or availability. Heme biosynthesis is not only regulated by the eight heme biosynthetic 
enzymes, in reality a multitude of factors may regulate the expression and maturation of the heme 
biosynthetic enzymes, as well as the concentrations of heme biosynthetic precursors. The network 
of proteins that directly or indirectly regulate heme synthesis is likely very substantial.  
In the case of the 114 deletion mutants exhibiting high cytosolic labile heme, we observed 
that the majority of these genes were enriched in the cytosol. This is not surprising given that we 
are probing cytosolic heme. A large number of the strains with high labile heme are ribosomal 
protein mutants. It is possible that certain ribosomal proteins bind and buffer heme. Upon their 
deletion, more heme would be accessible to the heme sensor. It is intriguing to speculate that the 
ribosome acts as a heme sink to provide heme for hemoproteins as they are being translated. It has 
been reported that hemin is responsible for enhancing polyribosome stabilization and lead 
treatments can cause a heme inhibition resulting into disaggregation of polyribosomes following 
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a decreased in protein synthesis51. Our future work will involve determining if heme associates 
with ribosomes and the specific ribosomal proteins identified in our deletion screen.  
Deletion mutants of certain cytoskeleton proteins were identified to exhibit an increase in 
heme availability. It has been previously demonstrated that heme can bind and alter the 
conformation of the cytoskeleton9, as well as increase the polymerization of actin 9. Previously a 
role for hemopexin in the reorganization of actin cytoskeleton specifically in podocytes was 
reported52. It was observed that WT podocytes cells reorganized the actin from a stress fiber to 
cytoplasmic aggregates and membrane ruffles after 30 minutes of hemopexin treatment52. 
However, it was thought to be by a nephrin dependent signaling, not necessarily by a direct 
interaction of heme and the cytoskeleton. It would be tempting to speculate that heme is transported 
along the cytoskeleton network. However, there is currently no direct evidence for this.   
Deletion mutants of cell division proteins also exhibited high heme. Cell cycle regulation by 
heme is a topic that has been studied in HeLA cells by Weizhen Ye and Li Zhang, who 
demonstrated heme control of the expression of some cell cycle regulators53. They observed that 
heme synthesis inhibition with succinylacetone caused a cell cycle arrest in the S phase and that it 
also induced the expression of molecular markers associated with senescence and apoptosis53. This 
could suggest heme having a signaling role for triggering cell cycle progression either by direct 
activation of cell cycle modulators or through changes in heme concentration acting as a signaling 
molecule and regulating the expression of the molecular factors favoring division.  
A large fraction of the 323 deletion mutants with low heme availability play a role in the 
ESCRT complex, vacuolar function, or Golgi-vacuolar protein trafficking via multivesicular 
bodies. We propose that heme could be mobilized from multivesicular bodies with the help of 
ESCRT proteins or possibly be sent to the vacuole where it can be transported out of. Heme could 
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be mobilized after its synthesis from the mitochondria to the ER or to the Golgi in order to be 
packaged into transport vesicles. This transport vesicle could be targeted to go to the membrane, 
cytosol or maybe even fuse with the early endosomes. The early endosomes could be sent to be 
recycled to the membrane that could transport heme into the cell membrane if necessary, but it 
could also merge with other early endosomes in order to form the late endosomes or multivesicular 
bodies. Transporters in these multivesicular bodies could mobilize heme into the cytosol, making 
it available for other heme buffering factors to regulate it and deliver it when necessary. These 
multivesicular bodies may also fuse with the vacuole /lysosome, where heme can be stored and 
transported out of. We are testing this hypothesis by deleting genes in the ESCRT pathway and 
measuring heme distribution in different organelles. (Figure 2.9) For example, VPH1 is a gene 
that displayed low labile heme but normal amount of total heme and is in responsible for the 
vacuolar ATPase. This gene would be a good target to test if heme is stored and trafficked from 
the vacuole and if vacuole function is crucial for heme distribution. We could also test proteins 
like Snf7, a subunit of ESCRT complex III, or Vps36, a subunit of the ESCRT complex II, or, 
Pep12, a target receptor for vesicular intermediates traveling between the Golgi and the vacuole. 
All of these experiments will reveal if vesicular sorting and ESCRT proteins are crucial for heme 
distribution and which step is the most important for making heme bioavailable. 
The notion that heme is trafficked via endosomes is supported by a number of lines of 
evidence. First, work performed by Di Fiore and Di Camilli has demonstrated membrane 
trafficking as a potential process for regulating and distributing various signaling metabolites. 54. 
In C. elegans, intracellular heme can be found in lysosomal related organelles that are very 
dynamic55. Zinc has also been found to be stored in and mobilized from these C. elegans 









In summary, we successfully utilized genetically encoded fluorescent heme sensors to screen 
the yeast haploid gene deletion collection to identify genes important for heme homeostasis. We 
not only identified genes known to affect heme biosynthesis, as expected, but we found a large 
number of new genes that impact both heme synthesis and availability. Two major findings include 
GAPDH, which was found to buffer and traffic heme to the nucleus and is discussed in Chapter 3, 
and endosomal trafficking of heme. Overall, this work will help in the understanding of heme 
trafficking, the regulation of heme homeostasis, and identifying heme buffering elements and new 
heme biosynthesis and degradation factors.  
 
Figure 2.9 – The proposed mechanism for heme mobilization via intracellular vesicle-
mediated trafficking.  Endocytic pathway it displayed, in which heme could be 
mobilized out of the Trans-Golgi Network (TGN) facilitated by Pep12, heme could be 
mobilized into early endosomes in which Vps36 could be playing a role for heme 
mobilization. Endosomes will mature into multivesicular bodies (MVB) with Snf7 
possible transporting out heme and making it bioavailable. Heme could also be 
mobilized to the cytosol and made bioavailable by Vph1, which is a vacuolar ATPase. 
 41 
 Materials and Methods 
2.4.1 Cell Strains, Transformation, Growth Conditions and Plasmids 
2.4.1.1 Yeast Strains and Growth 
S. cerevisiae strains used in this study were derived from BY4741 (MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ0). Deletion mutant strains were obtained from the yeast gene deletion collection 
(Thermo Fisher Scientific). We also utilized the previously reported strain DH001b-3 
(hem1∆::HIS3)3. All strains derived from the yeast deletion collection were confirmed by 
sequencing the unique barcodes flanking the KanMX4 deletion cassette. 
2.4.1.2 Yeast Transformation 
Yeast transformations were performed by the lithium acetate procedure 49. Strains were 
maintained at 30° C on either enriched yeast extract (1%) - peptone (2%) based medium 
supplemented with 2% glucose (YPD) and G418 (200 µg/mL) or synthetic complete medium (SC) 
supplemented with 2% glucose and the appropriate amino acids to maintain selection3. Cells 
cultured on solid media plates were done so with YPD or SC media supplemented with 2% agar 3. 
Selection for yeast strains containing the KanMX4 marker was done with YPD agar plates 
supplemented with G418 (200 μg/mL) 3. Cells for the screen were resuspended in SC media 
supplemented with 15 mg/mL of ergosterol and 0.5% Tween-80 (SCE). All liquid cultures were 
maintained at 30 °C and most were done in standing cultures. 
2.4.1.3 Plasmids 
Cytosolic, mitochondrial, and nuclear-targeted heme sensors, HS1, were sub-cloned into 
pRS415 and driven by ADH, TEF, or GPD promoters as previously described3. PCR based 
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mutagenesis was used to generate the affinity variants of HS1 (M7A)3. The Hap1 reporter plasmid 
in which eGFP is driven by the CYC1 promoter was also previously described 3. 
2.4.2 Experimental Methods 
2.4.2.1 High Through-put transformation 
Yeast high through-put transformations were performed in the standard clear sterile 96 well 
plates and by: a. preculturing the cells in 200 µL YPD G418 (200 µg/mL)  media until saturation 
(48 hours); b. diluted the cells in 200 µL of YPD G418 and grown for 14-16 hour at 30°C standing; 
c. transforming cells using the lithium acetate procedure adapted for 96 well plates57; d. incubating 
the cells with the transformation reagents for 6 hours at 42°C on the standing incubator on a Mary 
bath set up; e. resuspending cells in SCE media with the appropriate amino acids to maintain 
selection3. Plates were incubated for 96 hours and then diluted in fresh SCE media supplemented 
with the appropriate amino acids to confirm and maintain selection until saturation (48 hours.).  
2.4.2.2 High Through-put Screen 
Cytosolic HS1-M7A expressing cells were cultured in standard clear sterile 96 well plates. 
Duplicate cultures were seeded in 200 µLof SCE media with the appropriate amino acids to 
maintain selection3 standing until saturation (48 hours.). The cells were diluted into 200 µL SCE-
LEU and grown standing for 14-16 hours at 30°C. After culturing cells were harvested, washed 
twice in 200 µL of sterile ultrapure water and finally resuspended in 200 µL of 1x PBS. HS1-M7A 
fluorescence was monitored on 200 uL of a 4 OD/mL (2 x 107 cells/mL) cell suspension using 
black Greiner Bio-one flat bottom fluorescence plates and a Synergy Mx multi-modal plate reader. 
eGFP (ex. 488 nm, em. 510 nm) and mKATE2 (ex. 588 nm, em. 620 nm) fluorescence was 
recorded every 30 seconds for 5 min. Z-scores values were calculated by subtracting the sensor 
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fluorescence ratio for a given strain screened to the average sensor fluorescence ratio of the all 
samples screened in the plate and dividing it by the STDEV of the sensor fluorescence ratio of all 
the strains screened in the plate.  
2.4.2.3 Total heme quantification 
Measurements of total heme were accomplished using a fluorimetric assay designed to 
measure the fluorescence of protoporphyrin IX upon the release of iron from heme as previously 
described 58. For all total heme measurements, ~1 x 108 cells were harvested, washed in sterile 
ultrapure water, and resuspended in 500 μL of 20 mM oxalic acid and stored in a closed box at 4 
°C overnight (16-18 hours). Next, an equal volume (500 μL) of 2 M oxalic acid was added to the 
cell suspensions in 20 mM oxalic acid. The samples were split, with half the cell suspension 
transferred to a heat block set at 95 °C and heated for 30 minutes and the other half of the cell 
suspension kept at room temperature (~25 °C) for 30 minutes. All suspensions were centrifuged 
for 2 minutes on a table-top microfuge at 21000 x g and the porphyrin fluorescence (ex: 400 nm, 
em: 620 nm) of 200 μL of each sample was recorded on a Synergy Mx multi-modal plate reader 
using black Greiner Bio-one flat bottom fluorescence plates. Heme concentrations were calculated 
from a standard curve prepared by diluting 500-1500 μM hemin chloride stock solutions in 0.1 M 
NaOH into ultrapure water, which was then added back to extra cell samples as prepared above. 
In order to calculate heme concentrations, the fluorescence of the unboiled sample (taken to be the 
background level of protoporphyrin IX) is subtracted from the fluorescence of the boiled sample 
(taken to be the free base porphyrin generated upon the release of heme iron). The cellular 
concentration of heme is determined by dividing the moles of heme determined in this fluorescence 
assay and dividing by the number of cells analyzed, giving moles of heme per cell, and then 
converting to a cellular concentration by dividing by the volume of a yeast cell, taken to be 50 fL 
3.  
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CHAPTER 3. GLYCERALDEHYDE 3-PHOSPHATE       
  DEHYDROGENASE (GAPDH) AS A HEME BUFFERING FACTOR 
 Thesis Attributions Statement for Chapter 3. 
Portions of this chapter are adapted from previously published work: “David A. Hanna; Raven M. 
Harvey; Osiris Martinez-Guzman; Xiaojing Yuan; Bindu Chandrasekharan; Gheevarghese Raju; 
F. Wayne Outten; Iqbal Hamza; and Amit R. Reddi. ‘Heme Dynamics and Trafficking Factors 
Revealed by Genetically Encoded Fluorescent Heme Sensors. Proc Natl Acad Sci, 2016;113:7539-
7544.’” And also work from: “Elizabeth A. Sweeny; Anuradha Bharara Singh; Ritu Chakravarti; 
Osiris Martinez-Guzman; Arushi Saini; Mohammad Mahfuzul Haque; Greer Garee; Pablo D. 
Dans; Luciana Hannibal; Amit R. Reddi; and Dennis J. Stuehr. "Glyceraldehyde-3-phosphate 
dehydrogenase is a chaperone that allocates labile heme in cells." Journal of Biological Chemistry 
293(37): 14557-14568.” 
 Introduction 
Heme is an incredibly important metallonutrient for many essential biological functions, but 
very little is known about the proteins involved in its trafficking and homeostasis. As mentioned 
in Chapter 2, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was identified as a possible 
heme trafficking factor in a genome wide screen for cytosolic heme availability using genetically 
encoded fluorescent heme sensors. GAPDH is a member of the dehydrogenase enzyme family and 
an essential protein for glucose metabolism. GAPDH catalyzes the conversion of glyceraldehyde-
3-phosphate to 1,3 bis-phosphoglycerate, the sixth step on glycolysis. This glycolytic enzyme is 
ubiquitously expressed comprising around 10-20% of the total cellular protein content59, and is 
localized in different organelles such as the cytoplasm, mitochondria, nucleus lipid particles and 
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cell wall. GAPDH, which has a molecular mass of 37 kDa, is most typically a homotetramer, but 
can also be found as a monomer or dimer. 60, 61 Interestingly, the monomeric form is localized to 
the nucleus during cell proliferation62, 63. Saccharomyces cerevisiae encodes three isoforms of 
GAPDH: TDH1, TDH2, and TDH3. These isoforms are very similar in sequence and structure64, 
65.  Tdh2p and Tdh3p are expressed mainly during exponential growth, whereas Tdh1p is primarily 
expressed during stationary growth phase66. 
In addition to its role in glycolysis, GAPDH is known to have non-canonical roles in 
transcriptional activation by binding to DNA and RNA59, 67-69, regulating apoptosis70, catalyzing 
microtubule formation and polymerization71-73, NO sensing74, 75 and facilitating vesicular transport 
between the ER and Golgi76. Post-translational modification of GAPDH may play a critical role in 
regulating its diverse functions. For example, in the cytosol of human monocytes, it has been 
observed that a S-thiolation of the reactive sulfhydryl groups on GAPDH can facilitate a metabolic 
shift from anaerobic respiration to the pentose phosphate pathway77.  Another reversible 
modification in GAPDH is the S-nitrosylation, in which the addition of the nitric oxide (NO) group 
to the thiol side chain of cysteine regulates the activity of this protein. 78, 79.  Irreversible 
posttranslational modifications, e.g. sulfonation, mobilizes GAPDH from the cytosol to other 
cellular compartments for signaling purposes80.  
Previously, GAPDH from macrophages was proposed to be a heme binding protein on the 
basis of its interactions with hemin-agarose 81. They proposed GAPDH was able to control the 
activation of inducible NO synthase (iNOS) by regulating heme insertion in a NO-sensitive 
manner81. They observed that a GAPDH deficient cell was incapable of heme insertion into the 
iNOS and exposure to NO, which causes S-nitrosylation of GAPDH, inhibits glycolytic activity 
and heme binding81. Is GAPDH truly a heme binding protein? What role does GAPDH play in 
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heme homeostasis? Does GAPDH have a role for heme allocation in the cell? What is the affinity 
for heme? What are the heme binding residues of GAPDH?  
In order to provide some answers to these questions, we decided to screen the three isoforms 
of GAPDH in S. cerevisiae and measure heme availability using genetically encoded fluorescent 
heme sensors. We also wanted to measure how heme distribution was affected upon the deletion 
of this glycolytic protein through activity measurement of heme dependent processes in different 
organellar compartments.  By integrating our heme sensors with genetic screens, we found that the 
glycolytic enzyme glyceraldehyde phosphate dehydrogenase (GAPDH) is responsible for 
buffering intracellular heme and regulating the activity of the nuclear heme-dependent 
transcription factor heme activator protein (Hap1p). Additionally, the His53 for hGAPDH and 
His51in yeast GAPDH were identified as the residues crucial for heme binding and delivery to 
transcription factors such as Hap1. 
 Results 
3.3.1 GAPDH Regulates Cytosolic Heme Availability 
In order to identify genes that regulate LH, we transformed the cytosolic HS1-M7A into the 
yeast knockout collection and screened for mutants that exhibited altered sensor fluorescence 
ratios. After partial screening, we identified TDH3, which encodes an isoform of the glycolytic 
enzyme GAPDH, to be a determinant of LH. We observed that only the tdh3∆ mutant, but not 
tdh1∆ or tdh2∆ mutants, increases cytosolic labile heme as measured by HS1-M7A (Figure 3.1A). 
In-situ calibration of the sensors as described previously indicates that labile heme levels increase 
from ~20 nM to ~60 nM upon deletion of TDH3. These results suggest that the GAPDH isoform 
Tdh3p, buffers intracellular heme.  Quantification of total heme was done on all of the GAPDH 
isoforms to determine if the changes in labile heme were due to a disruption in heme biosynthesis. 
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Acid-acetone extraction of heme from cells and heme quantification using High-Performance 
Liquid Chromatography (HPLC) revealed that total heme levels are not affected by deletion of 
GAPDH isoforms (Figure 3.1B). These data suggest that Tdh3p regulates bioavailable heme 




3.3.2 Expression of GAPDH isoforms  
Why is the effect of GAPDH on labile heme specific for Tdh3p? In fact, Tdh1p and Tdh2p 
share > 95% sequence identity with Tdh3p. In order to test the contribution of each isoform to the 
total GAPDH pool, we immunoblotted for GAPDH in WT, tdh1∆, tdh2∆, and tdh3∆ cells. The 
results from the western blot suggest that the Tdh3p isoform is the primary contributor toward total 
GAPDH (Figure 3.2). These results explain the Tdh3p-specific effect on labile heme, namely that 





Figure 3.2 - Immunoblot analysis of GAPDH and SOD1 (loading control) for the three 
isoforms of GAPDH in yeast. Figure adapted with permission from: Hanna et al. (2016) 
Proc Natl Acad Sci USA 113(27):7539-7544. 
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Figure 3.1- Tdh3p regulates intracellular heme availability. (A) Fluorimetric determination of 
EGFP/mKATE2 fluorescence ratios of the indicated yeast strains expressing HS1-M7A. (B) 
Total heme levels of the indicated strains as determined by HPLC. Figure adapted with 





3.3.3 Heme Dependent Processes in a GAPDH Deficient Mutant 
Previously it was described how the glycolytic enzyme glyceraldehyde phosphate 
dehydrogenase (GAPDH) constitutes a major cellular heme buffer without affecting total heme 
levels. It is also very well-known that heme is involved in many biological functions like oxygen 
transfer, catalysis, electron transfer, energy metabolism, apoptosis, cell proliferation and gene 
expression5, 82. In order to characterize the role of GAPDH in heme homeostasis and the effect 
Tdh3p deletion has on the heme pool in other organelles, we decided to test the activity of several 
heme dependent processes. For example, cytosolic catalase (Ctt1p) activity provides an indicator 
of cytosolic heme homeostasis. The activity of the nuclear transcription factor heme activator 
protein, Hap1p, provides an indicator of nuclear heme homeostasis.  
3.3.3.1 Catalase Activity in a tdh3∆ 
 Catalase is a tetrameric enzyme that catalyzes the decomposition of hydrogen peroxide to 
water and oxygen. It requires four heme molecules, or one heme per monomer, in order to be 
active. A colorimetric assay for catalase was employed that exploits the ability of heme bound 
catalase to catalyze the peroxide-dependent oxidation of dopamine, which turns purple83. The 
amount of purple coloration reports on how active the protein is. Since tdh3D cells exhibit a defect 
in cytosolic labile heme levels, we probed the activity of the cytosolic catalase activity, Ctt1p. The 
tdh3D mutant did not display any disruption in catalase activity in comparison to the WT strain 
(Figure 3.3). 
 
Figure 3.3 – Tdh3 deficient mutant displayed normal amounts of catalase activity. In-gel activity 
assay for cytosolic catalase, Ctt1p, in the indicated strains. Cells were grown to mid-log phase in 
YPDE. Immunoblots and catalase activity are representative of two independent trials. Figure 
adapted with permission from: Hanna et al. (2016) Proc Natl Acad Sci USA 113(27):7539-7544. 
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3.3.3.2 Heme Activator protein, Hap1, activity in a tdh3∆ 
 Heme Activator Protein, Hap1p, is a zinc finger transcription factor involved in adapting 
metabolism to O2 via its ability to sense and bind heme, a O2-dependent metabolite.84, 85. In order 
to probe Hap1p activity, we designed a transcriptional reporter plasmid that drives the expression 
of green fluorescent protein (GFP) under the control of the CYC1 promoter, which is activated by 
Hap1p in the presence of heme. GFP fluorescence is therefore a measure of the availability of 
heme for Hap1p since heme-activation of Hap1p is required to turn-on CYC1 expression. Using 
this reporter construct, our data indicate that GAPDH seems to have a role in Hap1p activation 
since tdh3∆ cells have ~3-fold lower GFP expression comparted to WT (Figure 3.4). These data 




3.3.4 GAPDH Complementation  
To confirm the increase in cytosolic labile heme was due to the deletion of the major 
isoform of GAPDH, Tdh3p, complementation experiments were performed. In these experiments, 
the expression of GAPDH was reintroduced in a deficient mutant through the use of a p416-GPD 
plasmid. WT and tdh3∆ cells expressing empty vector (p416-GPD) or TDH3 (p416- GPD-TDH3) 
and p415-ADH1-HS1-M7A were cultured in order to measure the cytosolic heme availability. We 
Figure 3.4 - Hap1p activity in the indicated strains as measured by a transcriptional reporter 
that used EGFP driven by the CYC1 promoter, a Hap1p target gene. All data represent the 
mean ± SD of triplicate mid-log-phase yeast extract-peptone-dextrose media supplemented 
with ergosterol and tween-80 (YPDE) cultures. Figure adapted with permission from: Hanna 
et al. (2016) Proc Natl Acad Sci USA 113(27):7539-7544 
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observed that episomal expression of TDH3 in tdh3D cells restored cytosolic labile heme to WT 
levels (Figure 3.5A). Immunoblot analysis of GAPDH and SOD1 (loading control) were also done 
in these strains to confirm the recovery in expression of GAPDH in the TDH3 deficient mutants. 
A full restoration of GAPDH expression was observed in the tdh3D strains that were expressing 
the p416-GPD-TDH3 and not in the ones expressing empty vector (Figure 3.5B). It can be 
concluded that the phenotypes observed were due to the lack of GAPDH expression, and that 








3.3.5 Identification of Heme Binding Residues on GAPDH 
One of the most commons heme binding ligands in hemo-proteins is histidine (His)86. Previous 
studies with rabbit GAPDH (rGAPDH) identified a histidine residue as the ligand that would 
facilitate heme binding to GAPDH. In order to determine the important heme binding residues in 
human GAPDH (hGAPDH), our collaborators at the Cleveland Clinic performed sequencing 
alignments of GAPDH from a large number of species and selected three highly-conserved His 
residues in hGAPDH. According to our collaborator’s computer modeling of these residues, His53 
B A 
Figure 3.5 – Heme availability and expression measurements for the complemented 
GAPDH deficient strains. (A) WT and tdh3∆ cells expressing empty vector (p416-
GPD) or TDH3 (p416- GPD-TDH3) and p415-ADH1-HS1-M7A were cultured in 
SCE-LEU-URA media for 15 hours and EGFP:mKATE2 fluorescence ratios were 
recorded. The fluorescence data represent the mean ± SD of duplicate cultures. (B) 
Immunoblot analysis of GAPDH and SOD1 (loading control) in the strains from Panel 





was the most probable heme binding residue due to it being localized on a flexible loop at the inter-
protomer interface of the tetramer87. They also observed that only the H53A mutation cause a 
decrease in the hGAPDH heme binding affinity. In order to further study the role of GAPDH as a 
heme buffer and identify the crucial residues that facilitate this function, we decided to probe labile 
heme with various GAPDH mutants.  
First, we screened heme availability of a tdh3D strain and confirmed the increase in cytosolic 
heme levels. When we transformed the tdh3D mutant with the plasmid that provides the expression 
of the native TDH3 or hGAPDH, both of them resulted in the restoration of WT cytosolic labile 
heme levels. In the case of transforming the tdh3D strain with the TDH3 H51A mutant (S. 
cerevisiae mutant equivalent of H53A) or the hGAPDH H53A mutants, the WT cytosolic labile 
heme levels were not rescued. This data indicates that the heme coordinating ability of GAPDH 








Figure 3.6 - GAPDH heme binding is essential for regulating cytosolic labile heme and 
delivery to nuclear Hap1p. (A) Sensor-detected labile heme levels in WT and tdh3Δ 
(GAPDH deletion) yeast strains with or without transfection with yeast and human 
GAPDH variants.  (B) Corresponding Hap1p activation in yeast. Figure adapted from: 
Sweeny et al. (2018) Journal of Biological Chemistry. 293 (37):14557-14568. 
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We next wanted to study if the His heme binding residue also was required for the heme 
activation of Hap1p. We observed the tdh3D strain expressing the transcriptional reporter resulted 
in decreased levels of Hap1p activation in comparison to a WT. The tdh3D mutant transformed 
with yeast TDH3 or hGAPDH, resulted in restoration of Hap1p activity to WT levels. In the case 
of transforming the tdh3D strain with the TDH3 H51A mutant or the hGAPDH H53A mutants, we 
still observed the lower levels of Hap1p activation.  
 Discussion 
Although essential for life, heme may also act as a toxin, necessitating that cells carefully 
handle this compound2, 4. However, the factors that govern heme bioavailability, including the 
molecules that transport, traffic, and buffer it, are largely unknown. There are a number of proteins 
characterized as being heme binding proteins due to their in vitro interactions with hemin-agarose, 
including glutathione-S-transferase88, heme-binding proteins (HBPs)89, 90 and fatty acid binding 
proteins (FABPs)91. Direct evidence of heme binding ability and their role in heme homeostasis is 
often lacking. 
From the genome-wide screens for heme availability, we were able to identify GAPDH as a 
possible heme buffering factor that, upon deletion, increases the labile heme pool in the cytosol. 
Previous work proposed that GAPDH delivers heme to the inducible nitric oxide synthases (iNOS) 
in an NO-dependent manner, in which S-nitrosylation prevents heme binding in GAPDH81. Our 
results were able to confirm GAPDH is a heme buffering factor in the cytosol that also regulates 
heme mobilization and delivery to nuclear heme dependent transcription factors such as Hap1. 
Additionally, we also identified His53 in hGAPDH and His51 in yeast as crucial for heme binding, 
buffering, trafficking to Hap1. It has been demonstrated that oxidative stress such as NO 
supplementation can lead to S-nitrosylation, preventing heme binding to GAPDH81. Our lab has 
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also described how NO can dynamically mobilize heme, especially in the nucleus.3. Can GAPDH 
be responsible for the labile heme release observed upon NO supplementation? The addition of 
NO can cause posttranslational modifications on GAPDH such as S-nitrosylation in the catalytic 
cysteine. This can induce the release of heme from the glycolytic protein, generating an increase 
in heme availability. 
These results provide new insights into heme gets distributed within the cell. Instead of 
acting as a heme chelator or heme sink to protect the cell from heme toxicity, GAPDH seems to 
be acting more as a facilitator that makes heme bioavailable and regulates its delivery to 
downstream target proteins like Hap1. Our data suggest that the GAPDH heme pool is in 
equilibrium with the overall labile heme pool in the cell that is detected by the heme sensor, and 
that GAPDH is responsible to manage a significant portion of it. Once GAPDH binds heme, it 
makes it bioavailable for being inserted into cytosolic proteins like iNOS and for delivery to heme 
dependent transcription factors like Hap1p.  
The mechanism underlying GAPDH mediated heme delivery to Hap1p is still unknown. We 
speculate that one possibility is that GAPDH directly delivers heme to Hap1p via its nuclear 
translocation and interaction with Hap1. This idea is supported by evidence that demonstrates that 
GAPDH is mobilized from the cytosol to the nucleus under specific conditions92. In addition, it is 
known that the inhibition of GAPDH through S-nitrosylation leads to GAPDH binding to an E3 
ubiquitin ligase, Siah-1, which translocate as a GAPDH-Siah complex to the nucleus triggering 
apoptosis75, 93-95. We propose that there is a protein interaction or a posttranslational modification 
that can also cause the nuclear translocation of GAPDH in a similar manner, to deliver heme to 
Hap1. A second possibility is through an intermediary that could accept heme from GAPDH and 
deliver heme to Hap1 in the nucleus. The identification of GAPDH as a heme buffering factor 
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helps to expand the knowledge of how intracellular heme is trafficked and how heme homeostasis 
is maintained. It also validates the idea of the existence of heme chaperones and motivates the need 
to identify more proteins like this so we would get a better understanding of heme trafficking and 
regulation. 
 Materials and Methods 
3.5.1 Cell Strains, Culturing and Plasmids 
3.5.1.1 Yeast Strains, Media and Growth Conditions 
S. cerevisiae strains used in this study were derived from BY4741 (MATa, his3∆1, leu2∆0, 
met15∆0, ura3∆0). tdh1∆::kanMX4, tdh2∆::kanMX4, and tdh3∆::kanMX4 strains were obtained 
from the yeast gene deletion collection (Thermo Fisher Scientific). A hem1∆::HIS3 strain was 
generated by deleting HEM1 using the hem1::HIS3 deletion plasmid, pDH001. Yeast 
transformations were performed by the lithium acetate procedure96. Strains were maintained at 30° 
C on either enriched yeast extract-peptone based medium supplemented with 2% glucose (YPD), 
or synthetic complete medium (SC) supplemented with 2% glucose and the appropriate amino 
acids to maintain selection. Culturing of hem1∆ cells required supplementing YPD or SC media 
with 50 μg/mL of 5-aminolevulinic acid (5-ALA) or 15 mg/mL of ergosterol and 0.5% Tween-80 
(YPDE or SCE, respectively)97.  
3.5.1.2 E. coli Strains, Media and Growth Conditions 
For routine cloning, sub-cloning grade chemically competent E. coli cells, strain 10G E. 
cloni (Lucigen), were used according to the manufacturer’s specifications. Unless otherwise stated, 
all E. coli strains were cultured in Lysogeny broth (LB)98 with the appropriate antibiotic selection, 
either 100 μg/mL ampicillin or kanamycin.  
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3.5.1.3 Plasmids 
HAP1 Transcriptional Reporter, prCYC1-EGFP. In order to monitor HAP1 activity, a 
transcriptional reporter was generated in which EGFP was driven by the CYC1 promoter, which 
is a gene that is positively regulated by HAP1. A 5’/3’ BamHI/HindIII EGFP fragment was 
amplified and sub-cloned in p416-CYC1, containing the CYC1 promoter.  
GAPDH and mutant’s expression plasmids. The yeast Tdh3p expression plasmid was 
generated by amplifying TDH3 from yeast genomic DNA and sub-cloning it into the SpeI/BamHI 
sites of p416-GPD99 to generate plasmid pAR1031. The yeast Tdh3-H51A mutation was generated 
by Quick Change mutagenesis (Agilent Technologies) using pAR1031 as a template, generating 
pAR1033. The yeast hGAPDH and hGAPDH-H53A expression plasmids were generated by 
amplifying hGAPDH from pGex4T2-GST-hGAPDH or pGex4T2-GST- hGAPDH-H53A and 
sub-cloning it into the SpeI/BamHI sites of p416-GPD99 to generate plasmids pAR1035 and 
pAR1036, respectively.  
3.5.2 Experimental Methods 
3.5.2.1 Catalase Activity Measurements in Yeast 
WT yeast cells expressing empty vector (p415-GPD), or HS1-M7A driven by the GPD, 
TEF1, or ADH1 promoters (p415-GPD-HS1-M7A, p415-TEF1-HS1-M7A, p415-ADH1-HS1-
M7A) were cultured in SC-LEU media for ~14-16 hours to mid-exponential phase (an optical 
density at 600 nm of OD600 nm ~ 1-2). Cells were harvested and lysed in phosphate buffer and 
10 μg of protein lysate were subjected to native PAGE on a 10% tris-glycine gel (Invitrogen). 
After electrophoresis, an in-gel activity stain was utilized to measure catalase activity100. Briefly, 
a catalase staining solution containing 1 part Dopamine (20mg/mL) in pH 8 0.2 M KPi buffer, 1 
part para-phenylenediamine (3.5mg/mL) in pH 8 0.2M KPi, 1 part 15 % H2O2, and 2 parts DMSO 
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were mixed in the order listed. The staining solution was added directly to the gel and allowed to 
stain for 2 minutes, followed by rinsing in Milli-Q water and imaging.  
3.5.2.2 Total Heme Quantification in Yeast 
 Heme was quantified using a protocol adapted from the method of Woods and 
Simmonds101. Briefly, yeast was cultured in 25 mL of YPDE media for 15 hours to a density of 1 
OD600 nm /mL. Cells were harvested, washed in ice-cold Milli-Q water, and lysed in three pellet 
volumes of acid-acetone (9.75 mL acetone, 0.250 mL concentrated HCl). Lysis was achieved at 4 
C using one pellet volume of zirconium oxide beads and a bead beater (Bullet Blender, Next 
Advance) on a setting of 8 for 3 minutes. After homogenization, lysates were clarified by 
centrifugation at maximum speed on a table-top centrifuge. 50 μL of an acid-acetone extract of 
heme was diluted into 50 μL of 0.1% trifluoroacetic acid in a 1:1 mixture of water and acetonitrile. 
Heme was quantitated by HPLC using a flow rate of 1 mL/min and elution gradients going from 
50% acetonitrile in water, 0.1% TFA to 100% acetonitrile, 0.1% TFA over 10 minutes on a C-18 
column (Poroshell 120, SB-C18, 4.6 x 100 mm, 2.7 um). Heme was quantified relative to hemin 
chloride standards run in parallel and normalized for cell number. Cellular heme concentration 
was determined by assuming a yeast cell volume of 50 fL. Heme was unambiguously identified 
from its retention time and characteristic UV/visible spectrum using a photodiode array detector 
coupled to the HPLC.  
3.5.2.3 HAP1 Transcriptional Reporter Assay 
Yeast cells expressing p416-CYC1- EGFP, or EGFP driven by the Hap1p regulated CYC1 
promoter, were cultured in 10 mL of SCE-URA media for 15 hours to a to a density of 1 OD600 
nm /mL. Cells were resuspended in PBS to a concentration of 1 x 108 cells/mL and 100 uL was 
used to measure EGFP fluorescence (ex. 488 nm, em. 510 nm). As a positive and negative control, 
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WT and hem1∆ cells were cultured for each experiment. Background auto- fluorescence of cells 
not expressing EGFP was recorded and subtracted from the EGFP expressing strains.  
3.5.2.4 Immunoblotting 
Yeast were cultured in 10 mL of SC media for 15 hours to a density of 1 OD600 nm /mL. 
Cells were harvested, washed in ice-cold Milli-Q water, and lysed in two pellet volumes of 
phosphate buffer supplemented with protease inhibitors as described previously102, 103. Lysis was 
achieved at 4 C using one pellet volume of zirconium oxide beads and a bead beater (Bullet 
Blender, Next Advance) on a setting of 8 for 3 minutes102, 103. Lysate protein concentrations were 
determined by the Bradford method (Bio-rad) and 12% tris-glycine gels (Invitrogen) were 
employed for SDS-PAGE102, 103. Anti-GFP rabbit or anti-GAPDH polyclonal antibodies (Genetex) 
and a goat anti-rabbit secondary antibody conjugated to a 680 nm emitting fluorophore (Biotium) 









CHAPTER 4. THE HEME BIOSYNTHESIS ENZYME, 5-
AMINOLEVULINIC ACID SYNTHASE (ALAS), AND GTPASES IN 
CONTROL OF MITOCHONDRIAL DYNAMICS AND ER CONTACT 
SITES, REGULATE HEME MOBILIZATION TO THE NUCLEUS 
 Introduction 
Heme (iron protoporphyrin IX) is an essential but inherently cytotoxic metallocofactor and 
signaling molecule3. As a cofactor, heme facilitates diverse processes that span electron transfer, 
chemical catalysis, and gas synthesis, storage and transport3. As a signaling molecule, heme 
regulation of an array of proteins, including transcription factors85, 104-106, kinases107, 108, ion 
channels109,  and micro RNA processing proteins110, collectively control pathways spanning iron 
homeostasis, oxygen sensing, the oxidative stress response, mitochondrial respiration and 
biogenesis, mitophagy, apoptosis, circadian rhythms, cell cycle progression, proliferation, and 
protein translation and degradation2, 4. Although essential for life, heme and its biosynthetic 
precursors may also act as toxins, necessitating that cells carefully handle the synthesis and 
trafficking of this compound. The hydrophobicity and redox activity of heme causes it to disrupt 
membrane structure, become mis-associated with certain proteins, and deleteriously oxidize 
various biomolecules8, 9. Porphyrin and porphyrinogen, heme biosynthetic intermediates, are 
photosensitizers that can catalyze the formation of reactive oxygen species like singlet oxygen111. 
Indeed, a number of diseases are associated with defects in heme management, including certain 
cancers112, cardiovascular disease113, aging and age-related neurodegenerative diseases7, 114, 115, 
porphyrias116, and anemias117. Despite the tremendous importance of heme in physiology, the 
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cellular and molecular mechanisms that govern the safe assimilation of heme into metabolism 
remain poorly understood.  
In eukaryotes, heme is synthesized via a highly conserved eight-step process. The first and 
the last three reactions in metazoans (first and last two in the yeast Saccharomyces cerevisiae) take 
place in the mitochondria and the remaining reactions occur in the cytosol23. The first committed 
step of heme synthesis is the condensation of glycine with succinyl coenzyme A to form 5-
aminolevulinic acid (ALA), which is catalyzed by ALA synthase (ALAS). ALA is then exported 
from the mitochondria into the cytosol where it is converted to coproporphyrinogen III in four 
steps by the enzymes porphobilinogen synthase (PBGS), hydroxymethylbilane synthase (HMBS), 
uroporphyrinogen III synthase (UROS), and uroporphyrinogen III decarboxylase (UROD). 
Coproporphyrinogen III is transported back into the mitochondria where it is converted to 
protoporphyrin IX (PPIX) in two steps by the enzymes coproporphyrinogen oxidase (CPOX) and 
protoporphyrinogen oxidase (PPOX). In the final step of heme synthesis, ferrochelatase (FECH) 
catalyzes the insertion of ferrous iron into PPIX to make heme.  
Interestingly, it was recently proposed that the mitochondrial heme biosynthetic enzymes, 
ALAS, PPOX, and FECH, form a super complex, or metabolon, that includes additional factors 
like iron and porphyrinogen transporters, and putative heme chaperones24, 118. The biochemical 
rationale for the assembly of a heme metabolon is that it would facilitate the channeling of 
potentially toxic reactive substrates, including porphyrinogen, porphyrin, and iron, for efficient 
production and trafficking of heme, thereby mitigating their ability to diffuse freely throughout the 
cell in an unproductive and deleterious manner. However, given this rationale, it is unclear why 
ALAS would interact with FECH in the heme metabolon if the product of the ALAS-catalyzed 
reaction, ALA, were not the immediate substrate for super-complex factors PPOX or FECH. 
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Rather, ALAS may play a regulatory role in heme synthesis or trafficking from FECH beyond 
simply catalyzing the production of ALA.  
Once heme is synthesized by FECH on the matrix side of the mitochondrial inner membrane 
(IM), it must be mobilized to heme proteins present in virtually every subcellular compartment2, 4. 
However, the specific factors that govern the transport and trafficking of heme to target 
hemoproteins are not well-understood2, 4. The current paradigm for subcellular heme trafficking is 
a sequential one in which mitochondrial heme transporters export heme into the cytosol, where it 
can then be distributed to other locales. The transporter-mediated sequential paradigm for heme 
distribution was established with the discovery of feline leukemia virus subgroup C cellular 
receptor 1b (FLVCR1b), the only putative mitochondrial heme transporter identified to date30. 
FLVCR1b was proposed to transport heme from the mitochondria into the cytosol on the basis that 
it was required for the hemoglobinization of developing erythrocytes and its ablation results in 
increased mitochondrial heme content30.  
An alternative, but far less studied potential mechanism for heme distribution is through 
mitochondrial membrane contact sites2, 4, 23. Endoplasmic reticulum (ER)-mitochondrial encounter 
structures (ERMES), one type of mitochondrial-ER contact site119, are highly dynamic tethers that 
physically link the mitochondrial and ER networks and have been proposed to play a role in the 
transfer of lipids and regulate iron homeostasis120-122. The frequency of ERMES is in part 
dependent on mitochondrial division119. ER tubules facilitate mitochondrial fission by wrapping 
around and constricting mitochondria in an ERMES-dependent fashion, thereby ensuring that the 
GTPase Dnm1 can oligomerize around a compressed mitochondrial outer-membrane to catalyze 
the scission of mitochondria123. Following fission, the GTPase Gem1 disengages ERMES to 
dissolve the ER-mitochondrial contact site124. As a consequence, ERMES assembly may be 
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dependent on mitochondrial fission and fusion dynamics119 . Indeed, mutants with defects in 
fission have increased ERMES foci, presumably because Dnm1-dependent fission is required for 
Gem1 to disengage ERMES119 . On the other hand, mutants with defects in fusion have decreased 
ERMES foci119, presumably due to the relative increase in mitochondrial fission over fusion.  
Herein, using genetically encoded ratiometric fluorescent heme sensors (HS1) targeted to 
the mitochondrial matrix, cytosol, or nucleus3, 87, 125, we developed a live-cell assay in yeast to 
monitor heme distribution kinetics to probe the role of ALAS and ER-mitochondrial contact sites 
and dynamics on subcellular heme trafficking. Surprisingly, we find that heme trafficking rates 
from the matrix side of the IM to the mitochondrial matrix and cytosol are similar, while trafficking 
to the nucleus is ~25% faster. We propose that the increased rate of nuclear heme trafficking is 
required for heme-based mitochondrial-nuclear retrograde signaling. These data also indicate that 
heme is distributed from the mitochondrial IM to other locales simultaneously via multiple parallel 
pathways rather than sequentially. Moreover, we discovered that the heme biosynthetic enzyme, 
ALAS, negatively regulates mitochondrial-nuclear heme trafficking, highlighting the close 
coordination of heme synthesis and trafficking. In addition, we identified GTPases that directly 
(Gem1) and indirectly (Dnm1 and Mgm1) regulate ERMES as being modulators of nuclear heme 
transport. Based on our results, we propose a model in which heme is trafficked via ER- 
mitochondrial membrane contact sites to other organelles such as the nucleus. In total, the 
development of a live cell assay for probing heme trafficking dynamics coupled with molecular 





4.2.1 Inter-compartmental heme transport kinetics 
In order to probe inter-compartmental heme trafficking in yeast, we developed an in vivo 
pulse-chase assay in which, upon the initiation of heme synthesis, heme mobilization into the 
mitochondrial matrix, cytosol and nucleus is monitored using genetically encoded ratiometric 
fluorescent heme sensors (HS1)3. HS1 is a tri-domain fusion protein consisting of a heme-binding 
moiety, the His/Met coordinating 4-alpha-helical bundle hemoprotein cytochrome b562 (Cyt 
b562), fused to a pair of fluorescent proteins, eGFP and mKATE2, that exhibit heme-sensitive and 
–insensitive fluorescence, respectively3. Heme binding to the Cyt b562 domain results in the 
quenching of eGFP fluorescence via resonance energy transfer but has little effect on mKATE2 
fluorescence. Thus, the ratio of eGFP fluorescence (ex: 488 nm, em: 510 nm) to mKATE2 
fluorescence (ex: 588 nm, em: 620 nm) reports cellular heme independently of sensor 
concentration, with the eGFP/mKATE2 ratio inversely correlating with heme binding to the 
sensor3. Throughout this study, unless otherwise noted, the sensor is expressed on a centromeric 
plasmid and the GPD promoter (pGPD) is used to drive HS1 expression.  
HS1 is targeted to the mitochondria and nucleus by appending N-terminal Cox4 
mitochondrial matrix or C-terminal SV40 nuclear localization sequences, respectively, as 
previously demonstrated3  and indicated herein by microscopy (Figure 4.1a) and organelle 
isolation and immunoblotting (Figures 4.1b and 4.1c). Indeed, the eGFP and mKATE2 
fluorescence emission of nuclear and mitochondrial-targeted HS1 overlay with 4,6-diamidino-2-
phenylindole (DAPI) stained nuclei and mitochondria, respectively (Figure 4.1a), using a labeling 
procedure that enables the selective visualization of mitochondrial or nuclear DNA by varying 



















Figure 4.1 - (a) The sub-cellular localization of HS1 was assessed by laser scanning 
confocal microscopy. Cells expressing nuclear or mitochondrial targeted HS1 were 
stained with DAPI to label nuclei or mitochondria and live cells were imaged. 
“Merge” is the merged images of fluorescence from the DAPI, EGFP, and mKATE2 
fluorescence channels. (b and c) Confirmation of mitochondrial (mito), nuclear (nuc), 




mitochondrial targeting sequences results in a diffuse pattern of expression throughout the cytosol 
of the cell. Moreover, isolation of nuclei and mitochondria and immunoblotting for HS1 further 
confirms the subcellular targeting of mitochondrial and nuclear HS1 (Figures 4.1b and 4.1c). HS1 
lacking the nuclear or mitochondrial targeting sequence is found primarily in cytosolic fractions, 
i.e. post-nuclear (PNF) and post-mitochondrial (PMF) fractions and is not present in significant 
amounts in mitochondrial or nuclear fractions (Figure 4.1b and 4.1c).  
It is possible that a small fraction of mitochondrial or nuclear-targeted sensor may be present 
in the cytosol and confound analysis of sub-compartmental heme. In order to assess if this were 
the case, we permeabilized heme-deficient cells lacking HEM1, which encodes the first enzyme in 
the heme biosynthetic pathway, ALAS, with digitonin, a mild non-ionic detergent that selectively 
permeabilizes the plasma membrane but not mitochondrial or nuclear membranes, and treated cells 
with heme. As indicated in Figure 4.2, only cells expressing cytosolic HS1 exhibited a significant 
heme-dependent reduction in eGFP/mKATE2 fluorescence ratio, with no significant perturbations 
to the fluorescence of mitochondrial and nuclear-targeted HS1. These data indicate that 
mitochondrial and nuclear-targeted HS1 is unresponsive to cytosolic heme. Thus, altogether, our 
data indicate that cytosolic, nuclear, and mitochondrial heme can be robustly monitored in vivo 
using HS1.  
 
 
Figure 4.2 - Validation that mitochondrial and nuclear-targeted HS1 does not respond to 
cytosolic heme. hem1D cells expressing cytosolic, nuclear, or mitochondrial HS1 were 
permeabilized with digitonin, a plasma membrane specific permeabilizing agent, and incubated 
with the indicated concentration of heme. Fluorimetry data represent the mean ± SD of three 
biological replicates and the statistical significance relative to no heme treatment is indicated by 
asterisks using an ordinary one-way ANOVA with Dunnett’s post-hoc test. * p < 0.00001.  
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Inter-compartmental heme trafficking rates are monitored by: a. inhibiting heme synthesis 
with 500 µM succinylacetone (SA), an inhibitor of PBGS, for ~16 hours in sensor expressing cells; 
b. removing the block in heme synthesis by re-suspending cells into media lacking SA; and c. 
monitoring the time-dependent change in the eGFP/mKATE2 ratio (R) of HS1 localized to 
different locations upon the re-initiation of heme synthesis (Figures 4.3a-d). As described in the 
Materials and Methods section and Equation 1, the fractional saturation of HS1 (% Bound) is 
calculated by considering R relative to the HS1 fluorescence ratio when the sensor is 0% bound 
(Rmin) and 100% bound (Rmax) (Figure 4.3e), which are parameters derived from parallel 
cultures of cells continually maintained in media with and without SA3, 125 (Figures 4.3a-c).  
[% Bound] = ([R – Rmin] / [Rmax – Rmin])*100 Equation 1  
In order to confirm the SA-mediated block in heme synthesis, we determined that SA-
conditioned wild type (WT) cells exhibit intracellular heme concentrations128 (Figure 4.4a) and 
HS1 eGFP/mKATE2 ratios3 (Figure 4.4b) similar to hem1D cells, which cannot make heme due 
to the deletion of the first enzyme in the heme biosynthetic pathway, ALAS3. SA pre-conditioned 
cells shifted to media lacking SA exhibit a time-dependent decrease in HS1 eGFP/mKATE2 ratio 
(Figures 4.3a-c) in the cytosol, nucleus, and mitochondria, which is characteristic of increased 
heme loading of the sensor due to newly synthesized heme (Figure 4.3e). By contrast, the HS1 
eGFP/mKATE2 ratios in cells continuously maintained with or without SA remain 
characteristically high or low, respectively (Figures 4.3a-c), albeit there are some modest time 
dependent changes for currently unknown reasons.  
The change in sensor heme saturation (% Bound) following the re-initiation of heme 
synthesis reveals three distinct phases: a lag phase, an exponential phase, and a stationary phase 














Figure 4.3 - Inter-compartmental heme trafficking dynamics as measured by heme sensor HS1. 
WT cells expressing HS1 in the cytosol (a), nucleus (b), or mitochondria (c) were depleted of 
heme using 500 µM succinylacetone (SA), the heme biosynthetic inhibitor and, upon the re-
initiation of heme synthesis, the rates of heme trafficking to the indicated subcellular locations 
were monitored by measuring the time-dependent change in sensor eGFP/mKATE2 
fluorescence ratio (d) or the fractional saturation of HS1 (e), which is determined using 
equation 1 and the “raw” fluorescence ratio values in a-c. The data in d and e are fit to equation 
2. (f) The rate constants for cytosolic, nuclear, and mitochondrial heme trafficking, which were 
extracted from fits to the data represented in panel “e”, from triplicate cultures in nine 
independent experimental trials are shown. The statistical significance relative to the rate 
constants for cytosolic heme trafficking is indicated by an asterisk using an ordinary one-way 
ANOVA with Dunnett’s post-hoc test. * p < 0.0001. The heme trafficking kinetics data shown 
in all figure panels represent the mean ± SD of independent triplicate cultures.  
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block in heme synthesis and re-initiate heme production. The exponential phase represents the rate 
of heme binding to HS1, which is governed by the relative rates of heme synthesis and trafficking 
to the different subcellular locations. However, when comparing HS1 heme saturation kinetics 
between different compartments within a given strain, the data strictly represent the inter-
compartmental heme trafficking rates since the contribution from heme synthesis is a constant. 
Indeed, expression of cytosolic, nuclear, or mitochondrial HS1 does not perturb heme synthesis 
(Figure 4.5a). Since the final step of heme synthesis occurs with the insertion of ferrous iron into 
protoporphyrin IX, a reaction catalyzed by FECH at the matrix side of the mitochondrial IM, the 
heme trafficking rates reflect heme mobilization from the mitochondrial IM to the matrix, cytosol, 
or nucleus. Given the high affinity of HS1 for both ferric and ferrous heme, KDIII = 10 nM and KDII 
< 1 nM at pH 7.03, and the negligible differences in FRET between eGFP and ferric and ferrous 
heme3, we cannot resolve the two oxidation states of heme. The stationary phase represents the 
maximum limiting heme saturation of the sensor 4 hours after alleviating the SA-mediated block 
in heme synthesis and typically spans ~70-100%.  
The kinetics of heme binding to HS1 (Figure 4.3e) can be fit to the logistic function 
described in Equation 2, where [A] is the maximal value of HS1 fractional saturation (amplitude), 
k is the first order rate constant (min-1), t is the time (min), and t1/2 is the midpoint of the transition. 
The lag time can be defined as t1/2 – 2/k  129.  
{% Bound(t) = [A] / (1+e-
k(t-t1/2)) Equation 2  
Quite surprisingly, the kinetics of HS1 heme saturation indicate that heme trafficking to 
locations as disparate as the mitochondrial matrix, cytosol, and nucleus are similar, but with heme 
transport to the nucleus exhibiting a ~25% increase in rate constant relative to heme transport to 
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the cytosol and mitochondrial matrix (Figures 4.4e and 4.4f). This observation is highly 







) were found to be 0.030±.005 min-1, 0.039±.003 min-1, and 
0.031±.004 min-1, which are the average ± standard deviation from triplicate biological samples 
over nine independent experimental trials (Figure 4.3f). Importantly, in every trial conducted, 






. In addition, fitting of the “raw” unprocessed sensor ratios, R, reveal a 
similar trend in the relative rates of heme binding to HS1, with k
NUC (0.039±.003 min-1) > k
CYTO 
(0.026±.001 min-1) = k
MITO (0.027±.002 min-1) (Figure 4.4d), albeit the absolute rate constants 
are different when fitting processed “% Bound” traces. This is due to the fact that, for reasons not 
completely understood, there are fluctuations in Rmin and Rmax over the course of a heme 
trafficking dynamics experiment (Figures 4.3a-c). Although the qualitative trends are similar 
between analyzing changes in “% Bound” and “R”, “% Bound” is the preferred metric since it 
accounts for non-heme dependent changes in sensor fluorescence ratio, i.e. fluctuations in Rmin 
or Rmax over the course of an experiment.  
 
 
Figure 4.4 - A 500 μM dose of succinylacetone (SA) depletes (a) total heme and (b) heme-
loading of the heme sensor, HS1, to values similar to heme deficient hem1∆ cells, which 
lack the 1st enzyme in the heme biosynthetic pathway. All data represent the mean ± SD 









The remarkable similarity in the observed rates of heme trafficking to different locales 
might suggest that heme binding to the sensor is rate limiting. However, measurements of the rate 
of heme binding to HS1 in cell lysates of WT cells depleted of heme indicate that heme binding to 
the cytosolic, mitochondrial, and nuclear sensors occurs in less than 2 minutes (Figure 4.5c), 
which is much faster than the ~90-120 minutes it takes 50% of: (i) total cellular heme to be 
synthesized (Figure 4.5a) or (ii) HS1 to become heme saturated in the SA pulse-chase assays 
(Figure 4.3). 
Figure 4.5 - Heme sensor expression does not perturb (a) the rates of heme synthesis or 
(b) heme trafficking dynamics to the cytosol. (a) WT cells expressing GPD driven 
cytosolic (Cyto, black), mitochondrial (Mito, blue), or nuclear (Nuc, green) HS1, or empty 
vector (EV, grey) were heme depleted with 500 μM succinylacetone (SA) for 15 hours and 
then the cells were resuspended in fresh SC-LEU media lacking SA, where the re-synthesis 
of heme was monitored by harvesting 2 x 108 cells every hour and analyzed for heme 
content as described in the Methods section. (b) The heme trafficking dynamics assay was 
conducted on cells expressing ADH (black), TEF (green) and GPD (blue) driven cytosolic 
HS1. Despite the ~10-fold increase in HS1 expression between ADH and GPD promoters, 
as measured by mKATE2 fluorescence in the right panel (c), cytosolic heme trafficking 
rates are virtually identical. All data represent the mean ± SD of triplicate cultures. (d) 
Heme binding kinetics of cytosolic, nuclear, and mitochondrial-targeted HS1. 
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In order to rule out any potential artifacts associated with heme sensor expression itself 
perturbing the observed heme trafficking rates, we expressed cytosolic HS1 under the control of 
weak (pADH1), medium (pTEF1), or strong (pGPD) promoters and found that the observed heme 
trafficking rates were not affected despite a nearly 10-fold span in sensor expression (Figure 4.5b). 
These results are consistent with our previous findings that sensor expression does not perturb 
heme homeostasis or otherwise affect cell viability3. Analogous experiments titrating expression 
with mitochondrial and nuclear sensors could not be completed due to low sensor expression and 
correspondingly low sensor signal to noise ratios associated with pTEF1- or pADH1-driven 
expression. Altogether, our data indicate that the SA-pulse chase assays can be used to measure 
the rates of heme trafficking to multiple compartments and that the rates of mitochondrial-nuclear 
heme trafficking are 25% faster relative to heme trafficking to the cytosol and mitochondria.  
In order to rule out that the observed rates of inter-compartmental heme trafficking are due 
to artifacts associated with SA treatment, we re-capitulated the in vivo heme transport assay in 
hem1D cells pulsed with a bolus of ALA to initiate heme synthesis. As shown in Figure 4.6a, 
heme trafficking kinetics to the matrix, cytosol, and nucleus in hem1D cells are qualitatively 
similar to the results obtained from the SA pulse-chase assay using WT cells (Figures 4.3e and 
4.3f), with transport to the nucleus (k
NUC = 0.059±.005 min-1) being faster than to the cytosol 
(k
CYTO = 0.030±.003 min-1) and mitochondrial matrix (k
MITO = 0.028±.004 min-1) (Appendix 
Table 1). Notably, the rate enhancement for heme trafficking to the nucleus is greater in magnitude 
in hem1D cells pulsed with ALA (k
NUC / k
CYTO = 2.0 ± 0.1; Figure 4.6a) than in WT cells that have 
the SA- mediated block in heme synthesis alleviated (k
NUC / k
CYTO = 1.3 ± 0.2); Figures 4.3e and 
4.3f), one-way ANOVA, p < .01, n = 3. This observation suggests that either the use of SA 
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suppresses nuclear heme trafficking or that the first enzyme in the heme biosynthetic pathway, 
ALAS, is a negative regulator of mitochondrial-nuclear heme trafficking. 
4.2.2 ALA synthase (ALAS) regulates mitochondrial-nuclear heme trafficking 
In order to determine if ALAS plays a role in regulating heme distribution kinetics, we 
monitored inter-compartmental heme trafficking kinetics directly between WT and hem1D cells. 
Towards this end, we monitored heme distribution dynamics in WT and hem1D cells that had SA-
inactivated PBGS pulsed with 500 µM porphobilinogen (PBG), the product of the reaction 
catalyzed by PBGS, to re-initiate heme biosynthesis. As with the SA-pulse chase experiment in 
WT cells (Figures 4.3e and 4.3f), the rates of heme trafficking to the nucleus are greater than 
trafficking to the cytosol and mitochondrial matrix in SA-treated WT cells pulsed with PBG 
Figure 4.6 - ALA synthase (Hem1) negatively regulates mitochondrial-nuclear heme 
trafficking. (a) hem1D cells expressing HS1 in the cytosol (black), nucleus (green), or 
mitochondria (blue) were pulsed with a bolus of ALA to initiate heme synthesis and the rates 
of heme trafficking to the indicated subcellular locations were monitored by measuring the 
fractional saturation of HS1 over time. The reported averages and standard deviations are 
from three independent cultures. (b) WT and hem1D cells expressing sensor were pre-
cultured with succinylacetone (SA) to deplete heme and pulsed with a bolus of 
porphobilinogen (PBG) to re-initiate heme synthesis. The rates of heme trafficking to the 
indicated subcellular locations were monitored by measuring the fractional saturation of HS1 
over time. The indicated rate constants and data are the mean and standard deviations from 
independent triplicate cultures. (c) Analysis of total heme in WT and hem1 strains treated 
with succinylacetone (SA), aminolevulinic acid (ALA), or porphobilinogen (PBG). The data 





CYTO = 1.5 ± 0.2 vs. k
MITO / k
CYTO = 1.1 ± 0.2; one-way ANOVA, p = 0.05, 
n = 3. Strikingly, in SA-treated hem1D cells pulsed with PBG, heme trafficking to the nucleus is 
significantly augmented relative to WT cells (Figure 4.6b); k
NUC / k
CYTO = 2.0 ± 0.1 in hem1D cells 
vs. k
NUC / k
CYTO = 1.5 ± 0.2 in WT cells, one-way ANOVA, p = 0.05, n = 3. The relatively low 
final fractional saturation of the sensor using PBG can be attributed to the fact that heme-deprived 
cells are less efficient at using PBG to make heme (Figures 4.6c). WT and hem1D cells treated 
with SA and PBG make roughly ~33% of the heme that WT or hem1D cells treated with ALA 
make. Thus, it is all the more impressive that in hem1D cells pulsed with PBG, the nuclear sensor 
is completely saturated with heme, unlike in WT cells. Importantly, hem1D cells do not have a 
defect in synthesizing heme when supplied with PBG (Figures 4.6c). Thus, in total, our results 
demonstrate that ALAS negatively regulates mitochondrial-nuclear heme trafficking without 
impacting downstream steps of heme synthesis. 
4.2.3 Gem1, a GTPase that regulates ERMES, negatively modulates mitochondrial-nuclear 
heme trafficking 
Since the final step of heme synthesis occurs on the matrix side of the mitochondrial IM, our 
expectation was that heme would sequentially populate sensors in the mitochondrial matrix, 
cytosol, and nucleus. However, the data indicate that once heme is synthesized in the mitochondrial 
IM, it disperses to multiple compartments almost simultaneously, suggesting the existence of 
parallel routes for heme mobilization to distinct locales. Moreover, surprisingly, mitochondrial-
nuclear heme trafficking occurs ~25% faster than to other compartments. Since mitochondria form 
dynamic physical contacts with other organelles like the ER119, 121, we surmised that one potential 
route for the distribution of mitochondrial heme to other compartments like the nucleus could be 
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through such membrane contact sites. In this scenario, heme may be trafficked to the nucleus via 
the ER network, bypassing the cytosol, thereby accounting for the increased rate of nuclear heme 
trafficking. To test this idea, we probed heme distribution rates in deletion mutants with increased 
or decreased ER-mitochondrial contact sites.  
The ER-mitochondrial encounter structure (ERMES), which constitutes one type of physical 
interface between these organelles, is a complex that consists of four proteins, Mmm1, Mdm10, 
Mdm12, and Mdm34130-133. Mmm1 and Mdm10 are anchored in the ER and outer mitochondrial 
membranes, respectively, while the cytosolic protein Mdm12 and the mitochondrial protein 
Mdm34 help to bridge the interaction between Mmm1 and Mdm10 in the ERMES complex130-133. 
The absence of any single ERMES protein results in dissociation of the entire complex, 
compromising the formation of ER-mitochondrial contact sites, mitochondrial division and 
morphology 38-41,134. ERMES is negatively regulated by Gem1, which is a mitochondrial outer-
membrane localized GTPase that disengages ERMES after mitochondrial division124, 135.  
As shown in Figure 4.7a, gem1D cells, which have increased ERMES, exhibit a significantly 
increased rate of mitochondrial-nuclear heme trafficking, with minimal impact on heme trafficking 
to the cytosol and mitochondrial matrix; k
NUC / k
CYTO = 1.45 ± 0.05 in gem1 cells vs. k
NUC / k
CYTO 
= 1.1 ± 0.1 in WT cells, one-way ANOVA, p < 0.01, n = 3. These data suggest that more stable 
ER-mitochondrial contacts increase the flow of heme to the nucleus. However, in ERMES 
compromised mdm12D and mdm10D strains, heme trafficking rates are unaffected (Figures 4.8b 
and 4.8c).  
ERMES has been implicated in the transfer of lipids, e.g. phosphatidylserine (PS), between 
the ER and mitochondria131, 136, 137. PS, an ER-synthesized lipid, is a precursor for the synthesis of 
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phosphatidylethanolamine (PE) in the mitochondria, which itself is a precursor for 
phosphatidylcholine (PC) synthesis back in the ER. Both phospholipids are constituents of 
mitochondrial membranes138. In order to rule out confounding contributions that may arise due to 
general defects in PE or PC in ERMES mutants, we tested heme trafficking dynamics in psd1D 
cells, which lack PS decarboxylase, the enzyme that catalyzes the formation of PE. As shown in 
Figure 4.7d, there are no defects in heme trafficking dynamics in psd1D cells.  
ERMES are highly dynamic and sensitive to the presence of mitochondrial- vacuolar contact 
sites, termed vCLAMPs for vacuolar and mitochondrial patches. Like ERMES, vCLAMPs are 
important for lipid and metabolite trafficking between mitochondria and the endomembrane 
system119. The absence of one causes expansion of the other and ablation of both ERMES and 
vCLAMPs is lethal119. We therefore sought to determine if a defect in vCLAMPs also increases 
mitochondrial-nuclear heme trafficking rates as in gem1D cells, which have an increased number 
of ERMES foci like vCLAMP mutants. However, neither vps39D nor ypt7D cells (Figures 4.7e 
and 4.7f), which lack a component of the HOPS (‘homotypic fusion and protein sorting’) tethering 
complex (Vps39) and the Rab GTPase (Ypt7), core components of vCLAMPs119, 121, 139, exhibit 
defects in heme distribution kinetics. We conclude that Gem1, but not the core components of 
ERMES and vCLAMP machineries, regulates mitochondrial-nuclear heme trafficking.  
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4.2.3.1 Mgm1 and Dnm1 are positive and negative regulators of mitochondrial-nuclear heme 
trafficking, respectively 
The mitochondrial network is highly dynamic and is constantly remodeled by fusion and 
fission events. The dynamic behavior of the mitochondrial network is thought to be responsible 
for the proper cellular distribution and trafficking of a number of mitochondrial-derived 
metabolites, including various lipids140, 141. Given that we identified Gem1, an ERMES regulating 
GTPase that modulates mitochondrial-nuclear heme trafficking, and that ERMES are associated 
Figure 4.7 - Gem1 is a negative regulator of mitochondrial-nuclear heme trafficking. Inter- 
compartmental heme trafficking rates were monitored using the SA pulse- chase assay for 
(a) gem1D, (b) mdm12D, (c) mdm34D, (d) psd1D, (e) ypt7D, and (f) vps39D cells. The data 
represent the mean ± SD of independent triplicate cultures and the kinetic parameters 
derived from the fits to the data using equation 2 are indicated in Appendix Table 1.  
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with sites of mitochondrial division and their frequency can be impacted by mitochondrial fission 
and fusion dynamics119, 123, we reasoned that other GTPases that regulate mitochondrial dynamics 
might regulate mitochondrial-nuclear heme trafficking.  
4.2.3.2 Mitochondrial Fusion 
Mitochondrial fusion occurs at both the IM and OM in coordinated but physically separable 
steps. In yeast, a pair of dynamin-like GTPases, Fzo1 and Mgm1, drive OM and IM fusion, 
respectively142. In order to coordinate double membrane fusion, a protein spanning the 
mitochondrial intermembrane space, Ugo1, physically tethers Fzo1 and Mgm1. Mgm1 exists in 
equilibrium between long (l-Mgm1) and short (s-Mgm1) isoforms, which are generated upon 
proteolytic cleavage by the rhomboid protease Pcp1143, 144. It is thought that l-Mgm1, which has 
an inactive GTPase domain, acts as an anchor in the IM and interacts with and activates the GTPase 
activity of s-Mgm1 in the intermembrane space to promote IM fusion143, 144.  
Relative to WT cells, the mgm1D strain exhibits a marked defect in nuclear heme 
trafficking, with a > 50% reduction in HS1 heme loading (Figure 4.8a). On the other hand, heme 
trafficking to the mitochondrial matrix and cytosol is not significantly impacted in mgm1D cells. 
Interestingly, heme availability to HS1 in the nucleus is similar between WT and mgm1D cells 
after prolonged growth, ~16 hours, suggesting that there are compensatory mechanisms that 
overcome the defects in nuclear heme trafficking in mgm1D cells (Figure 4.9a). The rate of heme 
synthesis is un-perturbed by loss of Mgm1, indicating that the nuclear trafficking defect is not 
related to general defects in heme synthesis (Figure 4.9b). The effects of the mgm1D mutant on 
nuclear heme trafficking is not due to the loss of mitochondrial DNA, which occurs with high 
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frequency in mgm1D cells; rho0 cells that lack mitochondrial DNA do not exhibit an appreciable 
defect in nuclear heme trafficking (Figure 4.8b).  
In order to determine if the nuclear heme trafficking defect observed in mgm1D cells is 
specific to Mgm1 or more generally due to ablation of mitochondrial fusion, we tested other 
essential components of the mitochondrial fusion machinery, including Fzo1 and Ugo1. 
Interestingly, the fzo1D (Figure 4.8c) and ugo1D (Figure 4.8d) mutants do not exhibit defects in 
mitochondrial-nuclear heme trafficking, indicating that general perturbations to mitochondrial 
fusion do not impact nuclear heme trafficking.  
Since the regulation of nuclear heme transport is specific to Mgm1, we tested a mutant 
with altered Mgm1 function. pcp1D cells are defective in fusion due to an inability to 
proteolytically convert l-Mgm1 to its short isoform. As seen in Figure 4.8e, pcp1D cells do not 
exhibit a defect in mitochondrial-nuclear heme trafficking. These data indicate that full-length 
Mgm1 regulates mitochondrial-nuclear heme transport, but the short Mgm1 isoform is 
dispensable.  
In addition to mediating mitochondrial inner-membrane fusion, Mgm1 is also responsible 
for maintaining the proper folding and structure of cristae in the inner- membrane145. In order to 
determine if the defect in mitochondrial- nuclear heme trafficking in mgm1D cells is related to 
defects in inner-membrane architecture, we determined if heme trafficking was altered in a mutant 
with a defect in the mitochondrial contact site and cristae organizing system (MICOS). Mic60 is a 
core component of MICOS and is required for proper inner-membrane folding146. As seen in 
Figure 4.8f, mic60D cells do not exhibit a defect in mitochondrial-nuclear heme trafficking. 
Altogether, our data strongly suggest that full length Mgm1, but not mitochondrial fusion or inner-
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membrane architecture per se, positively regulates mitochondrial-nuclear heme trafficking 









4.2.3.3 Mitochondrial Fission 
  In yeast, mitochondrial fission involves recruitment of the GTPase Dnm1 to its receptor 
Fis1 on the mitochondrial outer-membrane (OM), which is dependent on paralogous adapter 
proteins Mdv1 and Caf4142. Once assembled and oligomerized around the OM, Dnm1 drives the 
GTP-dependent constriction and scission of mitochondrial tubules.  
Figure 4.8 - Mgm1 is a positive regulator of mitochondrial-nuclear heme trafficking. 
Inter- compartmental heme trafficking rates were monitored using the SA pulse- chase 
assay for (a) mgm1D, (b) rho0, (c) fzo1D, (d) ugo1D, (e) pcp1D cells, and (f) mic60D cells. 
The data represent the mean ± SD of independent triplicate cultures and the kinetic 
parameters derived from the fits to the data using equation 2 are indicated in Appendix 
Table 1.  
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Relative to WT cells, the dnm1D strain exhibits an increase in the rate of heme trafficking 
to the mitochondrial matrix, cytosol, and nucleus, with the most pronounced effect on nuclear 
heme trafficking; k
NUC / k
CYTO = 1.5 ± 0.1 in dnm1 cells vs. k
NUC / k
CYTO = 1.2 ± 0.1 in WT cells, 
one-way ANOVA, p < 0.01, n = 3 (Figure 4.10a). After prolonged growth, 16 hours, heme 
availability to HS1 in all three compartments is similar between WT and dnm1D cells (Figure 
4.9a). Additionally, the rate of heme synthesis is unperturbed by loss of Dnm1, indicating that the 
increase in the rate of heme trafficking is not due to an increase in the rate of heme synthesis 
(Figure 4.9c).  
 
Figure 4.9 - The effects of mgm1∆ and dnm1∆ on steady-state HS1 heme loading and heme 
synthesis. (a) Cytosolic (Cyto), nuclear (Nuc), or mitochondrial (Mito) HS1 expressed in WT 
(black, gray), dnm1∆ (dark and light green), and mgm1∆ (dark and light blue) cells were 
cultured for 16 hours in SCE-LEU media with (+SA, dark colors) or without (-SA, light colors) 
500 μM succinylacetone (SA). Following growth and washing cells with ultrapure water, HS1 
sensor fluorescence was measured in a 100 μL suspension of 5 OD’s/mL in PBS. (b and c) The 
rates of heme synthesis were measured in (b) mgm1∆ and (c) dnm1∆ cells by first heme 
depleting cells with 500 μM SA for 15 hours and then re-initiating heme synthesis by re-
suspending cells in media lacking SA. 2 x 108 cells were harvested every hour and analyzed for 















In order to determine if the increased rate of nuclear heme trafficking observed in dnm1D 
cells is specific to Dnm1 or more generally due to ablation of mitochondrial fission, we tested 
other essential components of the mitochondrial fission machinery, including Fis1, Caf4, and 
Mdv1. Interestingly, fis1D (Figure 4.10b) and caf4D mdv1D (Figure 4.10c) mutants do not exhibit 
perturbations to mitochondrial-nuclear heme trafficking. Altogether, our data indicate that Dnm1, 
Figure 4.10 - Dnm1 is a negative regulator of mitochondrial-nuclear heme trafficking. 
Inter- compartmental heme trafficking rates were monitored using the SA pulse- chase 
assay for (a) dnm1D , (b) fis1D , and (c) caf4D mdv1 cells, and (d) mgm1D dnm1D 
cells. Fluorimetry data represent the mean ± SD of three independent cultures and the 
kinetic parameters derived from the fits to the data using equation 2 are indicated in 
Appendix Table S1.  
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but not mitochondrial fission per se, negatively regulates mitochondrial-nuclear heme trafficking 
(Figure 4.10).  
We next sought to determine the consequence of ablating both Mgm1 and Dnm1 on 
mitochondrial-nuclear heme trafficking. Most interestingly, mgm1D dnm1D double mutants 
exhibit WT-like rates of mitochondrial-nuclear heme trafficking (Figure 4.10d). Therefore, Mgm1 
and Dnm1 regulate heme trafficking in opposing directions with similar magnitude.  
4.2.4 Mgm1 and Dnm1 regulate the activation of the nuclear heme-regulated transcription 
factor Hap1.  
Given that Mgm1 and Dnm1 are positive and negative regulators of mitochondrial-nuclear 
heme trafficking, we sought to determine their impact on the activation of the heme-regulated 
transcription factor Hap1. Heme binding to Hap1 alters its ability to promote or repress 
transcription of a number of target genes, including CYC1, which Hap1 positively regulates3, 85, 
147-149. In order to probe Hap1 activity, we used a transcriptional reporter that employs the promoter 
of a Hap1 target gene, pCYC1, driving the expression of enhanced green fluorescent protein 
(eGFP)3. Cells were first pre-cultured with 500 µM SA for 16 hours and, following this initial 
growth period, the SA conditioned cells were diluted into fresh media with (+) or without (-) 500 
µM SA for an additional 4 hours. A parallel set of cells continuously grown without SA (-) was 
cultured to provide a read out of steady-state Hap1 activity. As demonstrated in Figure 4.12a, not 
only is steady-state Hap1 activity greatly diminished in a heme deficient hem1D mutant and with 
SA conditioning (+), as expected, loss of Mgm1 results in a nearly 3-fold reduction in Hap1 
activity. On the other hand, loss of Dnm1 does not affect basal Hap1 activity (Figure 4.11a, -). 
Since basal Hap1 activity in WT cells may already reflect heme saturation of Hap1, it is possible 
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that the effects of the loss of Dnm1 are masked. To address this, we also measured Hap1 activity 
under non-heme saturating conditions in which Hap1 activity was probed just 4 hours after 
alleviation of the SA-mediated block in heme synthesis. Under these conditions, dnm1D cells have 
increased Hap1 activity and mgm1D cells exhibit diminished Hap1 activity relative to WT cells 
(Figure 4.11a, D).  
In order to determine if the effects of Hap1 activation by Mgm1 and Dnm1 are unique to 
these factors, and not general fusion and fission per se, we analyzed Hap1 activity in fis1D and 
fzo1D cells. While steady-state Hap1 activity is diminished in both fis1D and fzo1D strains (Figure 
4.11b, -), Hap1 activity probed 4 hours after alleviation of the SA mediated block in heme 
synthesis results in Hap1 activity that is similar to WT cells (Figure 4.11b, D). Altogether, the 
positive and negative effects of Mgm1 and Dnm1 on nuclear heme trafficking, respectively, 
correlate with their effects on heme activation of Hap1, and appear to be distinct from their roles 
in fusion and fission dynamics (Figures 4.11a and 4.11b, D).  
We next addressed if Mgm1- and Dnm1-regulated nuclear heme trafficking affected heme-
dependent growth of cells. Towards this end, we determined the degree to which heme depleted 
cells pre-cultured with SA were able to recover in media lacking SA (GDSA) relative to cells 
continually maintained with (G+SA) or without SA (G-SA). As such, the “% Recovery” can be 
calculated using Equation 3:  
[% Recovery] = ([GDSA – G+SA] / [G-SA – G+SA])*100 Equation 3 Equation 1  
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Interestingly, as seen in Figure 4.11c, after 12 hours of growth, mgm1D cells are better 
able to tolerate the re-synthesis of heme compared to WT cells. The superior ability of mgm1D 
cells grown with SA to recover in media lacking SA is not phenocopied by another fusion mutant, 
fzo1D, suggesting that Mgm1-mediated nuclear heme trafficking may be growth inhibitory. On the 
other hand, fission mutants, dnm1D and fis1D have WT levels of recovery from the alleviation of 
the SA-mediated block in heme synthesis, presumably because sufficient heme is accessing the 
nucleus to control growth in a WT-like manner. After 24 hours, all cells achieved maximal growth 
recovery after re- initiation of heme synthesis (Figure 4.11c). In total, our data suggests that Mgm1 
is not only a positive regulator of mitochondrial-nuclear heme trafficking, but this trafficking is 
negatively correlated with tolerance to the re-initiation of heme synthesis.  
Figure 4.11 - Mitochondrial-nuclear heme trafficking regulates Hap1 activity and sensitivity 
to new heme synthesis. (a and b) Hap1p activity in the indicated strains as measured by a 
transcriptional reporter that uses eGFP driven by the CYC1 promoter, a Hap1p target gene. We 
report HAP1 activity in cells that were untreated with succinylacetone (SA) (-), treated with 
500 µM SA (+), or were treated with 500 µM SA followed by shifting to media lacking SA for 
4 hours (D ). Fluorimetry data represent the mean ± SD of three biological replicates; *p<0.001 
using a one-way ANOVA with Bonferroni’s post-hoc test. Asterisks not associated with an 
indicated pair-wise comparison were compared to WT untreated samples (-SA). (c) Cellular 
tolerance to new heme synthesis. Cells were pre- cultured overnight with or without 500 µM 
SA then allowed to recover on media without SA. Sensitivity to new heme synthesis was scored 
as “% Recovery”, described in Equation 3, by comparing growth to cells continually maintained 
in media without SA and with SA. Growth data represent the mean ± SD of three biological 





Herein, we developed a live-cell assay in yeast to monitor inter-compartmental heme 
transport dynamics between the mitochondrial IM and the mitochondrial matrix, cytosol, and 
nucleus in order to identify new aspects of heme trafficking and distribution. S. cerevisiae is an 
unparalleled model system to probe heme distribution dynamics because, unlike many eukaryotes, 
including mammalian cells, yeast lacking heme can be made viable if supplemented with 
ergosterol and oleic acid. Thus, heme trafficking and transport dynamics can be monitored without 
a background associated with pre- existing heme pools. By integrating the heme trafficking 
dynamics assay with yeast molecular genetics approaches, we have for the first time probed the 
biodistribution of heme as it is being synthesized in live cells and identified new factors that 
regulate heme trafficking, including the heme biosynthetic enzyme, ALAS (Hem1) (Figure 4.6), 
and GTPases that regulate ERMES, Gem1 (Figure 4.7a), and mitochondrial fusion, Mgm1 
(Figure 4.8a), and fission, Dnm1 (Figure 4.10). As discussed below, our results provide 
fundamental new insights into heme trafficking and signaling.  
The heme trafficking kinetics data challenge the current conceptual paradigm for the cellular 
distribution of mitochondrial heme. The discovery of the first putative mitochondrial heme 
exporter, Flvcr1b, the only mitochondrial heme transporter identified to date30, has often been 
taken to imply that heme distribution is sequential, with heme first transported into the cytosol 
followed by its mobilization to other organelles2, 4, 87. However, we found that heme distribution 
to the mitochondrial matrix, cytosol, and nucleus occurs virtually simultaneously, suggesting the 
existence of parallel pathways for heme mobilization to different cellular locales (Figures 4.3 and 
4.6). Thus, there must be additional factors and mechanisms that distribute heme, in addition to 
mitochondrial heme transporters that export heme into the cytosol. Our data suggest that GTPases 
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that regulate mitochondrial dynamics and ER contact sites constitute novel components of a new 
heme distribution network.  
We propose that the 25% faster rate of heme trafficking to the nucleus relative to the cytosol 
or mitochondrial matrix (Figure 4.3f) is suggestive of heme acting as a mitochondrial-nuclear 
retrograde signal that enables cells to adapt metabolism and physiology for life with heme and 
properly functioning mitochondria. Indeed, the activity of the heme regulated nuclear transcription 
factor, Hap1, correlates with perturbations to mitochondrial-nuclear heme trafficking caused by 
deletion of Mgm1 or Dnm1, positive and negative regulators of heme trafficking, respectively 
(Figure 4.11a). Rather surprisingly, as part of this heme-based retrograde signal, diminished 
mitochondrial-nuclear heme trafficking in mgm1D cells correlate with enhanced cellular growth in 
response to the re-initiation of heme synthesis (Figure 4.11c). This may be due to the detrimental 
effects of potentially cytotoxic levels of heme accumulating in the nucleus. Indeed, as an iron 
containing, redox active, hydrophobic molecule, heme may catalyze spurious redox reactions that 
promote oxidative damage in the nucleus2-4. Alternatively, heme may act as an anti-proliferation 
signal through its ability to act as a transcriptional regulator by binding G-quadruplexes in DNA150-
152 or controlling transcription via Hap1 and the HAP complex147-149, 153, 154. Taken together, our 
results indicate that the relatively fast rate of nuclear heme acquisition may serve an important role 
in mitochondrial-nuclear retrograde signaling.  
Interestingly, we find that the first enzyme in the heme biosynthetic pathway, ALAS, 
negatively regulates mitochondrial-nuclear heme trafficking (Figure 4.6). This result may explain 
the functional role of a proposed heme biosynthetic supercomplex, or “heme metabolon”, in the 
IM. The heme metabolon includes the first and last enzymes in the heme synthesis pathway, ALAS 
and FECH, as well as mitochondrial iron importers and putative heme trafficking factors 
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PGRMC1/224, 118. The typical biochemical rationale for protein-protein interactions in a 
biosynthetic pathway usually invokes the requirement for substrate channeling in order to mitigate 
the dissociation of potentially toxic substrates and ensuring rapid flux. In the case of eukaryotic 
heme biosynthesis, which is an 8-step process, the first and last two steps occur in the mitochondria 
with the remaining steps occurring in the cytosol. Thus, the biochemical necessity for an ALAS 
interaction with FECH is not immediately clear in the context of substrate channeling. Our results 
suggest that the interaction between ALAS and FECH may be functionally significant from a 
regulatory perspective because we find that ALAS negatively regulates the flow of heme from 
FECH in the mitochondrial IM to the nucleus. Since a number of factors are known to regulate 
ALAS expression and/or mitochondrial import, including glucose, iron, and heme155, 156, we 
propose that the regulation of mitochondrial-nuclear heme trafficking by ALAS may be part of a 
complex circuit that links nutrient status to heme-based retrograde signaling. However, the precise 
physiological context and mechanism of ALAS-mediated regulation of mitochondrial-nuclear 
heme trafficking needs to be further explored.  
What is the elusive mechanism of mitochondrial-nuclear heme trafficking? Herein, we 
identified three conserved GTPases in control of mitochondrial fusion (Mgm1) and fission 
(Dnm1), and ER-mitochondrial contact sites (Gem1), as regulators of mitochondrial-nuclear heme 
trafficking. One unifying model consistent with our data is that mitochondrial-ER contact sites 
facilitate the distribution of heme to the nucleus and other extra-mitochondrial locales. ER tubules 
facilitate mitochondrial division by constricting mitochondrial tubules so that Dnm1 can 
oligomerize around the compressed mitochondrial outer-membrane and catalyze the GTP 
hydrolysis driven scission of mitochondria123. Gem1 is required to disengage ER- mitochondrial 
contacts after mitochondrial division124, 157. Therefore, both dnm1D and gem1D cells are expected 
to - and do - have more stable mitochondrial-ER contact sites119, 124. Thus, if heme were trafficked 
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through ER-mitochondrial contact sites to reach the ER and organelles contiguous with the ER 
like the nucleus, one would expect that dnm1D and gem1D cells exhibit increased rates of nuclear 
heme trafficking as was observed (Figure 4.7a and 4.10a).  
In accordance with the model just described, we suggest that Mgm1-mediated regulation of 
mitochondrial-nuclear heme trafficking occurs in a Dnm1 and ERMES- dependent manner. In 
such a model, Mgm1 promotes mitochondrial-nuclear heme trafficking because of its ability to 
drive mitochondrial fusion and provide a balancing force to oppose Dnm1-dependent 
mitochondrial fission. As a consequence, mgm1D cells would be expected to (and do) exhibit 
diminished mitochondrial-nuclear heme trafficking since there is no Mgm1 present to counteract 
Dnm1-mediated fission (Figure 4.8a). Consistent with this model, we observe a restoration of 
WT-levels of mitochondrial nuclear heme trafficking in mgm1D dnm1D cells (Figure 4.10d).  
However, a number of outstanding issues must be resolved regarding the proposed ERMES-
dependent model for mitochondrial-nuclear heme trafficking. First, we do not currently have a 
means to monitor heme in the ER to more directly assess the impact of ERMES and ER-
mitochondrial contact sites on heme trafficking via the ER. Second, it is unclear at this time why 
other fission and fusion mutants do not exhibit defects in heme trafficking (Figures 4.8 and 4.10). 
There may be some specific unknown additional roles of Mgm1 and Dnm1 that allow them to 
regulate heme trafficking. Third, we do no observe that mutants with defects in essential 
components of the ERMES complex, including mdm12D and mdm34D, exhibit altered 
mitochondrial-nuclear heme trafficking rates. One explanation is that there are multiple types of 
ER-mitochondrial contact sites in addition to ERMES that exist. Indeed, a number of factors in a 
conserved ER membrane protein complex (EMC) have also been found to facilitate physical 
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linkage between the ER and mitochondrial networks158. Thus, a heme distribution phenotype may 
only be observed in multigenic knockout cells defective in both ERMES and ECM factors.  
An alternative to the unified model that we present for heme trafficking via ER- 
mitochondrial contact sites is that each GTPase identified may play mechanistically distinct and 
unrelated roles in heme trafficking. For instance, the human homolog of Mgm1, OPA1, was 
previously found to physically associate with FECH in the heme metabolon24. As such, it is 
possible that Mgm1/OPA1 regulates the heme metabolon and its interactions with putative heme 
trafficking factors, e.g. PGRMC1/2, to effect mitochondrial-nuclear heme trafficking. Dnm1 and 
Gem1, as lipid- interacting outer-membrane associated GTPases, may play roles in heme 
sequestration. Binding of lipids such as cardiolipin, can stimulate GTPase activity and 
Dnm1/Drp1-dependent membrane fission events159. Given heme’s lipid-like properties4, we 
speculate that heme may be sequestered by Dnm1 or Gem1 in the OM to suppress heme trafficking. 
Gem1 also has roles in mitochondrial positioning and cytoskeleton anchoring that may contribute 
to heme distribution dynamics160. We are currently exploring the molecular mechanisms 
underlying Mgm1, Dnm1, and Gem1-mediated heme trafficking and if they cooperate through a 
common mechanism or act independently of each other.  
Our data indicates that factors that impact mitochondrial fission, Dnm1, and fusion, Mgm1, 
have a profound effect on heme distribution kinetics. Interestingly, our collaborators suggest the 
reverse may be true as well; namely that heme can impact mitochondrial dynamics. It is interesting 
to speculate that there may be feedback mechanisms by which heme itself, possibly acting through 
Mgm1 or Dnm1, can regulate heme distribution dynamics between the mitochondrial network and 
the nucleus. We are currently probing the underlying mechanisms that govern heme- regulation of 
mitochondrial fragmentation.  
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Altogether, the in vivo approach to monitor real-time dynamics of inter- compartmental 
heme trafficking coupled with molecular genetic approaches have uncovered fundamental aspects 
of the mechanisms underlying heme mobilization and utilization. We expect that the tools and 
approaches presented herein may be used to probe a number of human diseases, including certain 
cancers, neurodegenerative disorders, and blood diseases, that are associated with both defects in 
heme homeostasis and mitochondrial dynamics and membrane contact sites7, 114, 161. Indeed, given 
that mitochondrial dynamics and contact sites with the endomembrane system are conserved 
between yeast and man, and the factors that regulate them have homologs or functional analogs 
between lower and higher eukaryotes142, 162-165, our studies in yeast may be of broad applicability 
to better understand how membrane and organelle dynamics impacts heme transport and 
trafficking.  
 Materials and Methods 
4.4.1 Cell Strains, Transformation, Growth Conditions and Plasmids 
4.4.1.1 Yeast strains and Growth Conditions 
 S. cerevisiae strains used in this study were derived from BY4741 (MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ0). fis1∆::KanMX4, dnm1∆::KanMX4, mgm1∆::KanMX4, pcp1∆::KanMX4, 
ugo1∆::KanMX4, caf4∆::KanMX4, mdv1∆::KanMX4 strains were obtained from the yeast gene 
deletion collection (Thermo Fisher Scientific). We also utilized the previously reported strains, 
LJ109 (rho0) 102 and DH001b-3 (hem1∆::HIS3) 3. AR1029-3 (mdv1D::KanMX4 caf4D::HIS3) was 
generated by deleting CAF4 with pAR1047 in mdv1D::KanMX4 cells. OM232 (mgm1D::HIS3) 
and OM233 (dnm1D::KanMX4 mgm1D::HIS3) was generated by deleting MGM1 with pAR1051 
in WT and dnm1∆::KanMX4 cells, respectively. All strains were confirmed by PCR, mitochondrial 
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morphology (Figure Appendix 1), and, if derived from the yeast deletion collection, sequencing 
the unique barcodes flanking the KanMX4 deletion cassette.  
4.4.1.2 Yeast Transformation 
Yeast transformations were performed by the lithium acetate procedure 49. Strains were 
maintained at 30° C on either enriched yeast extract (1%) - peptone (2%) based medium 
supplemented with 2% glucose (YPD), or synthetic complete medium (SC) supplemented with 
2% glucose and the appropriate amino acids to maintain selection3. Cells cultured on solid media 
plates were done so with YPD or SC media supplemented with 2% agar 3. Selection for yeast 
strains containing the KanMX4 marker was done with YPD agar plates supplemented with G418 
(200 μg/mL) 3. WT cells treated with the heme synthesis inhibitor, succinylacetone (SA), and 
hem1Δ cells were cultured in YPD or SC media supplemented with 50 μg/mL of 5-aminolevulinic 
acid (ALA) or 15 mg/mL of ergosterol and 0.5% Tween-80 (YPDE or SCE, respectively) 3, 166. All 
liquid cultures were maintained at 30 °C and shaken at 220 RPM.  
4.4.1.3 Plasmids 
The caf4::HIS3 disruption plasmid, pAR1047, was generated by first PCR amplifying the 
upstream (-650 to -129) and downstream (+2110 to +2479) sequences relative to the CAF4 
translational start site, introducing 5’ BamHI / 3’ XhoI and 5’ XbaI / 3’ BamHI restriction sites, 
respectively. The CAF4 PCR products were digested with the enzymes indicated and ligated in a 
trimolecular reaction into the HIS3 integrating plasmid pRS403 167 digested with XhoI and XbaI, 
resulting in pAR1047. Transformation of yeast strains with pAR1047 linearized with BamHI 
resulted in deletion of CAF4 sequences from -128 to +2109. 
The mgm1::HIS3 disruption plasmid, pAR1051, was generated by first PCR amplifying 
the upstream (-532 to -5) and downstream (+2736 to +3023) sequences relative to the MGM1 
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translational start site, introducing 5’ BamHI / 3’ XhoI and 5’ XbaI / 3’ BamHI restriction sites, 
respectively. The MGM1 PCR products were digested with the enzymes indicated and ligated in a 
trimolecular reaction into the HIS3 integrating plasmid pRS403167 digested with XhoI and XbaI, 
resulting in pAR1051. Transformation of yeast strains with pAR1051 linearized with BamHI 
resulted in deletion of MGM1 sequences from -4 to +2735. 
Cytosolic, mitochondrial, and nuclear-targeted heme sensors, HS1, were sub-cloned into 
pRS415 and driven by ADH, TEF, or GPD promoters as previously described 3. The Hap1 reporter 
plasmid in which eGFP is driven by the CYC1 promoter was also previously described 3. 
4.4.2 Experimental Methods 
4.4.2.1 Heme Trafficking Dynamics Assay 
Overview. Inter-compartmental heme trafficking rates were monitored by: a. inhibiting 
heme synthesis with succinylacetone (SA) in sensor expressing cells; b. removing the block in 
heme synthesis by re-suspending cells into media lacking SA; and c. monitoring the time-
dependent change in the percentage of heme bound to heme sensor 1 (HS1) localized to the cytosol, 
nucleus, and mitochondrial matrix upon the re-initiation of heme synthesis. The fractional heme 
saturation of the sensor can be determined using previously established sensor calibration 
protocols3. The % of sensor bound to heme, % Bound, is calculated by determining the sensor 
eGFP/mKATE2 fluorescence ratio (R) under a given test condition relative to the eGFP/mKATE2 
fluorescence ratio when the sensor is 100% (Rmax) or 0% (Rmin) bound to heme as described in 
Equation 1 3.  
Rmin is determined by measuring the HS1 eGFP/mKATE2 ratio in parallel cultures that are 
conditioned with succinylacetone (SA), which inhibits the second enzyme in the heme biosynthetic 
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pathway, ALA dehydratase (ALAD) 168, and Rmax can be determined by permeabilizing cells and 
adding an excess of heme to saturate the sensor 3. Given HS1 is quantitatively saturated with heme 
in the cytosol, nucleus, and mitochondria of WT yeast, we typically determine Rmax by measuring 
the HS1 eGFP/mKATE2 ratio in parallel WT cultures grown without SA 3.  
Growth for SA-pulse chase assay. HS1-expressing cells were cultured with or without 500 
μM SA (Sigma-Aldrich) in SCE-LEU media. Triplicate 5 mL cultures were seeded at an initial 
optical density of OD600nm = .01-.02 (2-4 x 105 cells/mL) and grown for 14-16 hours at 30 °C and 
shaking at 220 RPM until cells reached a final density of OD600nm ~ 1.0 (2 x 107 cells/mL). After 
culturing, 1 OD or 2 x 107 cells were harvested, washed twice with 1 mL of ultrapure water, and 
resuspended in 1 mL of fresh SC-LEU media. The cells that were pre-cultured without SA provided 
HS1 Rmax values. The SA-conditioned cells were split into two 500 μL fractions. One fraction was 
treated with 500 μM SA to give HS1 Rmin values. The other fraction was not treated with SA so 
that heme synthesis could be re-initiated to give compartment-specific heme trafficking rates. HS1 
fluorescence was monitored on 200 uL of a 1 OD/mL (2 x 107 cells/mL) cell suspension using 
black Greiner Bio-one flat bottom fluorescence plates and a Synergy Mx multi-modal plate reader. 
eGFP (ex. 488 nm, em. 510 nm) and mKATE2 (ex. 588 nm, em. 620 nm) fluorescence was 
recorded every 5 minutes for 4 hours, with the plate being shaken at medium-strength for 30 
seconds prior to each read. Background fluorescence of cells not expressing the heme sensors were 
recorded and subtracted from the eGFP and mKATE2 fluorescence values.  
Growth for ALA pulse-chase assay. HS1-expressing hem1∆ cells were cultured with or 
without 400 μM 5-aminolevulinic acid (ALA) (Sigma-Aldrich) in SCE-LEU media. Triplicate 5 
mL cultures were seeded at an initial optical density of OD600nm = .01-.02 (2-4 x 105 cells/mL) and 
grown for 14-16 hours at 30 °C and shaking at 220 RPM until cells reached a final density of 
OD600nm ~ 1.0 (2 x 107 cells/mL). After culturing, 1 OD or 2 x 107 cells were harvested, washed 
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twice with 1 mL of ultrapure water, and resuspended in 1 mL of fresh SC-LEU media. The cells 
that were pre-cultured with ALA provided HS1 Rmax values. The cells that were cultured without 
ALA were split into two 500 μL fractions. One fraction was used to give HS1 Rmin values. The 
other fraction was treated with 400 μM ALA so that heme synthesis could be initiated to give 
compartment-specific heme trafficking rates. HS1 fluorescence was monitored on 200 uL of a 1 
OD/mL (2 x 107 cells/mL) cell suspension using black Greiner Bio-one flat bottom fluorescence 
plates and a Synergy Mx multi-modal plate reader. eGFP (ex. 488 nm, em. 510 nm) and mKATE2 
(ex. 588 nm, em. 620 nm) fluorescence was recorded every 5 minutes for 4 hours, with the plate 
being shaken at medium-strength for 30 seconds prior to each read. Background fluorescence of 
cells not expressing the heme sensors were recorded and subtracted from the eGFP and mKATE2 
fluorescence values.  
It should be noted that due to evaporation and drying of cell cultures in the plate reader, 
reliable measurements could not be achieved after 4 hours of continuous monitoring. 
4.4.2.2 Total heme quantification 
Measurements of total heme were accomplished using a fluorimetric assay designed to 
measure the fluorescence of protoporphyrin IX upon the release of iron from heme as previously 
described 58. For all total heme measurements, ~1 x 108 cells were harvested, washed in sterile 
ultrapure water, and resuspended in 500 μL of 20 mM oxalic acid and stored in a closed box at 4 
°C overnight (16-18 hours). Next, an equal volume (500 μL) of 2 M oxalic acid was added to the 
cell suspensions in 20 mM oxalic acid. The samples were split, with half the cell suspension 
transferred to a heat block set at 95 °C and heated for 30 minutes and the other half of the cell 
suspension kept at room temperature (~25 °C) for 30 minutes. All suspensions were centrifuged 
for 2 minutes on a table-top microfuge at 21000 x g and the porphyrin fluorescence (ex: 400 nm, 
em: 620 nm) of 200 μL of each sample was recorded on a Synergy Mx multi-modal plate reader 
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using black Greiner Bio-one flat bottom fluorescence plates. Heme concentrations were calculated 
from a standard curve prepared by diluting 500-1500 μM hemin chloride stock solutions in 0.1 M 
NaOH into ultrapure water, which was then added back to extra cell samples as prepared above. 
In order to calculate heme concentrations, the fluorescence of the unboiled sample (taken to be the 
background level of protoporphyrin IX) is subtracted from the fluorescence of the boiled sample 
(taken to be the free base porphyrin generated upon the release of heme iron). The cellular 
concentration of heme is determined by dividing the moles of heme determined in this fluorescence 
assay and dividing by the number of cells analyzed, giving moles of heme per cell, and then 
converting to a cellular concentration by dividing by the volume of a yeast cell, taken to be 50 fL 
3.  
In order to measure heme synthesis rates, exponential phase cells were pre-conditioned 
with 500 μM SA for 14-16 hours in SCE-LEU media as described above for the heme trafficking 
dynamics assay. Following this, cells were washed and resuspended in media lacking SA and 
aliquots of cells were harvested and washed for total heme quantification as described above.  
4.4.2.3 Hap1 activity  
Cells expressing p415-CYC1-eGFP, or eGFP driven by the Hap1 regulated CYC1 
promoter, were cultured in 50 mLs of SCE-LEU in 250 mL Erlenmeyer flasks, with or without 
500 μM SA, for 14-16 hours to an optical density of OD600nm ~ 1.0 (2 x 107 cells/mL). Cells were 
washed with sterile ultrapure water and diluted into fresh SC-LEU media at an optical density of 
OD600nm = 0.25 and allowed to grow for an additional 4 hours. The culture that was initially not 
conditioned with SA remained untreated during the 4-hour growth phase and these cultures 
represented basal Hap1 activity. The culture that was pre-conditioned with SA was split into two 
fractions. One fraction was treated with 500 μM SA for the 4-hour growth phase and these cultures 
served as a negative control, representing minimal Hap1 mediated activation of CYC1. The other 
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fraction was not treated with SA for the 4-hour growth phase and these cultures represented Hap1 
activity under conditions in which Hap1 was not saturated with heme. After growth for 4 hours, 
cells were washed in sterile ultrapure water and resuspended in PBS to a concentration of 1 x 108 
cells/mL and 100 uL was used to measure eGFP fluorescence (ex. 488 nm, em. 510 nm). 
Background auto-fluorescence of cells not expressing eGFP was recorded and subtracted from the 
p415-CYC1-eGFP expressing strains.  
4.4.2.4 Isolation of mitochondria and nuclei to confirm heme sensor localization 
Mitochondria and nuclei were isolated using yeast mitochondrial (Cat # K259-50) and 
nuclear (Cat # K289-50) isolation kits from BioVision according to the manufacturer’s 
instructions. All reagents were supplied by the isolation kits. For isolation of mitochondria, 50 
mLs of sensor expressing cells were cultured in SC-LEU in 250 mL Erlenmeyer flasks to a final 
density of OD600nm = 1.0 (2 x 107 cells/mL). 4 x 108 cells were harvested, washed in ultrapure 
water, and resuspended in “Buffer A” containing 10 mM DTT for 30 minutes at 30 °C with 
occasional gentle agitation. Cells were then harvested by centrifugation at 1,500 x g for 5 minutes 
at room temperature. Cells were then re-suspended in 1 mL of “Buffer B” containing manufacturer 
provided Zymolyase and incubated at 30 °C with occasional gentle inversion. Spheroplast 
formation was monitored by diluting 10 uL of the cell suspension into ultrapure water and 
monitoring the decrease in OD600nm such that it was > 80% less than the initial value, which 
typically took 30-60 minutes. Spheroplasts were harvested by centrifugation at 1500 x g for 5 
minutes, resuspended in “Homogenization Buffer” containing a protease inhibitor cocktail, and 
lysed with 15 strokes of a Dounce Homogenizer on ice. The lysate was centrifuged at 600 x g for 
5 minutes at 4 °C to remove cell debris. The supernatant, which contained the mitochondria, was 
again centrifuged for 5 minutes at 600 x g to remove additional debris. Finally, mitochondria was 
harvested by centrifugation at 12000 x g for 10 minutes at 4 °C. The mitochondrial pellet was 
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resuspended in 50 μL of “Storage Buffer”. In order to validate sensor mitochondrial localization, 
5% of the total spheroplast fraction, mitochondrial fraction, and the post-mitochondrial fraction 
(supernatant from the 12000 x g centrifugation step) were electrophoresed on a 14% tris-glycine 
SDS-PAGE gel and immunoblotted using α-PGK1 (Life Technologies; Cat # PA528612; 1:5000 
dilution), a cytosolic marker protein, α-porin (Life Technologies; Cat # 459500; 1:5000 dilution), 
a mitochondrial marker protein, and α-GFP (Genetex; Cat # GTX30738; 1:5000 dilution) to probe 
HS1 expression. A goat α-rabbit secondary antibody conjugated to a 680 nm emitting fluorophore 
(VWR/Biotium; Cat # 89138-520; 1:10000 dilution) was used to probe for PGK1 and GFP. A goat 
α-mouse secondary antibody conjugated to a 680 nm emitting fluorophore (VWR/Biotium; Cat # 
89138-516; 1:10000 dilution) was used to probe for Porin. All gels were imaged on a LiCOR 
Odyssey Infrared imager 3, 102. 
For isolation of nuclei, 50 mLs of sensor expressing cells were cultured in SC-LEU in 250 
mL Erlenmeyer flasks to a final density of OD600nm = 1.0 (2 x 107 cells/mL). 4 x 108 cells were 
harvested, washed in ultrapure water, and resuspended in “Buffer A” containing 10 mM DTT for 
30 minutes at 30 °C with occasional gentle agitation. Cells were then harvested by centrifugation 
at 1,500 x g for 5 minutes at room temperature. Cells were then re-suspended in 1 mL of “Buffer 
B” containing manufacturer provided Zymolyase and incubated at 30 °C with occasional gentle 
inversion. Spheroplast formation was monitored by diluting 10 uL of the cell suspension into 
ultrapure water and monitoring the decrease in OD600nm such that it was > 80% less than the initial 
value, which typically took 30-60 minutes. Spheroplasts were harvested by centrifugation at 1500 
x g for 5 minutes, resuspended in 1 mL of “Buffer N” containing a protease inhibitor cocktail, and 
lysed with 5 strokes of a Dounce Homogenizer on ice. The suspension was incubated for 30 
minutes at room temperature with gentle agitation every 3-5 minutes. The lysate was centrifuged 
at 1500 x g for 5 minutes at 4 °C to remove cell debris. Finally, nuclei were harvested by 
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centrifugation at 20000 x g for 10 minutes at 4 °C. The nuclear pellet was resuspended in 100 μL 
of “Buffer N”. In order to validate sensor nuclear localization, 5% of the total spheroplast fraction, 
nuclear fraction, and the post-nuclear fraction (supernatant from the 20000 x g centrifugation step) 
were electrophoresed on a 14% tris-glycine SDS-PAGE gel and immunoblotted using α-PGK1 
(Life Technologies; Cat # PA528612; 1:5000 dilution), a cytosolic marker protein, α-NOP1 (Life 
Technologies; Cat # MA110025; 1:10000 dilution), a nuclear marker protein, and α-GFP (Genetex; 
Cat # GTX30738; 1:5000 dilution) to probe HS1 expression. A goat α-rabbit secondary antibody 
conjugated to a 680 nm emitting fluorophore (VWR/Biotium; Cat # 89138-520; 1:10000 dilution) 
was used to probe for PGK1 and GFP. A goat α-mouse secondary antibody conjugated to a 680 
nm emitting fluorophore (VWR/Biotium; Cat # 89138-516; 1:10000 dilution) was used to probe 
for NOP1. All gels were imaged on a LiCOR Odyssey Infrared imager 3, 102. 
4.4.2.5 Confirmation of heme sensor localization by microscopy 
To confirm mitochondrial or nuclear localization of the sensors, prior to microscopy, 1 x 
107 exponential phase cells were incubated with 2.0 μg/mL 4’, 6-diamidino- 2-phenylindole 
(DAPI) (Invitrogen) in SC-LEU media for 45-60 minutes to stain nuclear or mitochondrial DNA3. 
Laser scanning confocal microscopy was accomplished on a Zeiss ELYRA LSM 780 Super-
resolution Microscope equipped with a 63x, 1.4 numerical aperture oil objective. DAPI was 
excited at 405 nm and emission was collected using 410-483 nm band pass filters. eGFP was 
excited with the 488 nm line of an argon ion laser, while mKATE2 was excited using the 594 nm 
of a HeNe laser line. The 491-588 nm and 599-690 nm band pass filters were used to filter emission 
for eGFP and mKATE, respectively. Images were collected using Zeiss software and analyzed with 
ImageJ 1.48v (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, 
USA, http://rsb.info.nih.gov/ij/, 1997-2007). Auto-fluorescence of unlabeled cells was subtracted 
from the DAPI, eGFP, and mKATE2 channels to produce the finalized images in Figure 1b. 
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4.4.2.6 Confirmation of mitochondrial morphology in fission and fusion 
To visualize the mitochondrial network, 1 x 107 exponential phase cells were incubated 
with 500 μM Mito Tracker Red CM-H2XRos (Thermo Fisher) in SC-LEU media for 45-60 
minutes. Confocal microscopy was done on a Zeiss ELYRA LSM 780 Super-resolution 
Microscope equipped with a 63x, 1.4 numerical aperture oil objective. Mito Tracker Red was 
excited using the 594 nm of a HeNe laser line and emission was collected using a 415-735 nm 
band pass filter. Images were collected using Zeiss software and analyzed with ImageJ 1.48v 
(Rasband, W.S.,ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://rsb.info.nih.gov/ij/, 1997-2007). The various mitochondrial network morphology types 
observed are outlined in Figure 1a Appendix and ~50 cells from each strain were analyzed to 
confirm the expected mitochondrial morphology (Figure 1b Appendix). A representative image 
of the mitochondrial network from each strain is depicted in Figure 1c Appendix. Fission and 









CHAPTER 5. UPTAKE AND UTILIZATION OF HEME AND HEME 
INTERMEDIATES. 
 Introduction 
Most heme requiring cells have the capacity to both acquire heme via de novo synthesis and 
import it from its environment. While heme synthesis is very well understood process, the 
mechanisms underlying heme uptake are not known. Moreover, it is important to understand if the 
imported heme can be used intact in metabolism. The current dogma is that every cell lives and 
dies with its own heme and any imported heme is degraded, with the released iron being recycled 
for new heme synthesis. In this context, the traditional view is that dietary heme acquisition is 
primarily a source for iron. However, if exogenous heme can be used intact, it is unclear how its 
bioavailability and subcellular distribution differs from endogenous heme.  
In order to identify factors that regulate heme uptake and distribution, we employed a hem1∆ 
strain of yeast that is incapable of synthesizing heme due to a deletion in the first enzyme in the 
heme synthesis pathway, aminolevulinic acid synthase (ALAS; Hem1). ALAS catalyzes the 
formation of aminolevulinic acid (ALA) from succinyl-CoA and glycine1. A hem1∆ deletion 
mutant is not viable unless cultured with ergosterol and oleic acid, two essential metabolites that 
are biosynthesized using heme-dependent cytochrome P450 enzymes. Thus, hem1∆ strains offer a 
unique model system to probe the biodistribution and availability of biosynthesized endogenous 
heme, through ALA supplementation, versus nutritionally acquired exogenous heme, through 
heme supplementation. Herein, we utilized genetically encoded heme sensors in hem1D cells to 
elucidate differences in heme utilization and distribution of endogenous and exogenous heme. 
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Moreover, we screened the haploid yeast deletion collection to identify factors, e.g. transporters 
or chaperones, that regulate heme uptake and availability.   
Our results demonstrated that indeed, S. cerevisiae could acquire and utilize exogenous heme 
under high concentrations but not in an efficient way. Endogenous heme is more bioavailable than 
exogenous heme as it can activate heme dependent processes such as catalase activity and Hap1 
activity, a heme dependent transcription factor, more efficiently. We observed that conditions like 
iron starvation promoted heme acquisition in a heme oxygenase (HO) depended manner. From the 
4,470 genes screened for heme availability under heme supplementation, we identified 33 deletion 
mutants that had improved heme uptake. One of these mutants is a mitochondrial magnesium 
transporter, Mfm1, which serves to facilitate heme uptake through a membrane potential 
dependent mechanism. 
 Results 
5.2.1 A hem1D mutant can use intact exogenous heme. 
In Saccharomyces cerevisiae eight enzymatic steps are responsible for heme biosynthesis. The 
condensation of succinyl-CoA with glycine to form aminoleuvilinic acid (ALA) is the first step. 
The aminolevulinic acid synthase (ALAS or Hem1) is an essential gene and is lethal upon deletion, 
but growth can be rescued by either supplementing with ALA or exogenous heme. Heme deficient 
cells such as hem1D, could also be rescued by the addition of ergosterol and oleic acid to the media. 
To investigate if exogenous heme could be acquired and utilized by S. cerevisiae, we compared 
the abilities of ALA and heme to rescue hem1∆ cells. 
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When heme deficient cells were titrated with ALA, we observed a dose dependent cell growth 
(Figure 5.1). We found that 50 µg/mL of ALA afforded the maximal rescue for hem1∆ cells, but 
this rescue never fully matched WT growth. This suggested that ALA uptake or integration into 
heme synthesis was limiting. To measure if higher doses of ALA would allow the heme deficient 
mutant to reach WT levels of cell growth, we decided to supplement with 400 µg/m/L and 800 
µg/mL of ALA. Higher doses of ALA did not seem to improve growth, since both of the high ALA 
supplementation only allowed half of the WT cell growth. (Figure 5.2) Supplementation with 
heme intermediate protoporphyrin IX (PPIX) and heme displayed similar cell growth as the cells 
treated with ALA, indicating a similar rescue and that heme was able to be acquired and utilized 





Overall, we observed that hem1D mutant growth could be recovered by heme and heme 
intermediates such as ALA and PPIX. The cell growth of a heme deficient mutant was not able to 
be matched to a WT through the supplementation of heme and heme intermediates judging by the 
lower cell growth. Because of the anionic carboxylates of ALA, heme, and PPIX, we surmise that 
transport across the cell membrane is limiting.  
Figure 5.1- Growth rescue of hem1D with ALA treatment. Heme deficient cells were 
supplemented with heme intermediates to rescue growth. Growth density reported 







We next quantified intracellular heme concentrations in order to determine the extent to 
which ALA, heme, and PPIX contributed to cellular heme stores for heme rescue. Total heme 
quantification was done with the high-performance liquid chromatography (HPLC) using a 
protocol adapted from the method of Woods and Simmonds101. In the initial trial, most 
interestingly, we observed hem1D cells supplemented with high doses of ALA contained similar 
levels of total heme as a WT cell. (Figure 5.3a) This indicated that there are other heme-
independent factors that limit the growth of hem1∆ cells supplemented with ALA. 
 ALA titrations revealed that 5 µg/mL ALA was a dose that resulted in similar intracellular 
total heme levels to the 25 µM concentration of heme and PPIX. (Figure 5.3b). Despite the fact 
that intracellular heme levels were identical between 5 µg/mL ALA and 25 µM heme, exogenous 
heme rescued hem1∆ cells better than ALA treatment. This suggested that exogenous heme was 
more efficient at rescuing growth per molecule of intracellular heme than ALA. 
 
Figure 5.2- Growth rescue of hem1D with higher concentrations of ALA, PPIX and heme 
treatment. Heme deficient cells were supplemented with heme intermediates to rescue 









5.2.2 Heme Availability for Different Compartments of a hem1D Mutant Provided with 
Exogenous Heme and Heme Intermediates.  
Given the fact that concentrations of 25 µM of heme, PPIX and 5 µg/ mL of ALA resulted in 
similar total heme levels, we sought to understand if endogenous and exogenous heme would be 
mobilized, distributed and used differently. To identify labile heme distribution, we used the 
genetically encoded fluorescent heme sensor HS1, which is the highest heme affinity from the 
library of heme sensors, being 100% bound in WT cells. Since the total heme levels from the 
supplemented cells are 25% of a WT strain, the tight binding heme sensor is the most appropriate 
sensor for these measurements. To study labile heme distribution and if there are any changes by 
supplementation of heme and heme intermediates, the HS1 sensor can be localized to the different 
organelles using specific organelle targeting sequences that allow them to be targeted to different 
compartments, including the cytosol, nucleus, and mitochondrial matrix. These sensors will help 
us determine differences in heme availability and distribution between endogenous and exogenous 
heme sources.  
a b 
Figure 5.3- Total heme concentrations of heme deficient cells supplemented with heme and 
heme intermediates. a. Total heme measurements for the initial concentrations with best 
growth rescue for hem1D. b. Concentrations of heme and heme intermediates that present 
similar total heme levels. Total heme concentrations represented in the figures were taken by 
three biological replicates and measure using the protocol for HPLC.  
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 Measurements of heme availability in the cytosol demonstrate none of the treatments were 
capable of generating enough heme to load the sensor more than 20%. (Figure 5.4) Additionally, 
we observed endogenous heme made from ALA was more efficiently distributed and more 
bioavailable in the cytosol than the porphyrins since the sensor had increased heme loading. PPIX 






In the case of heme availability for the nucleus, the result that stands out the most is the fact 
that PPIX seems to generate and make heme more bioavailable in the nucleus than ALA or heme. 
(Figure 5.5) The addition of ALA results in less bioavailable heme in the nucleus than the cytosol, 
while exogenous heme did not exhibit any bioavailable heme in the nucleus. Endogenous heme 
seems to be more efficiently mobilized and made bioavailable than exogenous heme for the 
nucleus and also the cytosol. It is surprising that PPIX and ALA, both heme biosynthetic 
intermediates, exhibit difference in heme loading in the nucleus. 
 
 
Figure 5.4 – ALA supplementation populates our sensor in the cytosol better than any other 
treatment. % Heme bound is calculated from the fluorimetric determination of 
EGFP/mKATE2 fluorescence ratios of the indicated yeast strains expressing HS1 in the 







For mitochondrial heme availability, it was very interesting to observe that supplementation 
with ALA, heme, or PPIX were incapable of making heme bioavailable to interact with our sensor. 
(Figure 5.6) It is possible that endogenous heme made in these supplemented cells with ALA and 
PPIX are being used for cytochromes in the mitochondria, preventing the formation of a labile 
pool. For the case of exogenous heme, it might not be regulated and delivered to the hemoproteins 





Overall, we were able to observe the changes in cellular heme distribution between exogenous 
and endogenous heme. Endogenous heme was more efficiently made bioavailable than exogenous 
Figure 5.5 - PPIX supplementation binds to our nuclear sensor more than any other 
treatment or compartment. % Heme bound is calculated from the fluorimetric determination 
of EGFP/mKATE2 fluorescence ratios of the indicated yeast strains expressing HS1 in the 
nucleus. Measurements represent the mean of three biological clones. 
Figure 5.6 – No treatment made heme bioavailable in the mitochondria. Only heme 
supplementation seemed to have some heme available in the mitochondria. % Heme bound 
is calculated from the fluorimetric determination of EGFP/mKATE2 fluorescence ratios of 
the indicated yeast strains expressing HS1 in the mitochondria. Measurements represent the 
mean of three biological clones. 
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heme, especially in cells supplemented with ALA. Cells provided with ALA showed a higher 
mobilization of heme in the cytosol than any other compartment measured. Upon addition of PPIX 
in the media, it was observed that the majority of the heme made was mobilized to the nucleus.  
5.2.3 Heme Dependent Processes of a hem1D with Supplementation of Exogenous Heme and 
Heme Intermediates.  
We next tested the activity of certain heme dependent processes upon the addition of 
exogenous heme or heme intermediates to make endogenous heme. The activation of heme 
dependent nuclear transcription factors such as Hap1 is one process we were very interested in 
measuring due to the relatively high amount of nuclear heme when cells are supplemented with 
PPIX. The other heme dependent process we were interested in measuring was the activity of 
catalase, a cytosolic protein that requires heme to facilitate the decomposition of hydrogen 
peroxide to water and oxygen. The activity readout of this heme dependent protein will allow us 
to confirm the heme levels in the cytosol observed with the thigh binding heme sensor. 
To further examine the activity of the heme dependent transcription factor Hap1, a 
transcriptional reporter was designed in which an eGFP expression is driven by Hap1 regulated 
CYC1. Upon heme binding, Hap1 protein will be heme loaded and activated, consequently leading 
to binding the CYC1 promoter and activating the expression of eGFP. The more eGFP present in 
the cell is translated as more heme available to activate Hap1 inducing the higher expression of 
this fluorescent protein. In these experiments we observed that only endogenous heme activated 
Hap1, especially the ALA treated sample. (Figure 5.7) The sample supplemented with PPIX 
displayed half the Hap1 activation than the ALA treated samples but double the activation than 
the exogenous heme treated. Even though ALA had half the heme availability than PPIX in the 
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nucleus according to the targeted sensor, we observed that it was more efficient at activating the 





For the catalase activity measurements, an in-gel activity stain was utilized that contains a 
staining solution of H2O2, DMSO, dopamine and para-phenylenediaminein dissolved in a 0.2 M 
potassium phosphate buffer. This staining method takes advantage of the catalase reaction by 
generating a 2-electron oxidation to dopamine that will facilitate the attack of para-
phenylenediamine to the quinone in the amine in a Michael type addition to make the 
benzoquinone, which is purple. The more the purple coloration corresponds with more catalase 
activity. This due to either increased heme availability or to increased catalase expression, which 
is addressed by the western blot probing for cytosolic catalase (Ctt1). When we tested the catalase 
activity for endogenous or exogenous heme, we observed that the only supplementation treatment 
capable of generating some active catalase was the heme intermediate ALA. (Figure 5.8) For the 
case of PPIX and heme, even though these supplementations generated similar total heme 
concentrations as the ALA treated sample, they did not make the heme bioavailable to the cytosol 
or catalase. According to the western blot, the lack of catalase activity is mainly due to the fact 
Figure 5.7 – PPIX displayed the highest Hap1 activity correlating with heme availability in 
the nucleus.  Hap1p activity in the indicated strains as measured by a transcriptional reporter 
that used EGFP driven by the CYC1 promoter, a Hap1p target gene. Measurements represent 
the mean of three biological clones. 
 108 
that there was not expression of catalase with the addition of heme or PPIX. This is consistent with 







5.2.4 Heme Uptake Improvement by Iron Starving S. cerevisiae.  
In order to identify conditions that improve heme acquisition in S. cerevisiae we decided to 
test labile heme availability for different organelles in a WT cell that has been iron starved. In C. 
albicans iron starvation models have been a crucial method for the identification of heme 
transporters such as Shu1 and Str341, 42. To test this model in Bakers’ yeast, we utilized the iron 
chelator bathiphenanthrolinedisulfonic acid disodium salt hydrate (BPS) in WT cells to generate 
the iron starvation conditions. Iron starve cells were then supplemented with or without heme and 
the labile heme was measured in the cytosol with our high affinity heme sensor. A heme acquisition 
improvement was observed for all the BPS plus heme samples and 10µM BPS was identified as 
the proper concentration for generating the iron starvation. (Figure 5.9) 
Figure 5.8 – Only endogenous heme by supplementing with ALA presented catalase 
activity and expression. In-gel activity assay for cytosolic catalase, Ctt1p, in the 
indicated strains. Cells were grown to mid-log phase in SC media. Immunoblots and 








To characterize the heme distribution upon heme uptake under iron starvation conditions, 
targeted sensors to the cytosol, nucleus, and mitochondria were used. In addition, heme synthesis 
inhibitor succinylacetone (SA) was used to test inorganic iron deficiency and not a heme 
deficiency was the reason of heme uptake improvement. Labile heme measurement demonstrated 
that heme acquisition was improved in every organelle upon iron starvation conditions. (Figure 
5.10) Heme starved cells in which SA was supplemented did not displayed a heme uptake in any 
of the organelles measured. Similar results were observed for WT iron starved cells expressing the 





Figure 5.9 – Heme acquisition improves during iron starvation conditions. Heme uptake 
was measured by titrating hem1D with iron chelator BPS and then treated with and without 
heme. % Heme bound is calculated from the fluorimetric determination of 
EGFP/mKATE2 fluorescence ratios of the indicated yeast strains expressing HS1 in the 
mitochondria. Measurements represent the mean of three biological clones. 
a b c 
Figure 5.10 – Iron starvation facilitates heme uptake in every quantified organelle. Heme uptake 
was measured by titrating hem1D with iron chelator BPS or SA and then treated with and without 
heme. % Heme bound is calculated from the fluorimetric determination of EGFP/mKATE2 
fluorescence ratios of the indicated yeast strains expressing HS1 in the a. cytosol, b. nucleus, c. 
mitochondria. Measurements represent the mean of three biological clones.  
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5.2.5 Heme uptake improvement under iron starvation is controlled by Heme Oxygenase  
To identify if the uptake improvement under iron starvation conditions in S. cerevisiae was 
heme oxygenase dependent, similar heme availability measurements in the cytosol were performed 
in a heme oxygenase deficient mutant. Heme oxygenase (Hmx1) is the protein in charge of 
degrading heme into biliverdin, ferrous iron and carbon monoxide. The majority of organisms that 
are capable of heme uptake, the heme is usually degraded providing an iron source for biological 
functions. The hmx1D cells treated with or without the iron chelator BPS displayed similar heme 
availability, indicating there was no uptake under iron starvation conditions. Additionally, BPS 





5.2.6 High through-put screen for the identification of genes that regulate heme uptake. 
To identify factors such as transporters or chaperones, that regulate heme uptake and 
availability, we screened the haploid yeast deletion collection by measuring heme acquisition using 
the weaker binding heme sensor, HS1-M7A. We based this method on the idea of if a certain gene 
that prevents uptake is deleted, we would observe an improvement in heme uptake, allowing us to 
Figure 5.11 - Heme acquisition improvement by iron starvation is dependent upon heme 
oxygenase expression. Heme uptake was measure by titrating hem1D with iron chelator BPS 
and then treated with and without heme. % Heme bound is calculated from the fluorimetric 
determination of EGFP/mKATE2 fluorescence ratios of the indicated yeast strains expressing 
HS1 in the mitochondria. Measurements represent the mean of three biological clones. 
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identify negative regulators for heme acquisition. From the screen we will be able to identify three 
possible groups: first, genes involved in a specific pathway that generates a condition that 
facilitates heme uptake. The second group is the transporters in which upon deletion they can no 
longer facilitate heme mobilization into the cell. Finally, the third group is the receptors that can 
sense heme outside the cell and prevent heme acquisition through signaling events.  
For the heme availability measurements, cells were grown until saturation and then diluted 
in media supplemented with and without heme. The next day, fluorescence reads for the eGFP and 
mKATE2 channels were measured and the sensor fluoresce ratio for cells supplemented with and 
without heme were calculated. To identify increases and decreases of heme uptake, a ratio of the 
ratios was calculated in which the sensor fluorescence ratio of the non-heme treated sample was 
divided by the ratio of the heme treated sample. A ratio of ratios that is higher than one means an 
increase in heme acquisition. If the ratio of ratios is lower than one, this indicates a decrease in 
heme acquisition or heme availability. Finally, if the number is one it indicates that both samples 








Figure 5.12 – Genome-wide high through-put screen data for heme acquisition. a. Ratio of 
ratios were calculated from the fluorescence ratios eGFP/mKATE2 expressed on the mutants 
with and without heme treatment. Positive numbers indicate high heme uptake and negative 
numbers indicate low heme uptake upon heme supplementation. b. Distribution of ratio of 
ratios in which the majority of the deletion mutants accumulate in no uptake change around a 
ratio of ratios of 1.  Data was calculated from duplicated samples. 
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In Figure 5.12a we can observe an overview of the data from the heme uptake screen in 
which shows the distribution of the ratio of ratios. It could be observed that the majority of the 
gene deletion mutants did not seem to present any changes in heme uptake since they clustered in 
the area of ratio of ratios of one. In the screen, 4,470 genes stably expressed the sensor and were 
screened in which we were able to identify 33 genes with a ratio of ratios of 2.0 or higher, 
indicating an increase in heme availability in the heme treated sample. (Figure 5.12a) Around 
3,438 genes, which accounts for 77% of all genes screened, displayed similar sensor fluorescence 
ratios for non-heme treated and heme treated samples. (Figure 5.12b)  
5.2.6.1 Genes that regulate heme acquisition.   
33 deletion mutants displayed a ratio of ratios of 2.0 or higher indicating that the heme 
availability for the heme treated sample in these mutants was higher than the non-treated sample. 
(Table 5.1) To identify localization enrichments for the 33 genes, we analysed the list of genes 
using PANTHER, which is a publicly available web-based resources that conducts gene ontology 
analysis. The results did not point out any specific compartment with a statistical significance and 
the majority of the cellular components had only one gene represented. We next assessed the 
biological function of these genes in order to determine if there were common pathways that might 
regulate heme availability. Similar to the cellular component classification data, the results did not 
point out any specific pathway or biological process with a statistical significance. 
Due to the inability to establish any cellular component or biological process relationship, 
we proceeded by analysing the genes individually. We identified a couple of genes involved in 
regulating protein expression such as GAT1, URM1 and MIG3. They genes are interesting in the 
sense that they could be regulating the expression of factors that facilitate heme uptake.  Ribosomal 
proteins were also identified including RSM23 and MRPL22, in which they could be acting as 
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heme delivery factors while they translate proteins. Two cell wall membranes were included in the 
list: BGL2, is a cell wall maintenance protein involved in newly synthesize mannoprotein 
incorporation. The second one was FLO1, which is a GPI-anchored cell surface glycoprotein 
required for the formation of fibrous interconnections between cells possibly helping in the 
communication between the cells about the environment. The ERV29 gene, involved in vesicle 
formation and incorporation of specific secretory cargo is also an interesting protein due to our 
conclusions in Chapter 2 of heme being mobilized through vesicles. And finally, two very 
compelling genes were identified for being transporters of metals into the cell, SFM3 that is an 
iron transporter and MFM1, a mitochondrial magnesium transporter.  
Table 5.1: Genes identified to improve heme acquisition from the high through-put screen. 
Systematic name Gene name 
Ratio of 
Ratios Name description 
YGR282C BGL2 2.5 Beta-GLucanase 
YIL088C AVT7 2.4 Amino acid Vacuolar Transport 
YGR284C ERV29 2.4 ER-Vesicle 
YER183C FAU1 2.4 Folinic Acid Utilization 
YIL059C YIL059C 2.4 Not characterized 
YGR287C IMA1 2.3 IsoMAltase 
YGR288W MAL13 2.3 MALtose fermentation 
YFL021W GAT1 2.3 Trancriptional activator 
YGL129C RSM23 2.3 Ribosomal Small subunit of Mitochondria 
YFL015C YFL015C 2.3 Not characterized 
YPR158W CUR1 2.2 Curing of [URe3] 
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Table 5.1 (continued)    
YIL084C SDS3 2.2 Suppressor of Defective Silencing 
YNL177C MRPL22 2.2 Mitochondrial ribosomal protein of large subunit 
YGR256W GND2 2.2 6-phosphoGlucoNateDehydrogenase 
YDR459C PFA5 2.2 Protein Fatty Acyltransferase  
YPL046C ELC1 2.2 ELongin C  
YHR033W YHR033W 2.2 Not characterized 
YPL056C LCL1 2.1 Long Chronological Lifespan 
YMR302C YME2 2.1 Yeast Mitochondrial Escape 
YIL087C AIM19 2.1 Altered Inheritance rate of Mitochondria 
YPL021W ECM23 2.1 ExtraCellular Mutant 
YIL008W URM1 2.1 Ubiquitin Related Modifier 
YIR019C FLO11 2.1 FLOcculation 
YGR122C-A YGR122C-A 2.0 Not characterized 
YFR016C YFR016C 2.0 Not characterized 
YER137C YER137C 2.0 Not characterized 
YGL151W NUT1 2.0 Negative regulation of URS Two 
YKR067W GPT2 2.0 Glycerol-3-Phosphate acylTransferase 
YER028C MIG3 2.0 Multicopy Inhibitor of Growth 
YLR034C SMF3 2.0 Metal ion trasnporter 
YPR106W ISR1 2.0 Inhibition of Staurosporine Resistance 
YOR241W MET7 2.0 METhionine requiring 
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5.2.7 Role of mfm1D in heme uptake.  
From the 33 genes identified to improve heme acquisition upon deletion, the protein Mfm1 
was one that displayed an extreme phenotype for heme uptake. Mfm1 is a mitochondrial inner 
membrane magnesium transporter involved in the maintenance of magnesium concentration in the 
mitochondria and also membrane potential. We observed a higher heme availability in a mfm1D 
cell when it was supplemented with heme. (Figure 5.13a) Total heme measurement in mfm1D and 
a WT were done in order to validate the heme mobilization into the cell. Total heme levels 







Since Mfm1 is responsible to maintain the membrane potential of the mitochondria, we 
wanted to understand if disruption in membrane potentials is a condition that favors heme 
acquisition. Heme uptake in a rho0 mutant, a strain that is deficient on mitochondrial DNA, 
displayed no changes in heme uptake between the heme supplemented and non-heme 
supplemented samples. Similar results of no heme acquisition were observed in the case of WT 
cells, while for the hem1D we noticed small increased in heme uptake. (Figure 5.14) 
a b 
Figure 5.13- Mfm1 is a negative regulator for heme acquisition. a. Cytosolic fluorimetric 
determination of EGFP/mKATE2 fluorescence ratios of the indicated yeast strains expressing 
HS1-M7A. b. Total heme levels of the indicated strains as determined by HPLC. Measurements 







In order to understand how S. cerevisiae is capable of importing heme into the cell and if 
endogenous and exogenous heme are distributed and utilized differently, we measured heme 
availability using genetically encoded fluorescent heme sensors under high supplementation of 
heme. The measurements of growth rescue displayed a rescue when supplemented with heme and 
heme intermediates, but not in the same degree or density as WT cells. For PPIX and heme 
supplementation, similar growth rescue to high ALA concentrations were achieved, but their total 
heme levels were half of the cells supplemented with ALA. Inefficient uptake of the 
protoporphyrin and accumulation of the heme intermediate could be causing PPIX to not be 
turnover into heme quickly enough by ferrochelatase. Cytotoxicity due to ALA accumulation in 
the supplemented cells might explain the similar cell rescue as the cells treated with PPIX and 
heme. Even though 5 µg/mL ALA only displayed half the growth rescue than 25 µM of heme and 
PPIX, we identified that they contain similar total heme concentrations. More readily and intact 
incorporation of heme in the PPIX and heme supplemented cells can explain the better rescue these 
samples have in comparison to the lower doses of ALA. A delay in heme biosynthesis in the ALA 
Figure 5.14- Mfm1 deletion facilitates heme uptake through changes in mitochondrial 
membrane potential. Heme uptake was measured by treating cells overnight with and without 
heme. Fluorimetric determination of EGFP/mKATE2 fluorescence ratios of the indicated 
yeast strains expressing HS1-M7A in the cytosol. Measurements represent the mean of three 
biological clones. 
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supplemented cell could be responsible for slower mobilization of heme and not incorporating it 
into the hemoproteins as fast and supplemented with heme.   
For the labile heme distribution, we observed endogenous heme was made bioavailable more 
efficiently than exogenous heme, localizing mainly in the cytosol and the nucleus. 
Supplementation with exogenous heme was observed to be made more bioavailable in the 
mitochondria. In erythroid cells, mitochondrial heme biosynthesis enzymes have been found to be 
through the formation of a metabolon or a heme biosynthetic complex in which PGRMC1, a 
progesterone receptor membrane component that required heme, was identified to interact with 
ferrochelatase and suggested to be a heme chaperone23, 24. If exogenous heme is not loaded into 
ferrochelatase in the same manner than when it is made endogenously, then it might not be able to 
be delivered to heme chaperones through a hem15 interaction. This would result in an 
accumulation of heme in the mitochondria since is not being mobilized through canonical 
pathways that can be detected by our heme sensors.  
Cells treated with PPIX displayed a higher labile heme pool in the nucleus than any other 
compartment and supplementation. This high accumulation of heme in the nucleus could be 
explained if once PPIX is introduced into the cell facilitated by its transporter Pug1169, it gets 
mobilized through intraorganellar membrane contact points in which it can get converted into 
heme and mobilized preferentially to the nucleus. Ferrochelatase activity has been identified in not 
only the mitochondria, but also the ER170 and intraorganellar contact points such as ERMES171, 172.  
The ER was also found to be a very important localization for the mobilization of exogenous and 
endogenous heme in mammalians cells, suggesting a hierarchical subcellular compartment 
localization for heme173. Perhaps PPIX gets mobilized to the ER, loaded with iron through the 
ferrochelatase activity there or in ERMES and favored to be moved into the nucleus. More 
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experiments will need to be done in order to test this model.  Heme trafficking kinetics experiments 
supplementing heme and ALA to the cell would determine if heme is mobilized to the nucleus first 
in PPIX supplementation, but not in ALA supplementation.  
To verify the heme availability levels for endogenous and exogenous heme determined by 
the heme sensor, we tested the activity of heme dependent proteins localized in a certain 
compartment. Using the transcriptional reporter for Hap1, a heme dependent transcription factor, 
we observed that indeed endogenous heme, preferentially heme synthesized after ALA 
supplementation, seemed to have a higher activation of Hap1 than any other supplementation. 
PPIX treatment indeed displayed the highest labile heme concentration in the nucleus but not the 
highest Hap1 activation, in which ALA was the most successful one. Overall, endogenous heme 
was more efficient than exogenous heme in the activation of heme dependent transcription factors 
possibly due to pathways of heme mobilization that are more efficient in delivering heme to the 
low affinity hemoproteins.  
In order to confirm the levels of bioavailable heme in the cytosol, catalase activity was 
measured using a colorimetric assay100. Only endogenous heme was capable of activating catalase 
activity, mainly because catalase expression was only active when supplemented with ALA. Why 
was catalase was not being expressed under PPIX and heme treatments, if all of the 
supplementation conditions generated similar levels of total heme? Since ALA treatment displayed 
the highest heme availability in the cytosol, catalase expression might be regulated by a specific 
cytosolic heme concentration that PPIX and heme are not necessarily reaching. Expression of 
catalase being regulated by ALA availability could be another possibility. Possible higher 
concentrations of PPIX and heme for supplementation that are buffered to prevent cytotoxicity and 
increase solubility could be used to test catalase expression in the future.  
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In S. pombe iron regulated heme transporters Shu1 and Str3 were identified under iron 
starvation conditions41, 42. Since S. cerevisiae has not been shown to be efficient at heme uptake in 
a high affinity manner, we decided to test if iron starvation affected heme uptake. Using the tight 
and weak binding sensors we observed iron starvation increased heme uptake in every single 
compartment measured. This increase was iron specific since heme depleted cells treated with and 
without heme did not seem to have any differences in heme availability. Cells seem to uptake heme 
mainly as an iron source since iron starve hmx1D cells supplemented with heme did not seem to 
uptake it. To characterize further the heme acquisition by iron starving the cells, more experiments 
will need to be done. For example, measuring iron levels on the samples treated with BPS and BPS 
plus heme to confirm iron starvation and heme degradation. Measuring transcriptional levels and 
increases upon iron starvation will allow us to elucidate factors facilitating heme insertion into the 
cell under these conditions.  
From the 4,470 genes screened for heme availability supplemented with and without heme, 
we observed that almost 77% of the deletion mutants did not displayed any divergence under the 
different conditions. This result establishes the high number of genes that are not related to heme 
acquisition; very different from what we observed for heme homeostasis, in which the majority of 
the deletion mutants displayed even a minimal change. From the screen we were able to identify 
33 genes acting as negative regulators, upon deletion they improve heme availability in the cell. 
While we were not able to identify a common function or cellular location that stood out form 
these genes, several were of interest. Two genes that we consider very compelling were SFM3 that 
is an iron transporter and MFM1, a mitochondrial magnesium transporter. We observed that iron 
starvation facilitates heme uptake which can explain the results of SMF3, but what is the effect of 
affecting magnesium uptake.   
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We were able to identify the negative regulator for heme uptake Mfm1 that upon deletion 
increased heme acquisition. Additionally, we were able to observe that mitochondrial membrane 
potential seems to play a role in heme uptake, since rho0 mutants displayed increased heme uptake 
similar to the mfm1D cells. It is known that under limited magnesium bioavailability, fluid-phase 
endocytosis seems to be upregulated facilitating the transferring of solutes taken into the 
vacuole174. Mfm1 deletions could cause disruptions of Mg2+ availability, activating then this fluid-
phase endocytosis that lead to the uptake of not only magnesium but heme as well since it is in 
high concentrations in the media. In the membrane potential case in rho0, the solutes inside the 
cell are disrupted and potentially signals the cell to activate diffusion in order to recover the 
membrane potential facilitating the entry of heme.  
Overall, we were able to demonstrate that exogenous and endogenous heme seem to 
distribute heme differently. We show S. cerevisiae is capable of heme acquisition under high heme 
conditions and that heme uptake could be improved by iron starving the cells. Endogenous heme 
seems to populate and activate heme dependent processes more efficiently than exogenous heme. 
We were also able to identify genes that act as negative regulators for heme uptake, Mfm1 being 
one that the deletion facilitated heme uptake. This might be due to a decrease of magnesium in the 
mitochondria upon deletion of Mfm1, which would upregulate endocytosis that might favor heme 
entry. Deletion of Mfm1, could also alter mitochondrial membrane potential, since a rho0 mutant 
similarly increased heme uptake. Experiments like overexpression screens, heme availability 
screen under iron starvation conditions and more characterization of the genes identify would help 
to elucidate more novel factors for heme acquisition. This work paves the path to further 
understanding of heme mobilization and utilization and identification of novels heme regulators 
for heme uptake. 
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 Materials and Methods 
5.4.1 Cell Strains, Transformation, Growth Conditions and Plasmids 
5.4.1.1 Yeast Strains and Growth 
S. cerevisiae strains used in this study were derived from BY4741 (MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ0). All yeast haploid deletion mutant strains were obtained from the yeast gene 
deletion collection (Thermo Fisher Scientific). We also utilized the previously reported strain 
DH001b-3 (hem1∆::HIS3) 3. All strains derived from the yeast deletion collection were confirmed 
by sequencing the unique barcodes flanking the KanMX4 deletion cassette. 
5.4.1.2 Yeast Transformation 
Yeast transformations were performed by the lithium acetate procedure 49. Strains were 
maintained at 30° C on either enriched yeast extract (1%) - peptone (2%) based medium 
supplemented with 2% glucose (YPD) and G418 (200 µg/mL) or synthetic complete medium (SC) 
supplemented with 2% glucose and the appropriate amino acids to maintain selection3. Cells 
cultured on solid media plates were done so with YPD or SC media supplemented with 2% agar 3. 
Selection for yeast strains containing the KanMX4 marker was done with YPD agar plates 
supplemented with G418 (200 μg/mL) 3. Cells for the screen were resuspended in SC media 
supplemented with 15 mg/mL of ergosterol and 0.5% Tween-80 (SCE). All liquid cultures were 
maintained at 30 °C and most were done in standing cultures. 
5.4.1.3 Plasmids 
Cytosolic, mitochondrial, and nuclear-targeted heme sensors, HS1, were sub-cloned into 
pRS415 and driven by ADH, TEF, or GPD promoters as previously described3. PCR based 
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mutagenesis was used to generate the affinity variants of HS1 (M7A)3. The Hap1 reporter plasmid 
in which eGFP is driven by the CYC1 promoter was also previously described 3. 
5.4.2 Experimental Methods 
5.4.2.1 Catalase Activity Measurements in Yeast 
WT yeast cells expressing empty vector (p415-GPD), or HS1-M7A driven by the GPD, 
TEF1, or ADH1 promoters (p415-GPD-HS1-M7A, p415-TEF1-HS1-M7A, p415-ADH1-HS1-
M7A) were cultured in SC-LEU media for ~14-16 hours to mid-exponential phase (an optical 
density at 600 nm of OD600 nm ~ 1-2). Cells were harvested and lysed in phosphate buffer and 
10 μg of protein lysate were subjected to native PAGE on a 10% tris-glycine gel (Invitrogen). 
After electrophoresis, an in-gel activity stain was utilized to measure catalase activity100. Briefly, 
a catalase staining solution containing 1 part Dopamine (20mg/mL) in pH 8 0.2 M KPi buffer, 1 
part para-phenylenediamine (3.5mg/mL) in pH 8 0.2M KPi, 1 part 15 % H2O2, and 2 parts DMSO 
were mixed in the order listed. The staining solution was added directly to the gel and allowed to 
stain for 2 minutes, followed by rinsing in Milli-Q water and imaging.  
5.4.2.2 Total Heme Quantification in Yeast 
 Heme was quantified using a protocol adapted from the method of Woods and 
Simmonds101. Briefly, yeast were cultured in 25 mL of YPDE media for 15 hours to a density of 
1 OD600 nm /mL. Cells were harvested, washed in ice-cold Milli-Q water, and lysed in three pellet 
volumes of acid-acetone (9.75 mL acetone, 0.250 mL concentrated HCl). Lysis was achieved at 4 
C using one pellet volume of zirconium oxide beads and a bead beater (Bullet Blender, Next 
Advance) on a setting of 8 for 3 minutes. After homogenization, lysates were clarified by 
centrifugation at maximum speed on a table-top centrifuge. 50 μL of an acid-acetone extract of 
heme was diluted into 50 μL of 0.1% trifluoroacetic acid in a 1:1 mixture of water and acetonitrile. 
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Heme was quantitated by HPLC using a flow rate of 1 mL/min and elution gradients going from 
50% acetonitrile in water, 0.1% TFA to 100% acetonitrile, 0.1% TFA over 10 minutes on a C-18 
column (Poroshell 120, SB-C18, 4.6 x 100 mm, 2.7 um). Heme was quantified relative to hemin 
chloride standards run in parallel and normalized for cell number. Cellular heme concentration 
was determined by assuming a yeast cell volume of 50 fL. Heme was unambiguously identified 
from its retention time and characteristic UV/visible spectrum using a photodiode array detector 
coupled to the HPLC.  
5.4.2.3 HAP1 Transcriptional Reporter Assay 
Yeast cells expressing p416-CYC1- EGFP, or EGFP driven by the Hap1p regulated CYC1 
promoter, were cultured in 10 mL of SCE-URA media for 15 hours to a to a density of 1 OD600 
nm/mL. Cells were resuspended in PBS to a concentration of 1 x 10
8 cells/mL and 100 uL was 
used to measure EGFP fluorescence (ex. 488 nm, em. 510 nm). As a positive and negative control, 
WT and hem1∆ cells were cultured for each experiment. Background auto- fluorescence of cells 
not expressing EGFP was recorded and subtracted from the EGFP expressing strains.  
5.4.2.4 Immunoblotting 
Yeast were cultured in 10 mL of SC media for 15 hours to a density of 1 OD600 nm /mL. 
Cells were harvested, washed in ice-cold Milli-Q water, and lysed in two pellet volumes of 
phosphate buffer supplemented with protease inhibitors as described previously102, 103. Lysis was 
achieved at 4 C using one pellet volume of zirconium oxide beads and a bead beater (Bullet 
Blender, Next Advance) on a setting of 8 for 3 minutes102, 103. Lysate protein concentrations were 
determined by the Bradford method (Bio-rad) and 12% tris-glycine gels (Invitrogen) were 
employed for SDS-PAGE102, 103. Anti-GFP rabbit or anti-GAPDH polyclonal antibodies (Genetex) 
and a goat anti-rabbit secondary antibody conjugated to a 680 nm emitting fluorophore (Biotium) 
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were used to probe for GAPDH. All gels were imaged on a LiCOR Odyssey Infrared imager102, 
103.  
5.4.2.5 High Through-put transformation 
Yeast high through-put transformations were performed in the standard clear sterile 96 well 
plates and by: a. preculturing the cells in 200 µL YPD G418 (200 µg/mL)  media until saturation 
(48 hours); b. diluted the cells in 200 µL of YPD G418 and grown for 14-16 hour at 30°C standing; 
c. transforming cells using the lithium acetate procedure adapted for 96 well plates57; d. incubating 
the cells with the transformation reagents for 6 hours at 42°C on the standing incubator on a Mary 
bath set up; e. resuspending cells in SCE media with the appropriate amino acids to maintain 
selection3. Plates were incubated for 96 hours and then diluted in fresh SCE media supplemented 
with the appropriate amino acids to confirm and maintain selection until saturation (48 hours.).  
5.4.2.6 High Through-put Screen 
Cytosolic HS1-M7A expressing cells were cultured in standard clear sterile 96 well plates. 
Duplicate cultures were seeded in 200 µLof SCE media with the appropriate amino acids to 
maintain selection3 standing until saturation (48 hours.). The cells were diluted into 200 µL SCE-
LEU supplemented with heme dissolved in 50% DMSO and 50% 0.1M Tris HCL and grown 
standing for 14-16 hours at 30°C. After culturing cells were harvested, washed twice in 200 µL of 
sterile ultrapure water and finally resuspended in 200 µL of 1x PBS. HS1-M7A fluorescence was 
monitored on 200 uL of a 4 OD/mL (2 x 107 cells/mL) cell suspension using black Greiner Bio-
one flat bottom fluorescence plates and a Synergy Mx multi-modal plate reader. eGFP (ex. 488 
nm, em. 510 nm) and mKATE2 (ex. 588 nm, em. 620 nm) fluorescence was recorded every 30 
seconds for 5 min. 
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CHAPTER 6. CONCLUSION AND FUTURE WORK 
During the last ten years the understanding of heme homeostasis mechanism has been 
transformed and advanced significantly. The view for this essential cofactor has evolved from 
being a static cofactor to be a signaling molecule involved in many biological functions. Even 
though the knowledge about heme has increased thanks to the development of imaging tool, more 
questions have risen about the factors that regulate its homeostasis. Despite the tremendous 
importance of heme in physiology, the cellular and molecular mechanisms that govern the safe 
assimilation of heme into metabolism remain poorly understood. All the work done in this thesis 
is to contribute in the understanding of heme homeostasis by identifying factors that regulate 
steady-state heme availability, the dynamics of heme mobilization to different subcellular 
compartments as it is being synthesized, and heme uptake. 
 Genome-Wide Determinants of Heme Homeostasis 
Through the use of the yeast haploid deletion collection in combination with genetically 
encoded fluorescent heme sensors we were able to identify genes involved in heme homeostasis. 
From the 4,470 genes screened, we were able to identify 114 strains that upon deletion displayed 
a higher cytosolic heme availability and 323 deletion mutants with low cytosolic heme availability. 
The screen was validated through the successful identification of heme biosynthetic factors 
including pyruvate transporters, pyruvate dehydrogenase, FAD transporters, glycine transporters, 
iron homeostasis, ALAS maturation and heme maturation as genes with low cytosolic heme 
availability. Proteins like GAPDH were identified from this screen as heme buffering factors, 
which was previously suggested as a heme binding protein. Functional groups like ESCRT 
proteins and vesicular trafficking proteins were identified to have an important role in heme 
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homeostasis and distribution. Even though this work will help in the understanding of heme 
trafficking, the regulation of heme homeostasis and as a tool for discovering heme buffering 
elements and new factors for heme biosynthesis and degradation, further characterization 
experiments are required. 
This screen has provided us with abundant information on heme homeostasis, but further 
characterization is needed to validate that the factors identified are indeed playing a role in heme 
homeostasis. The identified genes have been arranged by localization and function, but further 
characteristic analysis by size, abundance, or solubility could assist in predicting protein functions 
as either buffering factors or transporters. For the case of the vesicular proteins and the ESCRT 
complex, further experiments such as deletion of genes in the ESCRT pathway and measuring 
heme distribution in different organelles are required in order to identify the crucial point for heme 
mobilization and to validate our model.  
 GAPDH 
From the genome-wide screen for heme availability we were able to identify GAPDH as a 
possible heme buffering factor. This glycolytic enzyme was demonstrated to be a heme buffering 
factor that regulates heme mobilization and delivery to heme dependent transcription factors such 
as Hap1p. Additionally, the His53 in hGAPDH and His51 in yeast were characterized as crucial 
heme binding residue that not only regulated the heme buffering capacity but also the delivery to 
Hap1p. These results give us a new insight into how heme gets distributed and regulated within 
the cell. Our data suggest that the GAPDH heme pool is in equilibrium with the overall labile heme 
pool in the cell that is detected by the heme sensor, and that GAPDH is responsible for managing 
a significant portion of it. Once GAPDH binds heme, it makes it bioavailable to be inserted into 
cytosolic proteins like iNOS and for delivery to heme dependent transcription factors like Hap1p. 
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How exactly GAPDH is delivering heme to the Hap1p is still unknow, but we can suggest 
two possible pathways. One possibility is that GAPDH delivers heme through the direct contact 
with Hap1p, which could be supported by the idea of being able to shuttle or mobilized from the 
cytosol to the nucleus in specific conditions92. The alternative would be that heme delivery is 
mediated via an intermediary. Experiments to determine if the mechanism is through direct contact 
or an intermediary could be performed by targeting GAPDH to the mitochondria.  This would 
maintain glycolytic functions, while probing heme distribution to the nucleus or testing activity of 
the transcription factor Hap1. Hap1 could also be truncated or targeted in the nucleus and do 
similar experiments. Overall, the identification of GAPDH as a heme buffering factor helps to 
expand the knowledge on how intracellular heme is trafficked and how heme homeostasis is 
maintained. 
 The Heme Biosynthesis Enzyme, 5-aminolevulinic Acid Synthase (ALAS), and 
GTPases in Control of Mitochondrial Dynamics and ER Contact Sites, Regulate Heme 
Mobilization to the Nucleus. 
To understand the dynamics of heme mobilization out of the mitochondria, we developed a 
live-cell assay in yeast that uses the genetically encoded ratiometric fluorescent heme sensors 
(HS1) targeted to the mitochondrial matrix, cytosol, or nucleus3, 87, 125, to monitor heme distribution 
kinetics and identify processes important for subcellular heme trafficking. Surprisingly, we found 
that heme trafficking rates from the matrix side of the IM to the mitochondrial matrix and cytosol 
are similar, while trafficking to the nucleus is ~25% faster. This indicates that heme is distributed 
from the mitochondrial IM to other locales simultaneously via multiple parallel pathways rather 
than sequentially. We were able to discover that the heme biosynthetic enzyme, ALAS, negatively 
regulates mitochondrial-nuclear heme trafficking, highlighting the close coordination of heme 
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synthesis and trafficking. In addition, we identified GTPases that directly (Gem1) and indirectly 
(Dnm1 and Mgm1) regulate ERMES as being modulators of nuclear heme transport. Based on our 
results, we propose a model in which heme is trafficked via ER- mitochondrial membrane contact 
sites to other organelles such as the nucleus.  
One interesting observation from all of the deletion mutants analyzed for this project was 
how most of them presented their heme homeostasis disruptions mainly in the nucleus. Why 
mainly in the nucleus? There is the possibility that the disruption might be happening through the 
ER, but currently we do not possess an ER targeted sensor restricting our ability to observe it. The 
development of an ER targeted sensor would allow us to perform similar trafficking kinetics 
studies in the ER. Could it be due by nucleus volume and size? Titrations with the heme synthesis 
inhibitor SA, would allow us to measure if changes in total heme levels affect heme distribution 
only in the nucleus or if it gets disrupted in a similar manner as to the other compartments.  
Altogether, the in vivo approach to monitor real-time dynamics of inter- compartmental 
heme trafficking coupled with molecular genetic approaches have uncovered fundamental aspects 
of the mechanisms underlying heme mobilization and utilization. We expect that the tools and 
approaches presented here may be used to probe a number of human diseases, including certain 
cancers, neurodegenerative disorders, and blood diseases, that are associated with both defects in 
heme homeostasis and mitochondrial dynamics and membrane contact sites7, 114, 161. Indeed, given 
that mitochondrial dynamics and contact sites with the endomembrane system are conserved 
between yeast and man, and the factors that regulate them have homologs or functional analogs 
between lower and higher eukaryotes142, 162-165, our studies in yeast may be of broad applicability 
to better understand how membrane and organelle dynamics impacts heme transport and 
trafficking.  
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 Uptake and Utilization of Heme and Heme Intermediates 
In this chapter we demonstrated that exogenous and endogenous heme seem to distribute 
heme differently, showing S. cerevisiae is capable of heme acquisition under high heme conditions 
and iron starvation. We also identified genes that act as positive and negative regulators for heme 
uptake, Mfm1 being one that the deletion facilitated heme uptake. Membrane potential was 
observed to play a role since a rho0 mutant seem to improve heme uptake too. From the 4,470 
genes screened for heme availability supplemented with and without heme, we observed that 
almost 75% of the deletion mutants did not displayed any divergence under the different 
conditions. This result establishes the high number of genes that are not related to heme 
acquisition; very different from what we observed for heme homeostasis, in which the majority of 
the deletion mutants displayed even a minimal change. From the screen we were able to identify 
374 genes acting as negative regulators, upon deletion they improve heme insertion into the cell. 
We also identified 113 genes as possible positive regulators, since the deletion of the genes seemed 
to decrease the amount of heme inserted into the cell. 
Since in the screen we were mainly able to identify genes that acted as negative regulators 
for heme acquisition, we believed that an overexpression screen would be a good complementary 
data set to help us identify novel factors that regulate heme uptake. A heme availability screen 
under iron starvation conditions coupled with transcript expression levels will allow us to expand 
our knowledge of heme uptake factors and identify positive regulators for heme uptake. Further 
characterization of the genes identified in this screen would also help for elucidate the functional 
role these genes have in exogenous heme uptake and heme utilization. This body of work cements 
the foundation for further exploration of heme mobilization, utilization, and the identification of 
novel heme regulators for heme uptake. 
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 Conclusions 
• Genome-wide screen for bioavailable heme reveals that heme may be trafficked via 
intracellular vesicles. 
• We identified transporters, metabolic enzymes, and uncharacterized Open Reading 
Frames that impact heme bioavailability; they remain to be characterized. 
• GAPDH was identified as a heme chaperone responsible for the heme delivery to heme 
dependent transcription factors such as Hap1. 
• We identified His51 in yeast GAPDH and His53 in human GAPDH to be important for 
heme binding in GAPDH and for the delivery of heme to the heme dependent 
transcription factors such as Hap1.  
• Heme goes to the nucleus first, presumably to signal the presence of heme. 
• Heme synthesis and trafficking are closely coupled, suggesting ALAS to not only be 
involved in heme biosynthesis but also regulating heme mobilization throughout the cell.  
• Factors that regulate mitochondrial dynamics and ER-contact sites gate the flow of heme 
to the nucleus. 
• Endogenous heme is more efficient in distributing heme throughout the cell and 
activating heme dependent processes than exogenous heme.  
• Iron starvation is a condition that promotes heme uptake from the environment in 
Saccharomyces cerevisiae in a heme oxygenase dependent manner.  
• The mitochondrial magnesium transporter, Mfm1 was identified as a negative regulator 




APPENDIX A. SUPPLEMENTAL TABLES AND FIGURES  
A.1 Introduction 
 This appendix is meant to be used as supplementary information that was crucial for the 
research, but with much more detail. Kinetic information from the Pulse chase assay for measuring 
heme dynamics in Chapter 4 are also included. Microscopy data to confirm the mitochondrial 
phenotypes of the strains used in Chapter 4 are also included in this appendix.   
A.2 Supplemented Tables 
Table A.1 - Kinetic parameters derived from fits to the heme trafficking data using Equation 2. 
The values indicated represent the mean ± SD of independent triplicate cultures. *p<0.05, 
**p<0.01, ***p<0.001 by one-way ANOVA with Dunnett’s post-hoc test. Red asterisks indicate 
statistical significance relative to the cytosol within a given strain. Black asterisks indicate 






































































































































































































































































































































































































A.3 Supplemental Figure 
Figure A.1 - Validation of the mitochondrial network morphology defects in yeast fission and 
fusion mutants. (a) Sampling and classification of mitochondrial network morphologies 
observed using Mitotracker staining of cells. (b) Histograms of mitochondrial network 
morphology in the fission and fusion mutants used throughout this study. Mutants defective in 
mitochondrial fission exhibit an elongated mitochondrial network. Mutants defective in 
mitochondrial fusion exhibit a punctate mitochondrial network. WT and mgm1∆ dnm1∆ cells 
tend to have a more equal distribution of elongated and punctate   mitochondrial networks. The 
histograms were generated by analyzing ~50 cells per mutant. (c) Representative images of the 
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